n n u l r e p r march shareholders alex gorsky chairman board directors chief executive officer often asked led work perhaps theres better proof health care chose spend success johnson johnson achieved company career johnson johnson delivered solid financial results fullyear better first job janssen flagship company sales billion adjusted net positioned pharmaceutical segment current earnings billion also continuing help meet role companys chairman ceo make investments accelerate growth urgent years later answer always begins long term needs credo johnson pleased performance johnson simple yet powerful document penned know never rest general robert wood johnson son providing sustainable highquality health care founder companys first chairman one societys greatest challenges credo outlines companys commitments responsibilities people unprecedented era human history communities touch every day historic aging rate worlds population products services years along growing middle class around served moral compass world brings dramatically greater demand johnson johnson ensuring never lose higher quality health care governments sight strong values important health systems must manage needs many stakeholders serve increasingly strained resources thats consider credo one johnson johnson credo compels visionary statements corporate purpose us innovate areas unmet ever written medical needs overcome barriers advance chairmans letter ihealth care corners world us world today requires best involves preventing spread deadly johnson johnson offer infectious diseases solving twin challenges constantly striving come ways overnutrition undernutrition leading innovate lead made deliberate breakthrough medical research empowering choices portfolio focused citizens take responsibility managing energies capturing greatest opportunities health wellness advance patient care confident future company better positioned johnson johnson four reasons help meet urgent needs johnson johnson ur core businesses strong positioned continue expanding given progress weve made business leadership past several years evolving w e exciting deep product approach placing even greater emphasis pipeline across entire enterprise innovation accelerating growth continued w e changing way interact commitment excellence execution non customers negotiable part process w e evolving structure effective efficient drive growth succeed clear goals priorities approximately grow rd pipeline interconnected global society people coming years pharmaceutical pipeline live business come realize working poised yield consistent flow new product travels around world filings allow us bring new medicines johnson johnson health care local operating technologies patients continue personal approximately companies build pipeline order stay people working operating companies countries forefront countries across broad range medical specialties community health needs lead consumer health care markets unique insights capabilities aim expand leadership targeted help address formidable challenges markets holistically addressing criticalneed proud colleagues around states overthecounter medicines well globe focused oral care baby skin care markets every single day care world one person time strengthen position medical devices focus accelerating growth largest diversified health innovative products transforming care company world gotomarket models better serve opportunity responsibility help meet customers patients challenges boldness vision driving ii chairmans lettersense purpose acknowledged values come life ways give credo embraced responsibility many ways company enduring competitive advantage constant perhaps significantly efforts reminder address ebola epidemic ive always believed working health care work exceptional collaboration among global honor privilege cant think health community substantially accelerated better place carry incredible work values production ebola vaccine regimen johnson johnson thanks committed goal bringing vaccine approved small part legacy general robert wood upholding families frontline health care johnson credo together professionals risk quickly possible thank continued support credo constant reminder work investment johnson johnson values committed upholding together values us strive sincerely make real energy passion caring hard work every single day joined four longterm drivers growth creating value innovation expanding alex gorsky global reach local focus maintaining laser chairman board directors focus excellence execution leading chief executive officer purpose make difference world chairmans letter iiiour credo action year review dar es salaam tanzania johnson johnson partners ccbrt kupona foundation provide support rehabilitation people disabilities resulting childbirth injuries obstetric fistula remove barriers medical care treatment power credo unites shortage least one million health care professionals people johnson johnson around worlds poorest countries stepped collaborate multinational coalitions common set principles countries develop new generation nurses mid helpful framework understanding wives pharmacists community health workers fill approach driving growth meeting gap part commitment support nurses also gave educational grant nursecom make needs stakeholders therefore continuing education resources ebola available pleased highlight key achievements every nurse us date nurses taken part virtual training alex gorsky chairman board directors chief executive officer also delivering new products offer significant advancements customers insight believe first responsibility doctors driven approach innovation continuously nurses patients mothers fathers adjusting product brand portfolios meet others use products services exceed expectations strong pipelines recognition first important responsibility expected yield key consumer product launches johnson johnson supporting training protecting globally new major medical device product health care workers front lines helping filings major new people greatest need care services pharmaceutical filings line extensions world health organization estimates photo mark tuschman iv credo actionwe responsible employees men four johnson johnson innovation centers women work us throughout world located major science technology hubs caring world one person time unites london boston la jolla shanghai kept us inspires people johnson johnson includes forefront new ideas scientific breakthroughs approximately employees around globe jlabs strings attached incubators lead way managing health stimulating total innovation ecosystem helping young wellness employee programs forefront companies pioneering ideas get ground industries decades research proves healthy company productive profitable final responsibility shareholders company us health wellness programs operate according principles helped employees reduce risk factors stockholders realize fair return key health measures less half countrys gratifying shareholders supported general population includes areas smoking us years built worldwide high blood pressure high cholesterol inactivity business extended reach improve lives people everywhere employee engagement johnson johnson also alltime high continues measured rates strong performance enabled us meet well external benchmarks met talent commitments shareholder engagement objectives retained key talent strengthened talent pipeline improved employee engagement reputational standings measured credo survey employees responsible communities consecutive years consecutive years live work world community well dividend increases adjusted earnings commitment transforming lives patients increases communities includes contributions billion products cash last year support aaa programs address major healthrelated industrial issues local communities countries companies hold aaa credit rating around world also made great progress toward healthy future citizenship sustainability goals including efforts global health environment responsible transparent business practices must experiment new ideas research development productivity leading industry approach designed ensure continue lead last year invested industry sales come brands platforms leading billion also executed global generate strategic partnerships licenses acquisitions market share position billion sales apiece across pharmaceutical medical devices consumer segments nongaap measure excludes special items credo action v business highlights strong year johnson johnson delivered solid financial results continuing make investments accelerate growth long term built significant momentum pharmaceutical business realizing benefits innovation scale breadth medical devices business continuing market leadership iconic brands consumer business weve achieved nearterm priorities exceeding financial targets fullyear operational sales growth percent excluding net impact acquisitions divestitures operational basis worldwide sales increased percent pharmaceuticals golimumab remicade infliximab biologics worldwide pharmaceutical sales billion approved treatment number immune fullyear represented operational growth mediated inflammatory diseases percent new medicines launched since pharmaceutical segment fastest comes innovation ensuring growing top pharmaceutical businesses continuous access new ideas products us europe japan medicines earliest stages expect best science prevail making dramatic impact regardless whether comes sources inside outside johnson johnson made strong sales results driven new products two significant acquisitions add innovation strength core products new products portfolio alios biopharma inc privatelyheld clinical include olysiosovriad simeprevir stage biopharmaceutical company focused developing combination treatment chronic hepatitis c adult therapies viral diseases covagen ag privately patients xarelto rivaroxaban oral anticoagulant held biopharmaceutical company specializing zytiga abiraterone acetate oral oncedaily development multispecific protein therapeutics medication use combination prednisone fynomab technology platform treatment metastatic castrationresistant prostate cancer invokana canagliflozin treatment medical devices adults type diabetes imbruvica ibrutinib worldwide medical devices sales billion oral oncedaily therapy approved use treating fullyear represented operational decrease certain bcell malignancies blood cancers percent excluding net impact acquisitions divestitures operational basis worldwide sales additional contributors operational sales growth increased percent stelara ustekinumab biologic approved treatment moderate severe plaque psoriasis medical devices business holds strong leadership psoriatic arthritis invega sustennaxeplion position industry including platforms paliperidone palmitate oncemonthly longacting billion sales weve launched major injectable atypical antipsychotic treatment new products since major schizophrenia adults simponisimponi aria new filings planned end vi business highlightsprimary contributors operational growth broad year launched several new products portfolio orthopaedic products biosense websters including womens rogaine zyrtec dissolve tabs electrophysiology products cardiovascular care several new formulations listerine business biosurgicals international sales relaunched brands tylenol pm energy products specialty surgery business insightdriven innovation consumer business sales results vision care us diabetes care focused addressing key consumer need states led businesses negatively impacted competitive megabrands new product launches pricing dynamics planned key approvals launches year include citizenship sustainability us food drug administration fda approval managing social environmental economic animas vibe insulin pump continuous impacts locally globally important responsibility glucose monitoring system management citizenship sustainability strategic priorities focus insulinrequiring diabetes adults ages older efforts advance global health help safeguard incraft aaa stent graft system approved planet lead dynamic growing business launched treatment abdominal aortic responsibly aneurysms aaa europe canada saber pta dilatation catheter treatment patients continued make progress toward healthy peripheral arterial disease received fda future goals including leveraging research european commission approval fda approved development ability innovate collaborate thermocool smarttouch catheter find solutions global health issues response treatment patients suffering drugresistant ebola crisis collaboration us national paroxysmal atrial fibrillation institutes health bavarian nordic committed accelerate vaccine program stop june company completed tb partnerships global drug facility usaid divestiture orthoclinical diagnostics business expanding access multidrugresistant carlyle group approximately billion tuberculosis compound sirturo expanded collaboration international partnership consumer microbicides development commercialization worldwide consumer sales billion full dapivirine prevention sexual transmission hiv year represented operational increase working viiv healthcare develop percent excluding net impact acquisitions twodrug single tablet regimen maintenance treatment divestitures operational basis worldwide sales people living hiv increased percent legacy care environment protection positive contributors operational results sales natural resources continues working tylenol motrin analgesics zyrtec reduce energy consumption increasing allergy overthecounter products aveeno proportion energy use renewable sources neutrogena skin care products listerine thereby reducing carbon dioxide emissions oral care products continue look ways reduce water consumption business highlights vii business highlights waste production throughout products lifecycles health women children include work support example continue integrate expand millennium development goals addition earthwards approach drive continuous expanded programs using mobile technology sustainability improvements innovation across way disperse health information new expectant businesses date products mothers south africa india announced gained earthwards recognition ahead global partnership save children goal potential help improve survival healthy development millions children age remain committed enhanced transparency next three years engagements stakeholders serve improve health patients drive improved clinical outcomes commitment transforming lives patients announced extended agreement yale communities includes contributions open data access yoda project provide access approximately billion products cash last year clinical trial data pharmaceutical medical device support programs address major products setting new industry standards first healthrelated issues local communities company ongoing efforts improve countries around world nongaap measure see reconciliation nongaap financial measures pages annual report operational measures exclude impact currency translation ims midas data q growth versus previous year moving annual total local currency dollars note regarding forwardlooking statements chairmans letter business highlights section contain forwardlooking statements relating among things business strategy performance expectations product development reader cautioned rely statements review section cautionary factors may affect future results annual report important information statements including risks uncertainties factors could cause actual results vary materially assumptions expectations projections expressed forwardlooking statements johnson johnson undertake update forwardlooking statement result new information future events developments viii business highlightstable contents managementsdiscussionandanalysis ofresults ofoperationsandfinancialcondition organizationandbusinesssegments resultsofoperations analysisofsalesbybusinesssegments analysisofconsolidatedearningsbeforeprovisionfortaxesonincome liquidityandcapitalresources otherinformation cautionaryfactorsthatmayaffectfutureresults auditedconsolidatedfinancialstatements consolidatedbalancesheets consolidatedstatementsofearnings consolidatedstatementsofcomprehensiveincome consolidatedstatementsofequity consolidatedstatementsofcashflows notestoconsolidatedfinancialstatements reportofindependentregisteredpublicaccountingfirm managementsreportoninternalcontroloverfinancialreporting supportingschedules summaryofoperationsandstatisticaldata shareholderreturnperformancegraphs reconciliationofnongaapfinancialmeasures johnsonjohnsonannualreport managements discussion analysis results operations financial condition organization business segments descriptionofthecompanyandbusinesssegments johnsonjohnsonanditssubsidiariesthecompanyhaveapproximatelyemployeesworldwideengagedinthe researchanddevelopmentmanufactureandsaleofabroadrangeofproductsinthehealthcarefieldthecompany conductsbusinessinvirtuallyallcountriesoftheworldwiththeprimaryfocusonproductsrelatedtohumanhealthand wellbeing thecompanyisorganizedintothreebusinesssegmentsconsumerpharmaceuticalandmedicaldevicespreviously referredtoasmedicaldevicesanddiagnosticstheconsumersegmentincludesabroadrangeofproductsusedinthe babycareoralcareskincareoverthecounterpharmaceuticalwomenshealthandwoundcaremarketsthese productsaremarketedtothegeneralpublicandsoldbothtoretailoutletsanddistributorsthroughouttheworldthe pharmaceuticalsegmentisfocusedonfivetherapeuticareasincludingimmunologyinfectiousdiseasesneuroscience oncologyandcardiovascularandmetabolicdiseasesproductsinthissegmentaredistributeddirectlytoretailers wholesalershospitalsandhealthcareprofessionalsforprescriptionusethemedicaldevicessegmentincludesabroad rangeofproductsusedintheorthopaedicsurgicalcarespecialtysurgerycardiovascularcarediagnosticsdiabetes careandvisioncaremarketswhicharedistributedtowholesalershospitalsandretailersandusedprincipallyinthe professionalfieldsbyphysiciansnurseshospitalsandclinics thecompanysstructureisbasedupontheprincipleofdecentralizedmanagementtheexecutivecommitteeof johnsonjohnsonistheprincipalmanagementgroupresponsibleforthestrategicoperationsandallocationofthe resourcesofthecompanythiscommitteeoverseesandcoordinatestheactivitiesoftheconsumerpharmaceuticaland medicaldevicesbusinesssegments inallofitsproductlinesthecompanycompeteswithcompaniesbothlocallyandgloballythroughouttheworld competitionexistsinallproductlineswithoutregardtothenumberandsizeofthecompetingcompaniesinvolved competitioninresearchinvolvingthedevelopmentandtheimprovementofnewandexistingproductsandprocessesis particularlysignificantthedevelopmentofnewandinnovativeproductsisimportanttothecompanyssuccessinall areasofitsbusinessthisalsoincludesprotectingthecompanysportfolioofintellectualpropertythecompetitive environmentrequiressubstantialinvestmentsincontinuingresearchinadditionthedevelopmentandmaintenanceof customerdemandforthecompanysconsumerproductsinvolvessignificantexpendituresforadvertisingandpromotion managementsobjectives thecompanymanageswithinastrategicframeworkwithourcredoasthefoundationthecompanybelievesthatour strategicoperatingprinciplesbeingbroadlybasedinhumanhealthcaremanagingthebusinessforthelongterma decentralizedmanagementapproachandcommitmenttoourpeopleandvaluesarerequiredtosuccessfullymeetthe demandsoftherapidlyevolvingmarketsinwhichwecompetetothisendmanagementisfocusedonourgrowthdrivers creatingvaluethroughinnovationexpandingourglobalreachwithalocalfocusexcellenceinexecutionandleadingwith purpose thecompanyengagesinareasofhumanhealthcarewherethereisanopportunitytomakeameaningfuldifferenceand iscommittedtocreatingvaluebydevelopingbroadlyaccessiblehighqualityinnovativeproductsandservicesnew productsintroducedwithinthepastfiveyearsaccountedforapproximatelyofsalesinbillionor ofsaleswasinvestedinresearchanddevelopmentreflectingmanagementscommitmenttodeliveringnewand differentiatedproductsandservicestomeetevolvinghealthcareneedsandsustainthecompanyslongtermgrowth ourdiversebusinesseswithmorethanoperatingcompanieslocatedincountriesarethekeydriversofthe companyssuccessmaintainingthecompanysdecentralizedmanagementapproachwhileatthesametimeleveraging theextensiveresourcesoftheenterpriseuniquelypositionsthecompanytoinnovateexecuteandreachmarketsglobally whilefocusingontheneedsandchallengesofthelocalmarkets johnsonjohnsonannualreportinordertoremainaleaderinhealthcarethecompanystrivestomaintainapurposedrivenorganizationandiscommitted todevelopingglobalbusinessleaderswhocanachievethesegrowthobjectivesbusinessesaremanagedforthe longterminordertosustainmarketleadershippositionsandenablegrowthwhichprovidesanenduringsourceofvalue toourshareholders ourcredounifiesalljohnsonjohnsonemployeesinachievingtheseobjectivesandprovidesacommonsetofvalues thatserveasthefoundationofthecompanysresponsibilitiestoitscustomersemployeescommunitiesandshareholders thecompanybelievesthatthesebasicprinciplesandgrowthdriversalongwithitsoverallmissionofimprovingthequality oflifeforpeopleacrosstheglobewillenablejohnsonjohnsontocontinuetobealeaderinthehealthcareindustry results operations analysisofconsolidatedsales inworldwidesalesincreasedtobillioncomparedtoincreasesofinandin thesesaleschangesconsistedofthefollowing salesincreasedecreasedueto volume price currency total insalesofthecompanyshepatitiscproductsolysiosovriadsimeprevirandincivotelaprevirhad apositiveimpactofandthedivestitureoftheorthoclinicaldiagnosticsbusinesshadanegativeimpactofon theworldwideoperationalgrowththeacquisitionofsynthesincnetoftherelateddivestitureincreasedworldwide operationalgrowthbyandinandrespectively salesbyuscompanieswerebillioninbillioninandbillioninthisrepresentsincreases ofininandinsalesbyinternationalcompanieswerebillioninbillion inandbillioninthisrepresentsincreasesofininandin thefiveyearcompoundannualgrowthratesforworldwideusandinternationalsaleswereand respectivelythetenyearcompoundannualgrowthratesforworldwideusandinternationalsaleswereand respectively salesineuropeachievedgrowthofascomparedtotheprioryearincludingoperationalgrowthofpartially offsetbyanegativecurrencyimpactofsalesinthewesternhemisphereexcludingtheusexperiencedadecline ofascomparedtotheprioryearincludingoperationalgrowthofoffsetbyanegativecurrencyimpactof salesintheasiapacificafricaregionachievedgrowthofascomparedtotheprioryearincludingoperational growthofandanegativecurrencyimpactof inthecompanyhadonewholesalerdistributingproductsforallthreesegmentsthatrepresentedapproximately ofthetotalconsolidatedrevenuesinandthecompanydidnothaveacustomerthatrepresented ormoreoftotalconsolidatedrevenues ushealthcarereform undertheprovisionsofthepatientprotectionandaffordablecareactandthehealthcareandeducationreconciliation actofbeginninginthecompanybeganpayingataxdeductibleexcisetaximposedonthesaleof certainmedicaldevicesthefullyearimpactoftheexcisetaxwasapproximatelymillioninandmillionin onjulytheinternalrevenueserviceissuedfinalregulationsforthebrandedprescriptiondrugfeeanannual nontaxdeductiblefeeimposedonentitiesengagedinthebusinessofmanufacturingorimportingbrandedprescription drugscoveredentitiesenactedbysectionofthepatientprotectionandaffordablecareactthefinalregulations acceleratedtheexpenserecognitioncriteriaforthefeeobligationbyoneyearfromtheyearinwhichthefeeispaidtothe yearinwhichthesalesusedtocalculatethefeeoccurthischangeimpactedcoveredentitiesandresultedintheneedfor allentitiestorecordanadditionalexpenseinforthefeethatwouldhaveotherwisebeenexpensedwhenpaidin thecompanyaccruedanadditionalmillioninthefiscalthirdquarterofduetothischangethefee associatedwiththisacceleratedexpensewillbepaidasscheduledinandthereforehadnocashimpactin johnsonjohnsonannualreport analysis sales business segments consumersegment consumersegmentsalesinwerebillionadecreaseoffromwhichincludedoperational growthoffsetbyanegativecurrencyimpactofusconsumersegmentsaleswerebillionadecreaseof internationalsaleswerebillionadecreaseofwhichincludedoperationalgrowthoffsetbya negativecurrencyimpactof majorconsumerfranchisesales change dollarsinmillions vs vs otc skincare babycare oralcare woundcareother womenshealth totalconsumersales theoverthecounterotcfranchiseachievedsalesofbillionanincreaseoffromstrongussales growthofwasdrivenbyanalgesicsandupperrespiratoryproductsprimarilyduetocontinuedprogressinreturning asupplyofproductstothemarketplace mcneilppcinccontinuestooperateunderaconsentdecreesignedinwiththeusfoodanddrug administrationfdawhichgovernscertainmcneilconsumerhealthcaremanufacturingoperationstheconsent decreetheconsentdecreerequiresmcneilppctoremediatethefacilitiesitoperatesinlancasterpennsylvaniafort washingtonpennsylvaniaandlaspiedraspuertoricothefortwashingtonfacilitywasvoluntarilyshutdownin aprilhowevermanyproductspreviouslymadeinfortwashingtonhavebeentransferredtoothermanufacturing sitesandsuccessfullyreintroducedtothemarketthelancasterandlaspiedrasfacilitiescontinuetomanufactureand distributedrugswiththirdpartyoversightthirdpartyoversightwillceaseoncethefdahasdeterminedthatthefacilities appeartobeincompliancewithapplicablelawinfebruarythethirdpartyoverseersubmittedwrittencertification tothefdaforallthreemanufacturingsitesthetimelineforcompletionofanyfdainspectioniswithinthefdas discretion theskincarefranchiseachievedsalesofbillionanincreaseofascomparedtotheprioryearprimarilydueto strongresultsfromtheaveenoneutrogenaanddabaoproductlinesthebabycarefranchisesaleswere billioninadecreaseoffromsalesgrowthinlatinamericaandasiapacificwasoffsetbythe impactofnegativecurrencyinalltheregionsoutsidetheustheoralcarefranchisesaleswerebillionanincrease ofascomparedtotheprioryearthegrowthwasdrivenbyincreasedsalesoflisterineproductsasaresultof newproductlaunchesandsuccessfulmarketingcampaignsthewoundcareotherfranchisesaleswerebillionin adecreaseoffromprimarilyduetolowersalesofnutritionalsoutsidetheusthewomenshealth franchisesaleswerebillionadecreaseofprimarilyduetothedivestitureofwomenssanitaryprotection productsintheuscanadaandcaribbeanwhichwascompletedinthefiscalfourthquarterof consumersegmentsalesinwerebillionanincreaseoffromwhichincludedoperational growthandanegativecurrencyimpactofusconsumersegmentsaleswerebillionanincreaseof internationalsaleswerebillionanincreaseofwhichincludedoperationalgrowthandanegative currencyimpactof johnsonjohnsonannualreportpharmaceutical segment thepharmaceuticalsegmentachievedsalesofbillioninrepresentinganincreaseofovertheprior yearwithstrongoperationalgrowthofandanegativecurrencyimpactofussaleswerebillionan increaseofinternationalsaleswerebillionanincreaseofwhichincludedoperationalgrowth andanegativecurrencyimpactofinpharmaceuticalsegmentsalesincludedapositiveadjustmentto previousestimatesformanagedmedicaidrebatesthisnegativelyimpactedpharmaceuticaloperationalsales growthbyascomparedtotheprioryearinsalesofthecompanyshepatitiscproducts olysiosovriadsimeprevirandincivotelaprevirhadapositiveimpactofontheoperationalgrowthof thepharmaceuticalsegment majorpharmaceutical therapeuticareasales change dollarsinmillions vs vs totalimmunology remicade simponisimponiaria stelara otherimmunology totalinfectiousdiseases edurant incivo olysiosovriad prezista otherinfectiousdiseases totalneuroscience concertamethylphenidate invega invegasustennaxeplion risperdalconsta otherneuroscience totaloncology velcade zytiga otheroncology totalother procriteprex xarelto totalpharmaceuticalsales prioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation percentagegreaterthan immunologyproductsachievedsalesofbillioninrepresentinganincreaseofascomparedtotheprior yeartheincreasedsalesofstelaraustekinumabandsimponisimponiariagolimumabwereprimarilydue tomarketgrowthandmarketsharegainsremicadeinfliximabgrowthwasprimarilyduetomarketgrowth thepatentsforremicadeincertaincountriesineuropegermanyspainunitedkingdomswedenaustriabelgium switzerlanddenmarkfrancegreeceitalyluxembourgandthenetherlandsexpireinfebruarylossofexclusivity willlikelyresultinareductioninsalesasbiosimilarversionsareintroducedtothemarketseenotetothe consolidatedfinancialstatementsforlegalmattersregardingtheremicadepatents johnsonjohnsonannualreport infectiousdiseaseproductsachievedsalesofbillioninrepresentinganincreaseofascomparedtothe prioryearmajorcontributorstothegrowthwerethelaunchofolysiosovriadsimeprevirprezista darunavirduetomarketgrowthandsalesofedurantrilpivirinethiswaspartiallyoffsetbylowersalesof incivotelaprevirduetocompetitivepressuresandlowersalesofvaccineproductstheapprovalofcompetitive productstoolysiosovriadsimeprevirhadanegativeimpactinthefourthquarterofandisexpectedto continuetohaveasignificantnegativeimpactonfuturesalesofolysiosovriadsimeprevir neuroscienceproductssaleswerebillionadeclineofascomparedtotheprioryearstrongsalesof invegasustennaxeplionpaliperidonepalmitateandinvegapaliperidonepalmitatewerepartiallyoffset bylowersalesofrisperdalconstaadditionallyadeclineinsalesofconcertamethylphenidateand topamaxtopiramatewereduetocontinuedgenericcompetition oncologyproductsachievedsalesofbillioninrepresentinganincreaseofascomparedtotheprior yearmajorcontributorstothegrowthwerestrongsalesofzytigaabirateroneacetateaswellastherecentlaunchof imbruvicaibrutinibsalesgrowthofvelcadebortezomibwasmorethanoffsetbynegativecurrency otherpharmaceuticalsaleswerebillionanincreaseofascomparedtotheprioryearstrongsalesof xareltorivaroxabanandinvokanainvokametcanagliflozinwerepartiallyoffsetbylowersalesof aciphexparietrabeprazolesodiumandprocriteprexepoetinalfa duringthecompanyreceivedseveralregulatoryapprovalsincludingtheusfoodanddrugadministrationfda grantedapprovalofimbruvicaibrutinibcapsuleswhichisbeingjointlydevelopedandcommercializedby pharmacyclicsincforthetreatmentofpatientswithchroniclymphocyticleukemiacllwhohavereceivedatleastone priortherapytheeuropeancommissionecgrantedconditionalapprovalforsirturobedaquilineintheeuropean unionforuseaspartofanappropriatecombinationregimenforpulmonarymultidrugresistanttuberculosisinadult patientsthefdaandtheecgrantedapprovalofsylvantsiltuximabforthetreatmentofpatientswithmulticentric castlemansdiseasewhoarehumanimmunodeficiencyvirusnegativeandhumanherpesvirusnegativetheecgranted approvalforvokanametcanagliflozinmetforminhclafixeddosetherapycombiningcanagliflozinandimmediate releasemetforminhydrochlorideinasingletabletforthetreatmentofadultswithtypediabetesolysiosimeprevir forthetreatmentofadultpatientswithgenotypeorchronichepatitiscandforinvegapaliperidoneertoextend itsadultindicationofschizophreniatoincludeadolescentsagedyearsandolderthefdagrantedapprovalforathird indicationforimbruvicaibrutinibforthetreatmentofpatientswithcllwhohavethegeneticmutationpdeletion delpandalsograntedimbruvicaibrutinibfullapprovalforthetreatmentofpatientswithcllwhohavereceived atleastonepriortherapyfdagrantedapprovalforinvokametcanagliflozinmetforminhclforthetreatmentof adultswithtypediabetestheecapprovedimbruvicaibrutinibforthetreatmentofadultpatientswithrelapsedor refractorymantlecelllymphomaandadultpatientswithchroniclymphocyticleukemiawhohavereceivedatleastoneprior therapyorinfirstlineinthepresenceofpdeletionortpmutationinpatientsunsuitableforchemoimmunotherapy theecalsoapprovedrezolstadarunavircobicistatincombinationwithotherantiretroviralmedicinalproductsfor thetreatmentofhumanimmunodeficiencyvirusinfectioninadultsagedyearsorolder thecompanysubmittedseveralnewdrugapplicationsndastothefdaincludinganndaseekingapprovalfora oncedailyfixeddoseantiretroviralcombinationtabletcontainingdarunaviraproteaseinhibitordevelopedbyjanssen rdirelandandmarketedasprezistaintheuswithcobicistataninvestigationalpharmacokineticenhanceror boostingagentdevelopedbygileadsciencesincforuseincombinationwithotherhumanimmunodeficiencyvirus medicinesanndaforthreemonthatypicalantipsychoticpaliperidonepalmitateasatreatmentforschizophreniain adultsandanndaforyondelistrabectedinforthetreatmentofpatientswithadvancedsofttissuesarcoma includingliposarcomaandleiomyosarcomasubtypeswhohavereceivedpriorchemotherapyincludingananthracycline inadditionasupplementalnewdrugapplicationsndawasapprovedbythefdaforolysioincombinationwiththe nucleotideanalognsbpolymeraseinhibitorsofosbuvirdevelopedbygileadsciencesincforthetreatmentofchronic hepatitiscadditionalsndaswerealsosubmittedtothefdaforolysioforthetreatmentofadultpatientsin genotypechronichepatitiscandpatientscoinfectedwithhivoncemonthlyatypicallongactingantipsychotic invegasustennapaliperidonepalmitatewasapprovedtotreatschizoaffectivedisorderaseithermonotherapyor adjunctivetherapyandatypeiivariationapplicationwassubmittedtotheeuropeanmedicinesagencyemaforan additionalindicationofimbruvicaibrutinibforthetreatmentofpatientswithwaldenstrmsmacroglobulinemiaa raretypeofbcelllymphoma amarketingauthorizationapplicationwassubmittedtotheeuropeanmedicinesagencytoexpandthelabelfor velcadebortezomibtoincludeitsuseincombinationwithrituximabcyclophosphamidedoxorubicinandprednisone forthetreatmentofadultpatientswithpreviouslyuntreatedmantlecelllymphoma johnsonjohnsonannualreportpharmaceuticalsegmentsalesinwerebillionrepresentinganincreaseofovertheprioryearwith strongoperationalgrowthofandanegativecurrencyimpactofussaleswerebillionanincreaseof internationalsaleswerebillionanincreaseofwhichincludedoperationalgrowthanda negativecurrencyimpactofthepharmaceuticalsegmentoperationalgrowthwasimpactedbyindueto apositiveadjustmenttopreviousestimatesformanagedmedicaidrebates medicaldevicessegment themedicaldevicessegmentsalesinwerebillionadecreaseoffromwhichincludedan operationaldeclineofandanegativecurrencyimpactofussaleswerebillionadecreaseofas comparedtotheprioryearinternationalsaleswerebillionadeclineofascomparedtotheprioryearwith operationalgrowthofoffsetbyanegativecurrencyimpactofinthedivestitureoftheorthoclinical diagnosticsbusinesshadanegativeimpactofontheoperationalgrowthofthemedicaldevicessegment majormedicaldevicesfranchisesales change dollarsinmillions vs vs orthopaedics surgicalcare specialtysurgeryother visioncare cardiovascularcare diabetescare diagnostics totalmedicaldevicessales previouslyreferredtoasmedicaldevicesanddiagnosticsprioryearamountshavebeenreclassifiedtoconformtocurrentyear presentationinfectionpreventionisincludedinspecialtysurgeryother theorthopaedicsfranchiseachievedsalesofbillioninaincreaseovertheprioryeargrowthwas primarilydrivenbysalesoftraumasportsmedicinekneeandhipproductsgrowthwasnegativelyimpactedbycontinued pricingpressures thesurgicalcarefranchisesaleswerebillioninadecreaseoffromtheprioryearuspricingpressure lowersalesofwomenshealthandurologyproductsduetothecompanysdecisiontoexitfromcertainwomenshealth productsandtheimpactfromnegativecurrencywerepartiallyoffsetbyworldwidesalesgrowthofsuturesandthe successoftheechelonflexpoweredendopathstapleroutsidetheus thespecialtysurgeryotherfranchisesaleswerebillioninaincreaseovertheprioryearcontributors tothegrowthwerestrongsalesfrombiosurgicalproductssalesofenergyproductsoutsidetheusandmentorproducts duetonewproductlaunchesandmarketgrowth thevisioncarefranchisesaleswerebillioninadecreaseoffromtheprioryearthedeclinewas primarilyduetoincreasedcompetitionandpricingpressuresintheusandtheasiapacificregionpartiallyoffsetby salesgrowthineurope thecardiovascularcarefranchiseachievedsalesofbillionaincreaseovertheprioryeartheincreasedsales weredrivenbystronggrowthofbiosensewebsterproductsinallregions thediabetescarefranchisesaleswerebillionadecreaseofversustheprioryearintheuslowerprices werepartiallyoffsetbyvolumegrowth thediagnosticsfranchisesaleswerebillionadeclineofversustheprioryearthedeclinewasduetothe divestitureoftheorthoclinicaldiagnosticsbusinessthediagnosticsfranchisetothecarlylegrouponjune medicaldevicessegmentsalesinwerebillionrepresentinganincreaseofovertheprioryearwith operationalgrowthofandanegativecurrencyimpactofussaleswerebillionanincreaseofas comparedtotheprioryearinternationalsaleswerebillionanincreaseofovertheprioryearwithoperational johnsonjohnsonannualreport growthofandanegativecurrencyimpactoftheacquisitionofsynthesincnetoftherelatedtrauma businessdivestitureincreasedbothtotalsalesgrowthandoperationalgrowthforthemedicaldevicessegmentby andinandrespectively analysis consolidated earnings provision taxes income consolidatedearningsbeforeprovisionfortaxesonincomeincreasedtobillioninascomparedto billioninanincreaseofearningsbeforeprovisionfortaxesonincomewerefavorableduetostrongsales volumegrowthparticularlysalesofolysiosovriadsimeprevirpositivemixfromhighersalesofhighermargin productsinthepharmaceuticalbusinessdivestituresoflowermarginbusinessesandcostreductioneffortsacrossmany ofthebusinessesadditionallyincludedhighernetgainsondivestituresofbillionprimarilythedivestitureof theorthoclinicaldiagnosticsbusinesslowerlitigationexpenseofbillionlowerinprocessresearchand developmentcostsofbillionandlowerexpensesofbillionrelatedtothedepuyasrhipprogramas comparedtothefiscalyearthiswaspartiallyoffsetbytheinclusionofanadditionalyearofthebranded prescriptiondrugfeeofbillionandbillionofhighersynthesintegrationtransactioncostsinthefiscal yearincludedanetgainofbilliononequityinvestmenttransactionsprimarilythesaleofelanamerican depositaryshares consolidatedearningsbeforeprovisionfortaxesonincomeincreasedbybilliontobillioninas comparedtobillioninanincreaseofearningsbeforeprovisionfortaxesonincomewerefavorable duetoincreasedgrossprofitofbillionresultingfromhighersalesofhighermarginproductsandcostcontainment initiativesandabillionnetgainonequityinvestmenttransactionsprimarilyfromthesaleofelanamericandepositary sharesthiswaspartiallyoffsetbyhigherlitigationexpensesofbillionandhigherexpensesofbillionrelatedto thedepuyasrhipprogramascomparedtothefiscalyearincludedbillionofhigherwritedownsof intangibleassetsandinprocessresearchanddevelopmentandhighercostsofbillionrelatedtothesynthes acquisitionpartiallyoffsetbyhighergainsofbillionrelatedtodivestitures asapercenttosalesconsolidatedearningsbeforeprovisionfortaxesonincomeinwasversusin costofproductssoldandsellingmarketingandadministrativeexpensescostofproductssoldandselling marketingandadministrativeexpensesasapercenttosaleswereasfollows ofsales costofproductssold percentpointdecreaseincreaseovertheprioryear sellingmarketingandadministrativeexpenses percentpointdecreaseincreaseovertheprioryear incostofproductssoldasapercenttosalesdecreasedcomparedtotheprioryearthiswasprimarilytheresultof positivemixfromhighersalesofhighermarginproductsinthepharmaceuticalbusinessdivestituresoflowermargin businessesandcostimprovementsacrossmanyofthebusinessesthiswaspartiallyoffsetbypricingandtheimpactof negativetransactionalcurrencyinadditionincludedaninventorystepupchargeofbillionrelatedtothe synthesacquisitionintangibleassetamortizationexpenseincludedincostofproductssoldforbothandwas billiontherewasadecreaseinthepercenttosalesofsellingmarketingandadministrativeexpensesin comparedtotheprioryearprimarilyduetoleveragedcostsresultingfromgrowthinthepharmaceuticalbusiness particularlysalesofolysiosovriadsimeprevirandcostcontainmentinitiativesacrossmanyofthebusinesses thiswaspartiallyoffsetbytheinclusionofanadditionalyearofthebrandedprescriptiondrugfeeofmillioninthe fiscalthirdquarterof incostofproductssoldasapercenttosalesdecreasedcomparedtotheprioryearthiswasprimarilytheresultof positivemixresultingfromhighersalesofhighermarginproductslowercostsassociatedwithstrongvolumegrowthinthe pharmaceuticalbusinessandcostreductioneffortsacrossmanyofthebusinessesthedecreasewaspartiallyoffsetby incrementalintangibleassetamortizationexpenseprimarilyrelatedtosynthesthemedicaldeviceexcisetaxand increasedamortizationexpenseasaresultoftheroyaltybuyoutagreementwithvertexforincivointangibleasset amortizationexpenseforandwasbillionandbillionrespectivelyadditionallyincluded johnsonjohnsonannualreportbillionhigheramortizationoftheinventorystepupchargerelatedtothesynthesincacquisitiontherewasadecreasein thepercenttosalesofsellingmarketingandadministrativeexpensesincomparedtotheprioryearprimarilydueto costcontainmentinitiativesacrossmanyofthebusinesses researchanddevelopmentexpenseresearchanddevelopmentexpensebysegmentofbusinesswasasfollows dollarsinmillions amount ofsales amount ofsales amount ofsales consumer pharmaceutical medicaldevices totalresearchanddevelopmentexpense percentincreasedecreaseovertheprior year asapercenttosegmentsales researchanddevelopmentactivitiesrepresentasignificantpartofthecompanysbusinesstheseexpendituresrelateto theprocessesofdiscoveringtestinganddevelopingnewproductsimprovingexistingproductsaswellasensuring productefficacyandregulatorycompliancepriortolaunchthecompanyremainscommittedtoinvestinginresearchand developmentwiththeaimofdeliveringhighqualityandinnovativeproductsinworldwidecostsofresearchand developmentactivitiesincreasedbycomparedtothereductionasapercenttosaleswasprimarilydueto strongsalesgrowthinthepharmaceuticalbusinessresearchspendinginthepharmaceuticalsegmentincreasedin absolutedollarstobillionascomparedtobillionprimarilyduetohigherlevelsofspendingtoadvancethe companyspharmaceuticalpipelineinworldwidecostsofresearchanddevelopmentactivitiesincreasedby comparedtotheincreaseinthepharmaceuticalsegmentwasprimarilyduetohigherlevelsofspendingtoadvance thecompanyspharmaceuticalpipeline inprocessresearchanddevelopmentiprdinthecompanyrecordedchargesofbillionforthe impairmentofvariousiprdprojectsrelatedtorespivertcrucellmentorandsynthesforthedelayordiscontinuationof certaindevelopmentprojectsinthecompanyrecordedchargesofbillionprimarilyfortheimpairmentof variousiprdprojectsrelatedtocrucellcorimmunandacclarentforthedelayordiscontinuationofcertaindevelopment projectsinthecompanyrecordedchargesofbillionwhichincludedbillionfortheimpairmentofthe iprdrelatedtothediscontinuationofthephaseiiiclinicaldevelopmentofbapineuzumabivandthepartialimpairmentof theiprdrelatedtothecrucellvaccinebusinessintheamountofbillionofthebillionimpairmentofthe iprdrelatedtothediscontinuationofthephaseiiiclinicaldevelopmentofbapineuzumabivbillionisattributableto noncontrollinginterestthechargesrelatetodevelopmentprojectswhichhavebeendiscontinuedordelayed otherincomeexpensenetotherincomeexpensenetincludesroyaltyincomegainsandlossesrelatedtothe saleandwritedownofcertaininvestmentsinequitysecuritiesheldbyjohnsonjohnsondevelopmentcorporation gainsorlossesondivestiturescurrencygainsandlossesandlitigationaccrualsandsettlementsthechangeinother incomeexpensenetforthefiscalyearwasafavorablechangeofbillionascomparedtotheprioryearthe fiscalyearincludedhighernetgainsondivestituresofbillionprimarilythedivestitureoftheorthoclinical diagnosticsbusinesslowerlitigationexpenseofbillionandlowercostsofbillionrelatedtothedepuyasr hipprogramascomparedtothiswaspartiallyoffsetbyhighersynthesintegrationtransactioncostsofbillion andhigherintangibleassetwritedownsofbillionprimarilyrelatedtoincivotelaprevirinadditionallythe fiscalyearincludedahighernetgainofbillionascomparedtoonequityinvestmenttransactions primarilythesaleofelanamericandepositaryshares thechangeinotherincomeexpensenetforthefiscalyearwasanunfavorablechangeofbillionas comparedtotheprioryearthefiscalyearincludedanetgainofbilliononequityinvestmenttransactions primarilythesaleofelanamericandepositarysharesoffsetbyhigherlitigationexpensesofbillionhigherexpenses ofbillionrelatedtothedepuyasrhipprogramandhighercurrencylossesofbillionthefiscalyear includedhigherwritedownsofintangibleassetsofbillionprimarilyrelatedtothecrucellvaccinebusinessand highercostsofbillionrelatedtothesynthesacquisitionadditionallyincludedhighergainsofbillion relatedtodivestitures interestincomeexpenseinterestincomeinwascomparabletotheprioryearahigherbalanceincashcash equivalentsandmarketablesecuritieswasoffsetbylowerinterestratescashcashequivalentsandmarketablesecurities johnsonjohnsonannualreport totaledbillionattheendofandaveragedbillionascomparedtothebillionaveragecash balanceintheincreaseintheyearendcashbalancewasprimarilyduetocashgeneratedfromoperatingactivities interestexpenseinincreasedbymillionascomparedtoduetoahigheraveragedebtbalancethe averagedebtbalancewasbillioninversusbillioninthetotaldebtbalanceattheendof wasbillionascomparedtobillionattheendofthehigherdebtbalanceofapproximatelybillion wasduetoincreasedborrowingsinnovemberthecompanyincreasedborrowingscapitalizingonfavorableterms inthecapitalmarketstheproceedsoftheborrowingswillbeusedforgeneralcorporatepurposes interestincomeinincreasedbymillionascomparedtotheprioryearcashcashequivalentsandmarketable securitiestotaledbillionattheendofandaveragedbillionascomparedtothebillionaverage cashbalanceintheincreaseintheyearendcashbalancewasduetocashgeneratedfromoperatingactivities interestexpenseindecreasedbymillionascomparedtoduetoaloweraveragedebtbalancethe averagedebtbalancewasbillioninversusbillioninthetotaldebtbalanceattheendof wasbillionascomparedtobillionattheendofthehigherdebtbalanceofapproximatelybillion wasduetoincreasedborrowingsindecemberthecompanyincreasedborrowingscapitalizingonfavorableterms inthecapitalmarketstheproceedsoftheborrowingswereusedforgeneralcorporatepurposes segmentpretaxprofit pretaxprofitsbysegmentofbusinesswereasfollows percentof segmentsales dollarsinmillions consumer pharmaceutical medicaldevices total lessexpensesnotallocatedtosegments earningsbeforeprovisionfortaxesonincome seenotetotheconsolidatedfinancialstatementsformoredetails amountsnotallocatedtosegmentsincludeinterestincomeexpensenoncontrollinginterestsandgeneralcorporateincome expense consumersegmentinconsumersegmentpretaxprofitasapercenttosaleswasflattotheprioryear inconsumersegmentpretaxprofitasapercenttosaleswasversusinthefavorablepretax profitinversuswasprimarilyduetoagainofmilliononthesaleofintangibleandotherassetsaswellas costcontainmentinitiativesincludedinwereintangibleassetwritedownsofbillioninadditionincluded highergainsondivestituresofbillion pharmaceuticalsegmentinpharmaceuticalsegmentpretaxprofitasapercenttosaleswasversus inthefavorablepretaxprofitwasattributabletostrongsalesvolumegrowthparticularlysalesofolysio sovriadsimeprevirpositivesalesmixofhighermarginproductsandcostcontainmentinitiativesrealizedinselling marketingandadministrativeexpensesthiswaspartiallyoffsetbybillionforanadditionalyearofthebranded prescriptiondrugfeeandabillionintangibleassetwritedownrelatedtoincivotelapreviradditionally includedanetgainofbilliononequityinvestmenttransactionsprimarilythesaleofelanamericandepositary sharesandapositiveadjustmentofbilliontopreviousestimatesformanagedmedicaidrebatespartiallyoffsetby higherwritedownsofbillionfortheimpairmentofiprdascomparedtoinpharmaceuticalsegment pretaxprofitasapercenttosaleswasversusinthefavorablepretaxprofitwasattributableto positivesalesmixofhighermarginproductslowercostsassociatedwithstrongvolumegrowthanetgainofbillion onequityinvestmenttransactionsprimarilythesaleofelanamericandepositarysharesapositiveadjustmentof billiontopreviousestimatesformanagedmedicaidrebatesandcostcontainmentinitiativesthiswaspartiallyoffsetby increasedamortizationexpenseasaresultoftheroyaltybuyoutagreementwithvertexforincivoadditionally includedhighernetlitigationexpenseofbillionandhigherwritedownsofintangibleassetsandinprocessresearch anddevelopmentofbillionthiswaspartiallyoffsetbyhighergainsondivestituresofbillion johnsonjohnsonannualreportmedicaldevicessegmentinmedicaldevicessegmentpretaxprofitasapercenttosaleswasversus inthefavorablepretaxprofitwasattributabletothenetgainofbilliononthedivestitureofthe orthoclinicaldiagnosticsbusinessinandlowerlitigationexpenseofbillionascomparedtoin medicaldevicessegmentpretaxprofitasapercenttosaleswasversusinthemedicaldevices segmentpretaxprofitwasunfavorablyimpactedbyhighercostsofbillionforlitigationexpenseandbillion relatedtothedepuyasrhipprogramaswellasthemedicaldeviceexcisetaxascomparedtoinaddition includedhighergainsofbillionondivestiturespartiallyoffsetbyhigherwritedownsofintangibleassetsand inprocessresearchanddevelopmentofbillionandhighercostsofbillionrelatedtothesynthesacquisition provisionfortaxesonincometheworldwideeffectiveincometaxratewasininand intheincreaseintheeffectivetaxrateascomparedtowasattributabletothefollowingthe divestitureoftheorthoclinicaldiagnosticsbusinessatanapproximateeffectivetaxratelitigationaccrualsatlow taxratesthemixofearningsintohighertaxjurisdictionsprimarilytheustheaccrualofanadditionalyearofthebranded prescriptiondrugfeewhichisnottaxdeductibleandadditionalustaxexpenserelatedtoaplannedincreasein dividendsfromcurrentyearforeignearningsascomparedtotheprioryeartheseincreasestotheeffectivetaxrate werepartiallyoffsetbyataxbenefitofbillionassociatedwiththeconormedsystemsdivestiture theeffectivetaxratewasreducedbyataxbenefitassociatedwiththewriteoffofassetsfortaxpurposes associatedwithsciosincandtheinclusionofboththeandbenefitfromtheresearchanddevelopmenttax creditandthecontrolledforeigncorporationlookthroughprovisionsbecausethoseprovisionswereenactedintolawin januaryandwereretroactivetojanuary theeffectivetaxratewasalsoreducedasthecompanyadjusteditsunrecognizedtaxbenefitsasaresultofithe federalappealscourtsdecisioninomjpharmaceuticalsincslitigationregardingcreditsunderformersectionof theinternalrevenuecodeseenotetotheconsolidatedfinancialstatementsforadditionalinformationandiia settlementofsubstantiallyallissuesrelatedtothecompanysusinternalrevenueserviceauditoftaxyears noncontrollinginterestinachargeofbillionwasrecordedfortheimpairmentoftheiprdrelatedtothe discontinuationofthephaseiiiclinicaldevelopmentofbapineuzumabivofthebillionimpairmentbillionwas attributabletononcontrollinginterest liquidity capital resources liquiditycashflows cashandcashequivalentswerebillionattheendofascomparedwithbillionattheendofthe primarysourcesandusesofcashthatcontributedtothebilliondecreaseversustheprioryearwereapproximately billionofcashgeneratedfromoperatingactivitiesoffsetbybillionnetcashusedbyinvestingactivitiesand billionnetcashusedbyfinancingactivitiesseenotetotheconsolidatedfinancialstatementsforadditional detailsoncashinadditionthecompanyhadbillioninmarketablesecuritiesattheendofandbillionat theendof cashflowfromoperationsofbillionwastheresultofbillionofnetearningsandbillionofnoncash chargesandotheradjustmentsfordepreciationandamortizationstockbasedcompensationassetwritedowns venezuelaadjustmentsandbillionrelatedtodeferredtaxesaccountspayableandaccruedliabilitiesandcurrentand noncurrentassetscashflowfromoperationswasreducedbybillionrelatedtocurrentandnoncurrentliabilities inventoriesaccountsreceivableandnetgainsonsaleofassetsbusinesses investingactivitiesuseofbillionwasprimarilyfornetpurchasesofinvestmentsinmarketablesecuritiesof billionadditionstopropertyplantandequipmentofbillionacquisitionsnetofcashacquiredofbillionand otherprimarilyintangiblesofbillionpartiallyoffsetbybillionofproceedsfromthedisposalofassets businesses financingactivitiesuseofbillionwasprimarilyfordividendstoshareholdersofbillionandbillionforthe repurchaseofcommonstockfinancingactivitiesalsoincludedasourceofbillionfromnetproceedsofshortand longtermdebtandbillionofnetproceedsfromstockoptionsexercisedandassociatedtaxbenefits onjulythecompanyannouncedthatitsboardofdirectorsapprovedasharerepurchaseprogramauthorizing thecompanytopurchaseuptobillionofthecompanyssharesofcommonstockasofdecember johnsonjohnsonannualreport billionhasbeenrepurchasedundertheprogramsharerepurchaseswilltakeplaceontheopenmarketfromtimetotime basedonmarketconditionstherepurchaseprogramhasnotimelimitandmaybesuspendedforperiodsordiscontinued atanytimeanysharesacquiredwillbeavailableforgeneralcorporatepurposesthecompanyintendstofinancethe sharerepurchaseprogramthroughavailablecash inthecompanycontinuedtohaveaccesstoliquiditythroughthecommercialpapermarketforadditionaldetails onborrowingsseenotetotheconsolidatedfinancialstatements thecompanyanticipatesthatoperatingcashflowsexistingcreditfacilitiesandaccesstothecommercialpapermarkets willprovidesufficientresourcestofundoperatingneedsin concentrationofcreditrisk globalconcentrationofcreditriskwithrespecttotradeaccountsreceivablescontinuestobelimitedduetothelarge numberofcustomersgloballyandadherencetointernalcreditpoliciesandcreditlimitseconomicchallengesinitaly spaingreeceandportugalthesoutherneuropeanregionhaveimpactedcertainpaymentpatternswhichhave historicallybeenlongerthanthoseexperiencedintheusandotherinternationalmarketsthetotalnettradeaccounts receivablebalanceinthesoutherneuropeanregionwasapproximatelybillionasofdecemberand billionasofdecemberapproximatelybillionasofdecemberandapproximatelybillionasof decemberofthesoutherneuropeanregionnettradeaccountsreceivablebalancerelatedtothecompanys consumervisioncareanddiabetescarebusinessesaswellascertainpharmaceuticalandmedicaldevicescustomers whichareinlinewithhistoricalcollectionpatterns theremainingbalanceofnettradeaccountsreceivableinthesoutherneuropeanregionhasbeennegativelyimpacted bythetimingofpaymentsfromcertaingovernmentownedorsupportedhealthcarecustomersaswellascertain distributorsofthepharmaceuticalandmedicaldeviceslocalaffiliatesthetotalnettradeaccountsreceivablebalancefor thesecustomerswereapproximatelybillionatdecemberandbillionatdecemberthe companycontinuestoreceivepaymentsfromthesecustomersandinsomecaseslatepaymentpremiumsforcustomers wherepaymentisexpectedoverperiodsoftimelongerthanoneyearrevenueandtradereceivableshavebeen discountedovertheestimatedperiodoftimeforcollectionallowancesfordoubtfulaccountshavebeenincreasedfor thesecustomersbuthavebeenimmaterialtodatethecompanywillcontinuetoworkcloselywiththesecustomerson paymentplansmonitortheeconomicsituationandtakeappropriateactionsasnecessary financingandmarketrisk thecompanyusesfinancialinstrumentstomanagetheimpactofforeignexchangeratechangesoncashflows accordinglythecompanyentersintoforwardforeignexchangecontractstoprotectthevalueofcertainforeigncurrency assetsandliabilitiesandtohedgefutureforeigncurrencytransactionsprimarilyrelatedtoproductcostsgainsorlosses onthesecontractsareoffsetbythegainsorlossesontheunderlyingtransactionsaappreciationoftheusdollar fromthedecembermarketrateswouldincreasetheunrealizedvalueofthecompanysforwardcontractsby millionconverselyadepreciationoftheusdollarfromthedecembermarketrateswoulddecrease theunrealizedvalueofthecompanysforwardcontractsbymillionineitherscenariothegainorlossontheforward contractwouldbeoffsetbythegainorlossontheunderlyingtransactionandthereforewouldhavenoimpactonfuture anticipatedearningsandcashflows thecompanyhedgestheexposuretofluctuationsincurrencyexchangeratesandtheeffectoncertainassetsand liabilitiesinforeigncurrencybyenteringintocurrencyswapcontractsachangeinthespreadbetweenusand foreigninterestratesonthecompanysinterestratesensitivefinancialinstrumentswouldeitherincreaseordecreasethe unrealizedvalueofthecompanysswapcontractsbyapproximatelymillionineitherscenarioatmaturitythegainor lossontheswapcontractwouldbeoffsetbythegainorlossontheunderlyingtransactionandthereforewouldhaveno impactonfutureanticipatedcashflows thecompanydoesnotenterintofinancialinstrumentsfortradingorspeculativepurposesfurtherthecompanyhasa policyofonlyenteringintocontractswithpartiesthathaveatleastanaorequivalentcreditratingthecounterparties tothesecontractsaremajorfinancialinstitutionsandthereisnosignificantconcentrationofexposurewithanyone counterpartymanagementbelievestheriskoflossisremote thecompanyhasaccesstosubstantialsourcesoffundsatnumerousbanksworldwideinseptemberthe companysecuredanewdaycreditfacilitytotalcreditavailabletothecompanyapproximatesbillionwhich expiresonseptemberinterestchargedonborrowingsunderthecreditlineagreementisbasedoneitherbids providedbybankstheprimerateorlondoninterbankofferedratesliborplusapplicablemarginscommitmentfees undertheagreementarenotmaterial johnsonjohnsonannualreporttotalborrowingsattheendofandwerebillionandbillionrespectivelytheincreasein borrowingsbetweenandwasaresultoffinancingforgeneralcorporatepurposesinnetcashcash andcurrentmarketablesecuritiesnetofdebtwasbillioncomparedtonetcashofbillionintotaldebt representedoftotalcapitalshareholdersequityandtotaldebtinandoftotalcapitalin shareholdersequitypershareattheendofwascomparedtoatyearendadecreaseof asummaryofborrowingscanbefoundinnotetotheconsolidatedfinancialstatements contractualobligationsandcommitments thecompanyscontractualobligationsareprimarilyforleasesdebtandunfundedretirementplanstherearenoother significantobligationstosatisfytheseobligationsthecompanywillusecashfromoperationsthefollowingtable summarizesthecompanyscontractualobligationsandtheiraggregatematuritiesasofdecemberseenotes andtotheconsolidatedfinancialstatementsforfurtherdetails longterm intereston unfunded debt debt retirement operating dollarsinmillions obligations obligations plans leases total total fortaxmattersseenotetotheconsolidatedfinancialstatements dividends thecompanyincreaseditsdividendinforthendconsecutiveyearcashdividendspaidwerepersharein comparedwithdividendsofpershareinandpershareinthedividendsweredistributed asfollows firstquarter secondquarter thirdquarter fourthquarter total onjanuarytheboardofdirectorsdeclaredaregularquarterlycashdividendofpersharepayableon marchtoshareholdersofrecordasoffebruarythecompanyexpectstocontinuethepracticeof payingregularcashdividends information criticalaccountingpoliciesandestimates managementsdiscussionandanalysisofresultsofoperationsandfinancialconditionarebasedonthecompanys consolidatedfinancialstatementsthathavebeenpreparedinaccordancewithaccountingprinciplesgenerallyacceptedin theusgaapthepreparationofthesefinancialstatementsrequiresthatmanagementmakeestimatesand johnsonjohnsonannualreport assumptionsthataffecttheamountsreportedforrevenuesexpensesassetsliabilitiesandotherrelateddisclosures actualresultsmayormaynotdifferfromtheseestimatesthecompanybelievesthattheunderstandingofcertainkey accountingpoliciesandestimatesareessentialinachievingmoreinsightintothecompanysoperatingresultsand financialconditionthesekeyaccountingpoliciesincluderevenuerecognitionincometaxeslegalandselfinsurance contingenciesvaluationoflonglivedassetsassumptionsusedtodeterminetheamountsrecordedforpensionsandother employeebenefitplansandaccountingforstockbasedawards revenuerecognitionthecompanyrecognizesrevenuefromproductsaleswhengoodsareshippedordeliveredand titleandriskoflosspasstothecustomerprovisionsforcertainrebatessalesincentivestradepromotionscoupons productreturnsanddiscountstocustomersareaccountedforasreductionsinsalesinthesameperiodtherelatedsales arerecorded productdiscountsgrantedarebasedonthetermsofarrangementswithdirectindirectandothermarketparticipantsas wellasmarketconditionsincludingpriceschargedbycompetitorsrebateswhichincludethemedicaidrebateprovision areestimatedbasedoncontractualtermshistoricalexperiencepatientoutcomestrendanalysisandprojectedmarket conditionsinthevariousmarketsservedthecompanyevaluatesmarketconditionsforproductsorgroupsofproducts primarilythroughtheanalysisofwholesalerandotherthirdpartysellthroughandmarketresearchdataaswellas internallygeneratedinformation salesreturnsareestimatedandrecordedbasedonhistoricalsalesandreturnsinformationproductsthatexhibitunusual salesorreturnpatternsduetodatingcompetitionorothermarketingmattersarespecificallyinvestigatedandanalyzedas partoftheaccountingforsalesreturnaccruals salesreturnsallowancesrepresentareserveforproductsthatmaybereturnedduetoexpirationdestructioninthefield orinspecificareasproductrecallthereturnsreserveisbasedonhistoricalreturntrendsbyproductandbymarketasa percenttogrosssalesinaccordancewiththecompanysaccountingpoliciesthecompanygenerallyissuescreditto customersforreturnedgoodsthecompanyssalesreturnsreservesareaccountedforinaccordancewiththe usgaapguidanceforrevenuerecognitionwhenrightofreturnexistssalesreturnsreservesarerecordedatfullsales valuesalesreturnsintheconsumerandpharmaceuticalsegmentsarealmostexclusivelynotresalablesalesreturnsfor certainfranchisesinthemedicaldevicessegmentaretypicallyresalablebutarenotmaterialthecompanyinfrequently exchangesproductsfrominventoryforreturnedproductsthesalesreturnsreserveforthetotalcompanyhasbeen approximatelyofannualnettradesalesduringthefiscalreportingyearsand promotionalprogramssuchasproductlistingallowancesandcooperativeadvertisingarrangementsarerecordedinthe yearincurredcontinuingpromotionalprogramsincludecouponsandvolumebasedsalesincentiveprogramsthe redemptioncostofconsumercouponsisbasedonhistoricalredemptionexperiencebyproductandvaluevolumebased incentiveprogramsarebasedonestimatedsalesvolumesfortheincentiveperiodandarerecordedasproductsaresold thecompanyalsoearnsservicerevenueforcopromotionofcertainproductsforallyearspresentedservicerevenues werelessthanoftotalrevenuesandareincludedinsalestocustomersthesearrangementsareevaluatedto determinetheappropriateamountstobedeferred inadditionthecompanyentersintocollaborationarrangementsthatcontainmultiplerevenuegeneratingactivities amountsduefromcollaborativepartnersforthesearrangementsarerecognizedaseachactivityisperformedordelivered basedontherelativefairvalueupfrontfeesreceivedaspartofthesearrangementsaredeferredandrecognizedoverthe performanceperiodseenotetotheconsolidatedfinancialstatementsforadditionaldisclosuresoncollaborations reasonablylikelychangestoassumptionsusedtocalculatetheaccrualsforrebatesreturnsandpromotionsarenot anticipatedtohaveamaterialeffectonthefinancialstatementsthecompanycurrentlydisclosestheimpactofchanges toassumptionsinthequarterlyorannualfilinginwhichthereisamaterialfinancialstatementimpact johnsonjohnsonannualreportbelowaretablesthatshowtheprogressionofaccruedrebatesreturnspromotionsreservefordoubtfulaccountsand reserveforcashdiscountsbysegmentofbusinessforthefiscalyearsendeddecemberanddecember consumersegment balanceat balanceat beginningof payments endof dollarsinmillions period accruals credits period accruedrebates accruedreturns accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total accruedrebates accruedreturns accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total includesreserveforcustomerrebatesofmillionatdecemberandmillionatdecemberrecordedasa contraasset pharmaceutical segment balanceat balanceat beginningof payments endof dollarsinmillions period accruals credits period accruedrebates accruedreturns accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total accruedrebates accruedreturns accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total includesreserveforcustomerrebatesofmillionatdecemberandmillionatdecemberrecordedasa contraasset johnsonjohnsonannualreport medicaldevicessegment balanceat balanceat beginningof payments endof dollarsinmillions period accruals credits period accruedrebates accruedreturns accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total accruedrebates accruedreturns accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total includesreserveforcustomerrebatesofmillionatdecemberandmillionatdecemberrecordedasa contraasset incometaxesincometaxesarerecordedbasedonamountsrefundableorpayableforthecurrentyearandincludethe resultsofanydifferencebetweenusgaapaccountingandtaxreportingrecordedasdeferredtaxassetsorliabilities thecompanyestimatesdeferredtaxassetsandliabilitiesbasedonenactedtaxregulationsandratesfuturechangesin taxlawsandratesmayaffectrecordeddeferredtaxassetsandliabilities thecompanyhasunrecognizedtaxbenefitsforuncertaintaxpositionsthecompanyfollowsusgaapwhich prescribesarecognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementof ataxpositiontakenorexpectedtobetakeninataxreturnmanagementbelievesthatchangesintheseestimateswould nothaveamaterialeffectonthecompanysresultsofoperationscashflowsorfinancialposition atdecemberanddecemberthecumulativeamountsofundistributedinternationalearningswere approximatelybillionandbillionrespectivelyatdecemberanddecemberthe companysforeignsubsidiariesheldbalancesofcashandcashequivalentsintheamountsofbillionand billionrespectivelythecompanyhasnotprovideddeferredtaxesontheundistributedearningsfromcertaininternational subsidiarieswheretheearningsareconsideredtobepermanentlyreinvestedthecompanyintendstocontinueto reinvesttheseearningsininternationaloperationsifthecompanydecidedatalaterdatetorepatriatetheseearningsto theusthecompanywouldberequiredtoprovideforthenettaxeffectsontheseamountsthecompanydoesnot determinethedeferredtaxliabilityassociatedwiththeseundistributedearningsassuchdeterminationisnotpractical seenotetotheconsolidatedfinancialstatementsforfurtherinformationregardingincometaxes legalandselfinsurancecontingenciesthecompanyrecordsaccrualsforvariouscontingenciesincludinglegal proceedingsandproductliabilityclaimsastheseariseinthenormalcourseofbusinesstheaccrualsarebasedon managementsjudgmentastotheprobabilityoflossesandwhereapplicableactuariallydeterminedestimatesthe companyhasselfinsurancethroughawhollyownedcaptiveinsurancecompanyinadditiontoaccrualsintheself insuranceprogramclaimsthatexceedtheinsurancecoverageareaccruedwhenlossesareprobableandamountscanbe reasonablyestimatedadditionallythecompanyrecordsinsurancereceivableamountsfromthirdpartyinsurerswhen recoveryisprobableasappropriatereservesagainstthesereceivablesarerecordedforestimatedamountsthatmaynot becollectedfromthirdpartyinsurers thecompanyfollowstheprovisionsofusgaapwhenrecordinglitigationrelatedcontingenciesaliabilityisrecorded whenalossisprobableandcanbereasonablyestimatedthebestestimateofalosswithinarangeisaccruedhowever ifnoestimateintherangeisbetterthananyothertheminimumamountisaccrued johnsonjohnsonannualreportlonglivedandintangibleassetsthecompanyassesseschangesineconomicconditionsandmakesassumptions regardingestimatedfuturecashflowsinevaluatingthevalueofthecompanyspropertyplantandequipmentgoodwill andintangibleassetsastheseassumptionsandestimatesmaychangeovertimeitmayormaynotbenecessaryforthe companytorecordimpairmentcharges employeebenefitplansthecompanysponsorsvariousretirementandpensionplansincludingdefinedbenefit definedcontributionandterminationindemnityplanswhichcovermostemployeesworldwidetheseplansarebasedon assumptionsforthediscountrateexpectedreturnonplanassetsmortalityratesexpectedsalaryincreasesandhealth carecosttrendratesseenotetotheconsolidatedfinancialstatementsforfurtherdetailsontheseratesandthe effectaratechangetothehealthcarecosttrendwouldhaveonthecompanysresultsofoperations stockbasedcompensationthecompanyrecognizescompensationexpenseassociatedwiththeissuanceofequity instrumentstoemployeesfortheirservicesbasedonthetypeofequityinstrumentthefairvalueisestimatedonthedate ofgrantusingeithertheblackscholesoptionvaluationmodeloracombinationofboththeblackscholesoption valuationmodelandmontecarlovaluationmodelandisexpensedinthefinancialstatementsoverthevestingperiodthe inputassumptionsusedindeterminingfairvaluearetheexpectedlifeexpectedvolatilityriskfreerateandthedividend yieldseenotetotheconsolidatedfinancialstatementsforadditionalinformation newaccountingpronouncements refertonotetotheconsolidatedfinancialstatementsforrecentlyadoptedaccountingpronouncementsandrecently issuedaccountingpronouncementsnotyetadoptedasofdecember economicandmarketfactors thecompanyisawarethatitsproductsareusedinanenvironmentwhereformorethanadecadepolicymakers consumersandbusinesseshaveexpressedconcernsabouttherisingcostofhealthcareinresponsetotheseconcerns thecompanyhasalongstandingpolicyofpricingproductsresponsiblyfortheperiodintheunitedstates theweightedaveragecompoundannualgrowthrateofthecompanysnetpriceincreasesforhealthcareproducts prescriptionandoverthecounterdrugshospitalandprofessionalproductswasbelowtheusconsumerpriceindex cpi thecompanyoperatesincertaincountrieswheretheeconomicconditionscontinuetopresentsignificantchallengesthe companycontinuestomonitorthesesituationsandtakeappropriateactionsinflationratescontinuetohaveaneffecton worldwideeconomiesandconsequentlyonthewaycompaniesoperatethecompanyhasaccountedforoperationsin venezuelaashighlyinflationaryasthepriorthreeyearcumulativeinflationratesurpassedinthefaceofincreasing coststhecompanystrivestomaintainitsprofitmarginsthroughcostreductionprogramsproductivityimprovementsand periodicpriceincreases thevenezuelangovernmenthasestablishedorisintheprocessofestablishingalternativesystemsandofferingsof variousforeigncurrencyexchangesinthecompanycontinuedtohaveaccesstoanofficialgovernmentrateof bolivaresfuertestooneusdollartosettleimportsofvariousproductsintovenezuelathroughthefourthquarterof thecompanyhasprimarilyutilizedtheofficialgovernmentrateofbolivaresfuertestooneusdollarin preparingitsfinancialstatementsduringthesecondfiscalquarterthecompanyappliedtosettleanoutstandingdividend payableatoneofthealternativeforeignexchangeratesasaresultthecompanyhasappliedthisalternativeexchange ratetotranslatecertaintransactionsasappropriateasofdecemberthecompanysvenezuelansubsidiaries representedlessthanofthecompanysconsolidatedassetsliabilitiesrevenuesandprofitsthereforetheeffectof achangeintheexchangerateisnotexpectedtohaveamaterialadverseeffectonthecompanysfullyearresults thecompanyisexposedtofluctuationsincurrencyexchangeratesachangeinthevalueoftheusdollaras comparedtoallforeigncurrenciesinwhichthecompanyhadsalesincomeorexpenseinwouldhaveincreasedor decreasedthetranslationofforeignsalesbyapproximatelymillionandincomebymillion thecompanyfacesvariousworldwidehealthcarechangesthatmaycontinuetoresultinpricingpressuresthatinclude healthcarecostcontainmentandgovernmentlegislationrelatingtosalespromotionsandreimbursementofhealthcare products changesinthebehaviorandspendingpatternsofpurchasersofhealthcareproductsandservicesincludingdelaying medicalproceduresrationingprescriptionmedicationsreducingthefrequencyofphysicianvisitsandforegoinghealth careinsurancecoverageasaresultofthecurrentglobaleconomicdownturnmaycontinuetoimpactthecompanys businesses johnsonjohnsonannualreport thecompanyalsooperatesinanenvironmentincreasinglyhostiletointellectualpropertyrightsfirmshavefiled abbreviatednewdrugapplicationsorbiosimilarbiologicalproductapplicationswiththefdaorotherwisechallenged thecoverageandorvalidityofthecompanyspatentsseekingtomarketgenericorbiosimilarformsofmanyofthe companyskeypharmaceuticalproductspriortoexpirationoftheapplicablepatentscoveringthoseproductsintheevent thecompanyisnotsuccessfulindefendingthepatentclaimschallengedintheresultinglawsuitsgenericorbiosimilar versionsoftheproductsatissuewillbeintroducedtothemarketresultinginthepotentialforsubstantialmarketshareand revenuelossesforthoseproductsandwhichmayresultinanoncashimpairmentchargeinanyassociatedintangible assetforfurtherinformationseethediscussiononremicaderelatedcasesandlitigationagainstfilersof abbreviatednewdrugapplicationsinnotetotheconsolidatedfinancialstatements legalproceedings johnsonjohnsonandcertainofitssubsidiariesareinvolvedinvariouslawsuitsandclaimsregardingproductliability intellectualpropertycommercialandothermattersgovernmentalinvestigationsandotherlegalproceedingsthatarise fromtimetotimeintheordinarycourseofbusiness thecompanyrecordsaccrualsforsuchcontingencieswhenitisprobablethataliabilitywillbeincurredandtheamount ofthelosscanbereasonablyestimatedthecompanyhasaccruedforcertainlitigationmattersandcontinuestomonitor eachrelatedlegalissueandadjustaccrualsfornewinformationandfurtherdevelopmentsinaccordancewithaccounting standardscodificationascfortheseandotherlitigationandregulatorymatterscurrentlydisclosedfor whichalossisprobableorreasonablypossiblethecompanyisunabletodetermineanestimateofthepossiblelossor rangeoflossbeyondtheamountsalreadyaccruedthesematterscanbeaffectedbyvariousfactorsincludingwhether damagessoughtintheproceedingsareunsubstantiatedorindeterminatescientificandlegaldiscoveryhasnot commencedorisnotcompleteproceedingsareinearlystagesmatterspresentlegaluncertaintiestherearesignificant factsindisputeortherearenumerouspartiesinvolved inthecompanysopinionbasedonitsexaminationofthesemattersitsexperiencetodateanddiscussionswithcounsel theultimateoutcomeoflegalproceedingsnetofliabilitiesaccruedinthecompanysbalancesheetisnotexpectedto haveamaterialadverseeffectonthecompanysfinancialpositionhowevertheresolutioninanyreportingperiodofone ormoreofthesematterseitheraloneorintheaggregatemayhaveamaterialadverseeffectonthecompanysresultsof operationsandcashflowsforthatperiod seenotetotheconsolidatedfinancialstatementsforfurtherinformationregardinglegalproceedings commonstockmarketprices thecompanyscommonstockislistedonthenewyorkstockexchangeunderthesymboljnjasoffebruary therewererecordholdersofcommonstockofthecompanythecompositemarketpricerangesfor johnsonjohnsoncommonstockduringandwere high low high low firstquarter secondquarter thirdquarter fourthquarter yearendclose johnsonjohnsonannualreportcautionary factors may affect future results thisannualreportcontainsforwardlookingstatementsforwardlookingstatementsdonotrelatestrictlytohistoricalor currentfactsandanticipateresultsbasedonmanagementsplansthataresubjecttouncertaintyforwardlooking statementsmaybeidentifiedbytheuseofwordssuchasplansexpectswillanticipatesestimatesandother wordsofsimilarmeaninginconjunctionwithamongotherthingsdiscussionsoffutureoperationsfinancialperformance thecompanysstrategyforgrowthproductdevelopmentregulatoryapprovalmarketpositionandexpenditures forwardlookingstatementsarebasedoncurrentexpectationsoffutureeventsthecompanycannotguaranteethatany forwardlookingstatementwillbeaccuratealthoughthecompanybelievesthatithasbeenreasonableinitsexpectations andassumptionsinvestorsshouldrealizethatifunderlyingassumptionsproveinaccurateorthatknownorunknownrisks oruncertaintiesmaterializeactualresultscouldvarymateriallyfromthecompanysexpectationsandprojectionsinvestors arethereforecautionednottoplaceunduerelianceonanyforwardlookingstatementsthecompanydoesnotundertake toupdateanyforwardlookingstatementsasaresultofnewinformationorfutureeventsordevelopments risksanduncertaintiesincludebutarenotlimitedtoeconomicfactorssuchasinterestrateandcurrencyexchangerate fluctuationscompetitionincludingtechnologicaladvancesnewproductsandpatentsattainedbycompetitors challengesinherentinnewproductdevelopmentincludingobtainingregulatoryapprovalschallengestopatentsthe impactofpatentexpirationsuncertaintyofcommercialsuccessofnewandexistingproductssignificantadverselitigation orgovernmentactionincludingrelatedtoproductliabilityclaimsimpactofbusinesscombinationsanddivestitures significantchangesincustomerrelationshipsorchangesinbehaviorandspendingpatternsorfinancialdistressof purchasersofhealthcareproductsandserviceschangestolawsandregulationsandglobalhealthcarereformstrends towardhealthcarecostcontainmentincreasedscrutinyofthehealthcareindustrybygovernmentagenciesfinancial instabilityofinternationaleconomiesandsovereignriskmanufacturingdifficultiesordelayscomplexglobalsupplychains withincreasingregulatoryrequirementsproductefficacyorsafetyconcernsresultinginproductrecallsorregulatory actiondisruptionsduetonaturaldisastersandthepotentialfailuretomeetobligationsincomplianceagreementswith governmentbodies adiscussionoftheseandotherfactorsthatcouldcauseactualresultstodiffermateriallyfromexpectationscanbefound inthisannualreportonformkforthefiscalyearendeddecemberincludinginexhibitthecompany notesthesefactorsaspermittedbytheprivatesecuritieslitigationreformactof johnsonjohnsonannualreport johnson johnson subsidiaries consolidated balance sheets atdecemberanddecember dollarsinmillionsexceptshareandpershareamountsnote assets currentassets cashandcashequivalentsnotesand marketablesecuritiesnotesand accountsreceivabletradelessallowancesfordoubtfulaccounts inventoriesnotesand deferredtaxesonincomenote prepaidexpensesandotherreceivables totalcurrentassets propertyplantandequipmentnetnotesand intangibleassetsnetnotesand goodwillnotesand deferredtaxesonincomenote otherassets totalassets liabilitiesandshareholdersequity currentliabilities loansandnotespayablenote accountspayable accruedliabilities accruedrebatesreturnsandpromotions accruedcompensationandemployeerelatedobligations accruedtaxesonincome totalcurrentliabilities longtermdebtnote deferredtaxesonincomenote employeerelatedobligationsnotesand otherliabilities totalliabilities shareholdersequity preferredstockwithoutparvalueauthorizedandunissuedshares commonstockparvaluepersharenoteauthorizedsharesissued shares accumulatedothercomprehensiveincomenote retainedearnings lesscommonstockheldintreasuryatcostnotesharesandshares totalshareholdersequity totalliabilitiesandshareholdersequity seenotestoconsolidatedfinancialstatements johnsonjohnsonannualreportjohnson johnson subsidiaries consolidated statements earnings dollarsandsharesinmillionsexceptpershareamountsnote salestocustomers costofproductssold grossprofit sellingmarketingandadministrativeexpenses researchanddevelopmentexpense inprocessresearchanddevelopment interestincome interestexpensenetofportioncapitalizednote otherincomeexpensenet earningsbeforeprovisionfortaxesonincome provisionfortaxesonincomenote netearnings addnetlossattributabletononcontrollinginterest netearningsattributabletojohnsonjohnson netearningspershareattributabletojohnsonjohnsonnotesand basic diluted cashdividendspershare averagesharesoutstandingnotesand basic diluted seenotestoconsolidatedfinancialstatements johnsonjohnsonannualreport johnson johnson subsidiaries consolidated statements comprehensive income dollarsinmillionsnote netearnings othercomprehensiveincomelossnetoftax foreigncurrencytranslation securities unrealizedholdinggainlossarisingduringperiod reclassificationstoearnings netchange employeebenefitplans priorservicecostamortizationduringperiod priorservicecreditcostcurrentyear gainamortizationduringperiod gainlosscurrentyear effectofexchangerates netchange derivativeshedges unrealizedgainlossarisingduringperiod reclassificationstoearnings netchange othercomprehensiveincomeloss comprehensiveincome comprehensivelossattributabletononcontrollinginterestnetoftax comprehensiveincomeattributabletojohnsonjohnson thetaxeffectsinothercomprehensiveincomeforthefiscalyearsendedandrespectivelysecurities millionmillionandmillionemployeebenefitplansmillionmillionandmillion derivativeshedgesmillionmillionandmillion seenotestoconsolidatedfinancialstatements johnsonjohnsonannualreportjohnson johnson subsidiaries consolidated statements equity dollarsinmillionsnote accumulated treasury retained comprehensive commonstock stock total earnings income issuedamount amount balancejanuary netearningsattributabletojohnsonjohnson cashdividendspaid employeecompensationandstockoptionplans issuanceofcommonstockassociatedwiththe acquisitionofsynthesinc repurchaseofcommonstock othercomprehensiveincomelossnetoftax balancedecember netearningsattributabletojohnsonjohnson cashdividendspaid employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomelossnetoftax balancedecember netearningsattributabletojohnsonjohnson cashdividendspaid employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomelossnetoftax balancedecember includesrepurchaseofcommonstockassociatedwiththeacquisitionofsynthesinc seenotestoconsolidatedfinancialstatements johnsonjohnsonannualreport johnson johnson subsidiaries consolidated statements cash flows dollarsinmillionsnote cashflowsfromoperatingactivities netearnings adjustmentstoreconcilenetearningstocashflowsfromoperatingactivities depreciationandamortizationofpropertyandintangibles stockbasedcompensation noncontrollinginterest venezuelaadjustments assetwritedowns netgainonsaleofassetsbusinesses netgainonequityinvestmenttransactions deferredtaxprovision accountsreceivableallowances changesinassetsandliabilitiesnetofeffectsfromacquisitionsanddivestitures increaseinaccountsreceivable increaseininventories increaseinaccountspayableandaccruedliabilities decreaseincreaseinothercurrentandnoncurrentassets decreaseincreaseinothercurrentandnoncurrentliabilities netcashflowsfromoperatingactivities cashflowsfrominvestingactivities additionstopropertyplantandequipment proceedsfromthedisposalofassetsbusinessesnet acquisitionsnetofcashacquirednote purchasesofinvestments salesofinvestments otherprimarilyintangibles netcashusedbyinvestingactivities cashflowsfromfinancingactivities dividendstoshareholders repurchaseofcommonstock proceedsfromshorttermdebt retirementofshorttermdebt proceedsfromlongtermdebt retirementoflongtermdebt proceedsfromtheexerciseofstockoptionsexcesstaxbenefits netcashusedbyfinancingactivities effectofexchangeratechangesoncashandcashequivalents decreaseincreaseincashandcashequivalents cashandcashequivalentsbeginningofyearnote cashandcashequivalentsendofyearnote supplementalcashflowdata cashpaidduringtheyearfor interest interestnetofamountcapitalized incometaxes supplementalscheduleofnoncashinvestingandfinancingactivities issuanceofcommonstockassociatedwiththeacquisitionofsynthesinc treasurystockissuedforemployeecompensationandstockoptionplansnetofcashproceeds conversionofdebt acquisitions fairvalueofassetsacquired fairvalueofliabilitiesassumedandnoncontrollinginterests netfairvalueofacquisitions lessissuanceofcommonstockassociatedwiththeacquisitionofsynthesinc netcashpaidforacquisitions seenotestoconsolidatedfinancialstatements johnsonjohnsonannualreportnotes consolidated financial statements summaryofsignificantaccountingpolicies principlesofconsolidation theconsolidatedfinancialstatementsincludetheaccountsofjohnsonjohnsonanditssubsidiariesthecompany intercompanyaccountsandtransactionsareeliminated descriptionofthecompanyandbusinesssegments thecompanyhasapproximatelyemployeesworldwideengagedintheresearchanddevelopmentmanufacture andsaleofabroadrangeofproductsinthehealthcarefieldthecompanyconductsbusinessinvirtuallyallcountriesof theworldanditsprimaryfocusisonproductsrelatedtohumanhealthandwellbeing thecompanyisorganizedintothreebusinesssegmentsconsumerpharmaceuticalandmedicaldevicespreviously referredtoasmedicaldevicesanddiagnosticstheconsumersegmentincludesabroadrangeofproductsusedinthe babycareoralcareskincareoverthecounterpharmaceuticalwomenshealthandwoundcaremarketsthese productsaremarketedtothegeneralpublicandsoldbothtoretailoutletsanddistributorsthroughouttheworldthe pharmaceuticalsegmentisfocusedonfivetherapeuticareasincludingimmunologyinfectiousdiseasesneuroscience oncologyandcardiovascularandmetabolicdiseasesproductsinthissegmentaredistributeddirectlytoretailers wholesalershospitalsandhealthcareprofessionalsforprescriptionusethemedicaldevicessegmentincludesabroad rangeofproductsusedintheorthopaedicsurgicalcarespecialtysurgerycardiovascularcarediagnosticsdiabetes careandvisioncaremarketswhicharedistributedtowholesalershospitalsandretailersandusedprincipallyinthe professionalfieldsbyphysiciansnurseshospitalsandclinics newaccountingpronouncements recentlyadoptedaccountingpronouncements duringthefiscalfirstquarterofthecompanyadoptedthefinancialaccountingstandardsboardfasbguidance clarifyingthereleaseofaccumulatedforeigncurrencytranslationfromothercomprehensiveincomeociintocurrent yearnetearningstheamendmentrequiresthatwhentheparentcompanyceasestohaveacontrollinginterestina subsidiaryorabusinesswithinaforeignentitytheparentistoreleaseaccumulatedforeigncurrencytranslationfrom ocithisupdatebecameeffectiveforallannualperiodsandinterimreportingperiodsbeginningafterdecember theadoptionofthisstandarddidnothaveamaterialimpactonthecompanysresultsofoperationscashflowsor financialposition duringthefiscalfirstquarterofthecompanyadoptedthefasbguidanceonthepresentationofunrecognizedtax benefitswhenvariousqualifyingtaxcreditsexisttheamendmentrequiresthatunrecognizedtaxbenefitsbepresentedon theconsolidatedbalancesheetasareductiontodeferredtaxassetscreatedbynetoperatinglossesorothertaxcredits frompriorperiodsthatoccurinthesametaxingjurisdictiontotheextentthattheunrecognizedtaxbenefitexceedsthese creditsitshallbepresentedasaliabilitythisupdatebecameeffectiveforallannualperiodsandinterimreportingperiods beginningafterdecembertheadoptionofthisstandarddidnothaveamaterialimpactonthepresentationof thecompanysfinancialposition duringthefiscalsecondquarterofthefasbissuedamendedguidanceontheuseandpresentationof discontinuedoperationsinanentitysfinancialstatementsthenewguidancerestrictsthepresentationofdiscontinued operationstobusinesscircumstanceswhenthedisposalofbusinessoperationsrepresentsastrategicshiftthathasorwill haveamajoreffectonanentitysoperationsandfinancialresultsexamplesofastrategicshiftcouldincludebutnotbe limitedtodisposalofmajorgeographicsegmentsamajorlineofbusinessorothermajorbusinesscomponentofan entitythenewguidancealsoexpandstherequireddisclosuresforentitiesthathaveassetsheldforsalebutdonotmeet thenewdefinitionofdiscontinuedoperationsthisamendmentincludesearlyadoptionprovisionsallowingthecompany toimplementthisupdateimmediatelyforthefirstquarterofthecompanyelectedtoadoptthisstandardforthefirst quarterofthebalancesandupdateddisclosuresrequiredbytheamendedguidanceareincludedinnoteinthe notestotheconsolidatedfinancialstatements duringthefiscalsecondquarterofthefasbissuedaccountingstandardsupdateaccountingfor sharebasedpaymentswhenthetermsofanawardprovidethataperformancetargetcouldbeachievedafterthe johnsonjohnsonannualreport requisiteserviceperiodthisstandardclarifiesthecurrentaccountingguidanceforentitiesthatissuesharebased paymentawardsthatrequireaspecificperformancetargetbeachievedforemployeestobecomeeligibletovestinthe awardswhichmayoccursubsequenttoarequiredserviceperiodcurrentaccountingguidancedoesnotexplicitly addresshowtoaccountforthesetypesofawardsthenewstandardprovidesexplicitguidanceandclarifiesthatthese typesofperformancetargetsshouldbetreatedasperformanceconditionstheaccountingforsharebasedawardswith performanceconditionsisalreadyspecifiedincurrentaccountingguidancethisupdateisrequiredtobeadoptedbyall publiccompaniesforallannualperiodsandinterimreportingperiodsbeginningafterdecemberearlyadoption ofthisstandardwaspermittedandthecompanyhadelectedtoadoptthisstandardforthesecondquarterofthe adoptionofthisstandarddidnothaveamaterialimpactonthecompanysresultsofoperationscashflowsorfinancial position recentlyissuedaccountingstandards notadoptedasofdecember duringthefiscalsecondquarterofthefasbissuedaccountingstandardsupdaterevenuefrom contractswithcustomersthisstandardreplacessubstantiallyallcurrentrevenuerecognitionaccountingguidancethis updateisrequiredtobeadoptedbyallpubliccompaniesforallannualperiodsandinterimreportingperiodsbeginning afterdecemberearlyadoptionofthisstandardisnotpermittedthecompanyiscurrentlyassessingtheimpact ofthefutureadoptionofthisstandardonitsfinancialstatements duringthefiscalsecondquarterofthefasbissuedamendedguidanceaccountingstandardsupdateno developmentstageentitieseliminationofcertainfinancialreportingrequirementsincludinganamendmentto variableinterestentityguidanceintopicconsolidationthechangeinthecurrentguidancewillrequirethe companytodetermineifitshouldconsolidateoneoftheseentitiesbasedonthechangeintheconsolidationanalysis thisupdatetotheconsolidationanalysiswillbecomeeffectiveforallannualperiodsandinterimreportingperiods beginningafterdecembertheadoptionofthisstandardisnotexpectedtohaveamaterialimpactonthe presentationofthecompanysresultsofoperationscashflowsorfinancialposition duringthefiscalthirdquarterofthefasbissuedaccountingstandardsupdatenodisclosureof uncertaintiesaboutanentitysabilitytocontinueasagoingconcernthisstandardrequiresmanagementtoevaluate foreachannualandinterimreportingperiodwhetherthereareconditionsandeventsconsideredintheaggregatethat raisesubstantialdoubtaboutanentitysabilitytocontinueasagoingconcernwithinoneyearafterthedatethefinancial statementsareissuedorareavailabletobeissuedifsubstantialdoubtisraisedadditionaldisclosuresaround managementsplantoalleviatethesedoubtsarerequiredthisupdatewillbecomeeffectiveforallannualperiodsand interimreportingperiodsbeginningafterdecemberthisstandardisnotexpectedtohaveanyimpactoncurrent disclosuresinthefinancialstatements cashequivalents thecompanyclassifiesallhighlyliquidinvestmentswithstatedmaturitiesofthreemonthsorlessfromdateofpurchase ascashequivalentsandallhighlyliquidinvestmentswithstatedmaturitiesofgreaterthanthreemonthsfromthedateof purchaseascurrentmarketablesecuritiesthecompanyhasapolicyofmakinginvestmentsonlywithcommercial institutionsthathaveatleastanaorequivalentcreditratingthecompanyinvestsitscashprimarilyinreverse repurchaseagreementsrrasgovernmentsecuritiesandobligationscorporatedebtsecuritiesandmoneymarket funds rrasarecollateralizedbydepositsintheformofgovernmentsecuritiesandobligationsforanamountnotlessthan oftheirvaluethecompanydoesnotrecordanassetorliabilityasthecompanyisnotpermittedtosellor repledgetheassociatedcollateralthecompanyhasapolicythatthecollateralhasatleastanaorequivalentcredit ratingthecompanyutilizesathirdpartycustodiantomanagetheexchangeoffundsandensurethatcollateralreceivedis maintainedatofthevalueoftherrasonadailybasisrraswithstatedmaturitiesofgreaterthanthreemonths fromthedateofpurchaseareclassifiedasmarketablesecurities investments shorttermmarketablesecuritiesarecarriedatcostwhichapproximatesfairvalueinvestmentsclassifiedasavailablefor salearecarriedatestimatedfairvaluewithunrealizedgainsandlossesrecordedasacomponentofaccumulatedother comprehensiveincomelongtermdebtsecuritiesthatthecompanyhastheabilityandintenttoholduntilmaturityare carriedatamortizedcostmanagementdeterminestheappropriateclassificationofitsinvestmentindebtandequity johnsonjohnsonannualreportsecuritiesatthetimeofpurchaseandreevaluatessuchdeterminationateachbalancesheetdatethecompany periodicallyreviewsitsinvestmentsinequitysecuritiesforimpairmentandadjuststheseinvestmentstotheirfairvalue whenadeclineinmarketvalueisdeemedtobeotherthantemporaryiflossesonthesesecuritiesareconsideredtobe otherthantemporarythelossisrecognizedinearnings propertyplantandequipmentanddepreciation propertyplantandequipmentarestatedatcostthecompanyutilizesthestraightlinemethodofdepreciationoverthe estimatedusefullivesoftheassets buildingandbuildingequipment years landandleaseholdimprovements years machineryandequipment years thecompanycapitalizescertaincomputersoftwareanddevelopmentcostsincludedinmachineryandequipmentwhen incurredinconnectionwithdevelopingorobtainingcomputersoftwareforinternalusecapitalizedsoftwarecostsare amortizedovertheestimatedusefullivesofthesoftwarewhichgenerallyrangefromtoyears thecompanyreviewslonglivedassetstoassessrecoverabilityusingundiscountedcashflowswhencertaineventsor changesinoperatingoreconomicconditionsoccuranimpairmentassessmentmaybeperformedontherecoverabilityof thecarryingvalueoftheseassetsiftheassetisdeterminedtobeimpairedthelossismeasuredbasedonthedifference betweentheassetsfairvalueanditscarryingvalueifquotedmarketpricesarenotavailablethecompanywillestimate fairvalueusingadiscountedvalueofestimatedfuturecashflows revenue recognition thecompanyrecognizesrevenuefromproductsaleswhenthegoodsareshippedordeliveredandtitleandriskofloss passtothecustomerprovisionsforcertainrebatessalesincentivestradepromotionscouponsproductreturnsand discountstocustomersareaccountedforasreductionsinsalesinthesameperiodtherelatedsalesarerecorded productdiscountsgrantedarebasedonthetermsofarrangementswithdirectindirectandothermarketparticipantsas wellasmarketconditionsincludingpriceschargedbycompetitorsrebateswhichincludemedicaidareestimatedbased oncontractualtermshistoricalexperiencepatientoutcomestrendanalysisandprojectedmarketconditionsinthevarious marketsservedthecompanyevaluatesmarketconditionsforproductsorgroupsofproductsprimarilythroughthe analysisofwholesalerandotherthirdpartysellthroughandmarketresearchdataaswellasinternallygenerated information salesreturnsaregenerallyestimatedandrecordedbasedonhistoricalsalesandreturnsinformationproductsthatexhibit unusualsalesorreturnpatternsduetodatingcompetitionorothermarketingmattersarespecificallyinvestigatedand analyzedaspartoftheaccountingforsalesreturnsaccruals salesreturnsallowancesrepresentareserveforproductsthatmaybereturnedduetoexpirationdestructioninthefield orinspecificareasproductrecallthereturnsreserveisbasedonhistoricalreturntrendsbyproductandbymarketasa percenttogrosssalesinaccordancewiththecompanysaccountingpoliciesthecompanygenerallyissuescreditto customersforreturnedgoodsthecompanyssalesreturnsreservesareaccountedforinaccordancewithusgaap guidanceforrevenuerecognitionwhenrightofreturnexistssalesreturnsreservesarerecordedatfullsalesvaluesales returnsintheconsumerandpharmaceuticalsegmentsarealmostexclusivelynotresalablesalesreturnsforcertain franchisesinthemedicaldevicessegmentaretypicallyresalablebutarenotmaterialthecompanyinfrequently exchangesproductsfrominventoryforreturnedproductsthesalesreturnsreserveforthetotalcompanyhasbeen approximatelyofannualsalestocustomersduringthefiscalreportingyearsand promotionalprogramssuchasproductlistingallowancesandcooperativeadvertisingarrangementsarerecordedinthe yearincurredcontinuingpromotionalprogramsincludecouponsandvolumebasedsalesincentiveprogramsthe redemptioncostofconsumercouponsisbasedonhistoricalredemptionexperiencebyproductandvaluevolumebased incentiveprogramsarebasedontheestimatedsalesvolumesfortheincentiveperiodandarerecordedasproductsare soldthecompanyalsoearnsservicerevenueforcopromotionofcertainproductsandincludesitinsalestocustomers thesearrangementsareevaluatedtodeterminetheappropriateamountstobedeferred johnsonjohnsonannualreport shippingandhandling shippingandhandlingcostsincurredweremillionmillionandmillioninand respectivelyandareincludedinsellingmarketingandadministrativeexpensetheamountofrevenuereceivedfor shippingandhandlingislessthanofsalestocustomersforallperiodspresented inventories inventoriesarestatedatthelowerofcostormarketdeterminedbythefirstinfirstoutmethod intangibleassetsandgoodwill theauthoritativeliteratureonusgaaprequiresthatgoodwillandintangibleassetswithindefinitelivesbeassessed annuallyforimpairmentthecompanycompletedtheannualimpairmenttestforinthefiscalfourthquarterfuture impairmenttestswillbeperformedannuallyinthefiscalfourthquarterorsoonerifwarrantedpurchasedinprocess researchanddevelopmentisaccountedforasanindefinitelivedintangibleassetuntiltheunderlyingprojectiscompleted atwhichpointtheintangibleassetwillbeaccountedforasadefinitelivedintangibleassetorabandonedatwhichpoint theintangibleassetwillbewrittenofforpartiallyimpaired intangibleassetsthathavefiniteusefullivescontinuetobeamortizedovertheirusefullivesandarereviewedfor impairmentwhenwarrantedbyeconomicconditionsseenoteforfurtherdetailsonintangibleassetsandgoodwill financialinstruments asrequiredbyusgaapallderivativeinstrumentsarerecordedonthebalancesheetatfairvaluefairvalueistheexit pricethatwouldbereceivedtosellanassetorpaidtotransferaliabilityfairvalueisamarketbasedmeasurement determinedusingassumptionsthatmarketparticipantswoulduseinpricinganassetorliabilitytheauthoritativeliterature establishesathreelevelhierarchytoprioritizetheinputsusedinmeasuringfairvaluewithlevelhavingthehighest priorityandlevelhavingthelowestchangesinthefairvalueofderivativesarerecordedeachperiodincurrentearnings orothercomprehensiveincomedependingonwhetherthederivativeisdesignatedaspartofahedgetransactionandif sothetypeofhedgetransaction thecompanydocumentsallrelationshipsbetweenhedgeditemsandderivativestheoverallriskmanagementstrategy includesreasonsforundertakinghedgetransactionsandenteringintoderivativestheobjectivesofthisstrategyare minimizeforeigncurrencyexposuresimpactonthecompanysfinancialperformanceprotectthecompanyscash flowfromadversemovementsinforeignexchangeratesensuretheappropriatenessoffinancialinstrumentsand managetheenterpriseriskassociatedwithfinancialinstitutionsseenoteforadditionalinformationonfinancial instruments productliability accrualsforproductliabilityclaimsarerecordedonanundiscountedbasiswhenitisprobablethataliabilityhasbeen incurredandtheamountoftheliabilitycanbereasonablyestimatedbasedonexistinginformationtheaccrualsare adjustedperiodicallyasadditionalinformationbecomesavailablethecompanyaccruesanestimateofthelegaldefense costsneededtodefendeachmatterthisisreferredtoasdefensecostsinconnectionwithproductliabilitylitigationin certainmattersanindemnityamountisalsorecordedthisisreferredtoasproductliabilityaccrual asaresultofcostandavailabilityfactorseffectivenovemberthecompanyceasedpurchasingthirdparty productliabilityinsurancethecompanyhasselfinsurancethroughawhollyownedcaptiveinsurancecompanyin additiontoaccrualsintheselfinsuranceprogramclaimsthatexceedtheinsurancecoverageareaccruedwhenlossesare probableandamountscanbereasonablyestimatedbasedontheavailabilityofpriorcoveragereceivablesforinsurance recoveriesrelatedtoproductliabilityclaimsarerecordedonanundiscountedbasiswhenitisprobablethatarecoverywill berealizedasappropriatereservesagainstthesereceivablesarerecordedforestimatedamountsthatmaynotbe collectedfromthirdpartyinsurers concentrationofcreditrisk globalconcentrationofcreditriskwithrespecttotradeaccountsreceivablescontinuestobelimitedduetothelarge numberofcustomersgloballyandadherencetointernalcreditpoliciesandcreditlimitseconomicchallengesinitaly spaingreeceandportugalthesoutherneuropeanregionhaveimpactedcertainpaymentpatternswhichhave johnsonjohnsonannualreporthistoricallybeenlongerthanthoseexperiencedintheusandotherinternationalmarketsthetotalnettradeaccounts receivablebalanceinthesoutherneuropeanregionwasapproximatelybillionasofdecemberand approximatelybillionasofdecemberapproximatelybillionasofdecemberand approximatelybillionasofdecemberofthesoutherneuropeanregionnettradeaccountsreceivable balancerelatedtothecompanysconsumervisioncareanddiabetescarebusinessesaswellascertain pharmaceuticalandmedicaldevicescustomerswhichareinlinewithhistoricalcollectionpatterns theremainingbalanceofnettradeaccountsreceivableinthesoutherneuropeanregionhasbeennegativelyimpacted bythetimingofpaymentsfromcertaingovernmentownedorsupportedhealthcarecustomersaswellascertain distributorsofthepharmaceuticalandmedicaldeviceslocalaffiliatesthetotalnettradeaccountsreceivablebalancefor thesecustomerswereapproximatelybillionatdecemberandbillionatdecemberthe companycontinuestoreceivepaymentsfromthesecustomersandinsomecaseslatepaymentpremiumsforcustomers wherepaymentisexpectedoverperiodsoftimelongerthanoneyearrevenueandtradereceivableshavebeen discountedovertheestimatedperiodoftimeforcollectionallowancesfordoubtfulaccountshavebeenincreasedfor thesecustomersbuthavebeenimmaterialtodatethecompanywillcontinuetoworkcloselywiththesecustomerson paymentplansmonitortheeconomicsituationandtakeappropriateactionsasnecessary researchanddevelopment researchanddevelopmentexpensesareexpensedasincurredupfrontandmilestonepaymentsmadetothirdpartiesin connectionwithresearchanddevelopmentcollaborationsareexpensedasincurreduptothepointofregulatoryapproval paymentsmadetothirdpartiessubsequenttoregulatoryapprovalarecapitalizedandamortizedovertheremaininguseful lifeoftherelatedproductamountscapitalizedforsuchpaymentsareincludedinotherintangiblesnetofaccumulated amortization thecompanyentersintocollaborativearrangementstypicallywithotherpharmaceuticalorbiotechnologycompaniesto developandcommercializedrugcandidatesorintellectualpropertythesearrangementstypicallyinvolvetwoormore partieswhoareactiveparticipantsinthecollaborationandareexposedtosignificantrisksandrewardsdependentonthe commercialsuccessoftheactivitiesthesecollaborationsusuallyinvolvevariousactivitiesbyoneormoreparties includingresearchanddevelopmentmarketingandsellinganddistributionoftenthesecollaborationsrequireupfront milestoneandroyaltyorprofitsharepaymentscontingentupontheoccurrenceofcertainfutureeventslinkedtothe successoftheassetindevelopmentamountsduefromcollaborativepartnersrelatedtodevelopmentactivitiesare generallyreflectedasareductionofresearchanddevelopmentexpensebecausetheperformanceofcontract developmentservicesisnotcentraltothecompanysoperationsingeneraltheincomestatementpresentationforthese collaborationsisasfollows naturetypeofcollaboration statementofearningspresentation thirdpartysaleofproduct salestocustomers royaltiesmilestonespaidtocollaborativepartner costofproductssold postregulatoryapproval royaltiesreceivedfromcollaborativepartner otherincomeexpensenet upfrontpaymentsmilestonespaidtocollaborativepartner researchanddevelopmentexpense preregulatoryapproval researchanddevelopmentpaymentstocollaborative researchanddevelopmentexpense partner researchanddevelopmentpaymentsreceivedfrom reductionofresearchanddevelopmentexpense collaborativepartner milestonesarecapitalizedasintangibleassetsandamortizedtocostofgoodssoldovertheusefullife forallyearspresentedtherewasnoindividualprojectthatrepresentedgreaterthanofthetotalannualconsolidated researchanddevelopmentexpense advertising costsassociatedwithadvertisingareexpensedintheyearincurredandareincludedinsellingmarketingand administrativeexpensesadvertisingexpensesworldwidewhichcomprisedtelevisionradioprintmediaandinternet advertisingwerebillionbillionandbillioninandrespectively johnsonjohnsonannualreport incometaxes incometaxesarerecordedbasedonamountsrefundableorpayableforthecurrentyearandincludetheresultsofany differencebetweenusgaapaccountingandtaxreportingrecordedasdeferredtaxassetsorliabilitiesthecompany estimatesdeferredtaxassetsandliabilitiesbasedonenactedtaxregulationsandratesfuturechangesintaxlawsand ratesmayaffectrecordeddeferredtaxassetsandliabilitiesinthefuture thecompanyhasunrecognizedtaxbenefitsforuncertaintaxpositionsthecompanyfollowsusgaapwhich prescribesarecognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementof ataxpositiontakenorexpectedtobetakeninataxreturnmanagementbelievesthatchangesintheseestimateswould nothaveamaterialeffectonthecompanysresultsofoperationscashflowsorfinancialposition atdecemberanddecemberthecumulativeamountsofundistributedinternationalearningswere approximatelybillionandbillionrespectivelyatdecemberanddecemberthe companysforeignsubsidiariesheldbalancesofcashandcashequivalentsintheamountsofbillionand billionrespectivelythecompanyhasnotprovideddeferredtaxesontheundistributedearningsfromcertaininternational subsidiarieswheretheearningsareconsideredtobepermanentlyreinvestedthecompanyintendstocontinueto reinvesttheseearningsininternationaloperationsifthecompanydecidedatalaterdatetorepatriatetheseearningsto theusthecompanywouldberequiredtoprovideforthenettaxeffectsontheseamountsthecompanydoesnot determinethedeferredtaxliabilityassociatedwiththeseundistributedearningsassuchdeterminationisnotpractical seenotetotheconsolidatedfinancialstatementsforfurtherinformationregardingincometaxes netearningspershare basicearningspershareiscomputedbydividingnetearningsavailabletocommonshareholdersbytheweightedaverage numberofcommonsharesoutstandingfortheperioddilutedearningspersharereflectsthepotentialdilutionthatcould occurifsecuritieswereexercisedorconvertedintocommonstockusingthetreasurystockmethod useofestimates thepreparationofconsolidatedfinancialstatementsinconformitywithaccountingprinciplesgenerallyacceptedinthe usrequiresmanagementtomakeestimatesandassumptionsthataffecttheamountsreportedestimatesareusedwhen accountingforsalesdiscountsrebatesallowancesandincentivesproductliabilitiesincometaxesdepreciation amortizationemployeebenefitscontingenciesandintangibleassetandliabilityvaluationsactualresultsmayormaynot differfromthoseestimates thecompanyfollowstheprovisionsofusgaapwhenrecordinglitigationrelatedcontingenciesaliabilityisrecorded whenalossisprobableandcanbereasonablyestimatedthebestestimateofalosswithinarangeisaccruedhowever ifnoestimateintherangeisbetterthananyothertheminimumamountisaccrued annualclosingdate thecompanyfollowstheconceptofafiscalyearwhichendsonthesundaynearesttotheendofthemonthof decembernormallyeachfiscalyearconsistsofweeksbuteveryfiveorsixyearsthefiscalyearconsistsofweeks aswasthecaseinandisthecaseagainin reclassification certainpriorperiodamountshavebeenreclassifiedtoconformtocurrentyearpresentation johnsonjohnsonannualreport cashcashequivalentsandcurrentmarketablesecurities attheendofandcashcashequivalentsandcurrentmarketablesecuritieswerecomprisedof dollarsinmillions cash governmentsecuritiesandobligations reverserepurchaseagreements corporatedebtsecurities moneymarketfunds timedeposits totalcashcashequivalentsandcurrentmarketablesecurities theestimatedfairvalueapproximatedcostasofdecemberanddecember asofdecembercurrentmarketablesecuritiesconsistedofmillionandmillionofgovernment securitiesandobligationsandcorporatedebtsecuritiesrespectivelywithnoreverserepurchaseagreements asofdecembercurrentmarketablesecuritiesconsistedofmillionmillionandmillionof governmentsecuritiesandobligationsreverserepurchaseagreementsandcorporatedebtsecuritiesrespectively fairvalueofgovernmentsecuritiesandobligationsandcorporatedebtsecuritieswereestimatedusingquotedbroker pricesandsignificantotherobservableinputs thecompanyinvestsitsexcesscashinbothdepositswithmajorbanksthroughouttheworldandotherhighquality moneymarketinstrumentsthecompanyhasapolicyofmakinginvestmentsonlywithcommercialinstitutionsthathaveat leastanaorequivalentcreditrating inventories attheendofandinventorieswerecomprisedof dollarsinmillions rawmaterialsandsupplies goodsinprocess finishedgoods totalinventories propertyplantandequipment attheendofandpropertyplantandequipmentatcostandaccumulateddepreciationwere dollarsinmillions landandlandimprovements buildingsandbuildingequipment machineryandequipment constructioninprogress totalpropertyplantandequipmentgross lessaccumulateddepreciation totalpropertyplantandequipmentnet thecompanycapitalizesinterestexpenseaspartofthecostofconstructionoffacilitiesandequipmentinterestexpense capitalizedinandwasmillionmillionandmillionrespectively johnsonjohnsonannualreport depreciationexpenseincludingtheamortizationofcapitalizedinterestinandwasbillion billionandbillionrespectively uponretirementorotherdisposalofpropertyplantandequipmentthecostsandrelatedamountsofaccumulated depreciationoramortizationareeliminatedfromtheassetandaccumulateddepreciationaccountsrespectivelythe differenceifanybetweenthenetassetvalueandtheproceedsarerecordedinearnings intangibleassetsandgoodwill attheendofandthegrossandnetamountsofintangibleassetswere dollarsinmillions intangibleassetswithdefinitelives patentsandtrademarksgross lessaccumulatedamortization patentsandtrademarksnet customerrelationshipsandotherintangiblesgross lessaccumulatedamortization customerrelationshipsandotherintangiblesnet intangibleassetswithindefinitelives trademarks purchasedinprocessresearchanddevelopment totalintangibleassetswithindefinitelives totalintangibleassetsnet goodwillasofdecemberanddecemberasallocatedbysegmentofbusinesswasasfollows dollarsinmillions consumer pharmaceutical meddevices total goodwillatdecember goodwillrelatedtoacquisitions goodwillrelatedtodivestitures currencytranslationother goodwillatdecember goodwillrelatedtoacquisitions goodwillrelatedtodivestitures currencytranslationother goodwillatdecember theweightedaverageamortizationperiodsforpatentsandtrademarksandcustomerrelationshipsandotherintangible assetsareyearsandyearsrespectivelytheamortizationexpenseofamortizableassetsincludedincostof productssoldwasmillionmillionandmillionbeforetaxforthefiscalyearsendeddecember decemberanddecemberrespectivelytheestimatedamortizationexpenseforthefive succeedingyearsapproximatesmillionbeforetaxperyear seenotetotheconsolidatedfinancialstatementsforadditionaldetailsrelatedtoacquisitionsanddivestitures fairvaluemeasurements thecompanyusesforwardforeignexchangecontractstomanageitsexposuretothevariabilityofcashflowsprimarily relatedtotheforeignexchangeratechangesoffutureintercompanyproductandthirdpartypurchasesofmaterials denominatedinaforeigncurrencythecompanyusescrosscurrencyinterestrateswapstomanagecurrencyrisk primarilyrelatedtoborrowingsbothtypesofderivativesaredesignatedascashflowhedges johnsonjohnsonannualreportadditionallythecompanyusesinterestrateswapsasaninstrumenttomanageinterestrateriskrelatedtofixedrate borrowingsthesederivativesaretreatedasfairvaluehedgesthecompanymayuseforwardforeignexchangecontracts designatedasnetinvestmenthedgesadditionallythecompanyusesforwardforeignexchangecontractstooffsetits exposuretocertainforeigncurrencyassetsandliabilitiestheseforwardforeignexchangecontractsarenotdesignatedas hedgesandthereforechangesinthefairvaluesofthesederivativesarerecognizedinearningstherebyoffsettingthe currentearningseffectoftherelatedforeigncurrencyassetsandliabilities thecompanydoesnotenterintoderivativefinancialinstrumentsfortradingorspeculativepurposesorthatcontaincredit riskrelatedcontingentfeaturesorrequirementstopostcollateralonanongoingbasisthecompanymonitors counterpartycreditratingsthecompanyconsiderscreditnonperformancerisktobelowbecausethecompanyenters intoagreementswithcommercialinstitutionsthathaveatleastanaorequivalentcreditratingasofdecember thecompanyhadnotionalamountsoutstandingforforwardforeignexchangecontractscrosscurrencyinterest rateswapsandinterestrateswapsofbillionbillionandbillionrespectively allderivativeinstrumentsarerecordedonthebalancesheetatfairvaluechangesinthefairvalueofderivativesare recordedeachperiodincurrentearningsorothercomprehensiveincomedependingonwhetherthederivativeis designatedaspartofahedgetransactionandifsothetypeofhedgetransaction thedesignationasacashflowhedgeismadeattheentrancedateofthederivativecontractatinceptionallderivatives areexpectedtobehighlyeffectivechangesinthefairvalueofaderivativethatisdesignatedasacashflowhedgeandis highlyeffectivearerecordedinaccumulatedothercomprehensiveincomeuntiltheunderlyingtransactionaffectsearnings andarethenreclassifiedtoearningsinthesameaccountasthehedgedtransactiongainsandlossesassociatedwith interestrateswapsarerecordedtointerestexpenseintheperiodinwhichtheyoccurgainsandlossesonnetinvestment hedgesareaccountedforthroughthecurrencytranslationaccountandareinsignificantonanongoingbasisthe companyassesseswhethereachderivativecontinuestobehighlyeffectiveinoffsettingchangesofhedgeditemsifand whenaderivativeisnolongerexpectedtobehighlyeffectivehedgeaccountingisdiscontinuedhedgeineffectivenessif anyisincludedincurrentperiodearningsinotherincomeexpensenetforforwardforeignexchangecontractsand crosscurrencyinterestrateswapsforinterestrateswapsdesignatedasfairvaluehedgeshedgeineffectivenessifany isincludedincurrentperiodearningswithininterestexpenseforthecurrentreportingperiodhedgeineffectiveness associatedwithinterestrateswapsarenotmaterial asofdecemberthebalanceofdeferrednetgainsonderivativesincludedinaccumulatedothercomprehensive incomewasmillionaftertaxforadditionalinformationseetheconsolidatedstatementsofcomprehensiveincome andnotethecompanyexpectsthatsubstantiallyalloftheamountsrelatedtoforwardforeignexchangecontractswill bereclassifiedintoearningsoverthenextmonthsasaresultoftransactionsthatareexpectedtooccuroverthat periodthemaximumlengthoftimeoverwhichthecompanyishedgingtransactionexposureismonthsexcluding interestratecontractstheamountultimatelyrealizedinearningsmaydifferasforeignexchangerateschangerealized gainsandlossesareultimatelydeterminedbyactualexchangeratesatmaturityofthederivative thefollowingtableisasummaryoftheactivityrelatedtoderivativesdesignatedascashflowhedgesforthefiscalyears endeddecemberanddecember gainloss gainloss gainloss reclassifiedfrom recognizedin recognizedin accumulatedoci dollarsinmillions accumulatedoci intoincome incomeexpense cashflowhedgesbyincomestatementcaption salestocustomers costofproductssold researchanddevelopmentexpense interestincomeinterestexpensenet otherincomeexpensenet total allamountsshowninthetableabovearenetoftax effectiveportion ineffectiveportion forwardforeignexchangecontracts crosscurrencyinterestrateswaps johnsonjohnsonannualreport forthefiscalyearsendeddecemberanddecemberagainofmillionandagainofmillion respectivelywasrecognizedinotherincomeexpensenetrelatingtoforwardforeignexchangecontractsnot designatedashedginginstruments fairvalueistheexitpricethatwouldbereceivedtosellanassetorpaidtotransferaliabilityfairvalueisamarketbased measurementdeterminedusingassumptionsthatmarketparticipantswoulduseinpricinganassetorliabilitythe authoritativeliteratureestablishesathreelevelhierarchytoprioritizetheinputsusedinmeasuringfairvaluethelevels withinthehierarchyaredescribedbelowwithlevelhavingthehighestpriorityandlevelhavingthelowest thefairvalueofaderivativefinancialinstrumentieforwardforeignexchangecontractsinterestratecontractsisthe aggregationbycurrencyofallfuturecashflowsdiscountedtoitspresentvalueattheprevailingmarketinterestratesand subsequentlyconvertedtotheusdollaratthecurrentspotforeignexchangeratethecompanydoesnotbelievethat fairvaluesofthesederivativeinstrumentsmateriallydifferfromtheamountsthatcouldberealizeduponsettlementor maturityorthatthechangesinfairvaluewillhaveamaterialeffectonthecompanysresultsofoperationscashflowsor financialpositionthecompanyalsoholdsequityinvestmentswhichareclassifiedaslevelbecausetheyaretradedin anactiveexchangemarketthecompanydidnothaveanyothersignificantfinancialassetsorliabilitieswhichwould requirerevisedvaluationsunderthisstandardthatarerecognizedatfairvalue thefollowingthreelevelsofinputsareusedtomeasurefairvalue levelquotedpricesinactivemarketsforidenticalassetsandliabilities levelsignificantotherobservableinputs levelsignificantunobservableinputs thecompanyssignificantfinancialassetsandliabilitiesmeasuredatfairvalueasofdecemberand decemberwereasfollows dollarsinmillions level level level total total derivativesdesignatedashedginginstruments assets forwardforeignexchangecontracts interestratecontracts total liabilities forwardforeignexchangecontracts interestratecontracts total derivativesnotdesignatedashedginginstruments assets forwardforeignexchangecontracts liabilities forwardforeignexchangecontracts otherinvestments assetsandliabilitiesareallclassifiedaslevelwiththeexceptionofotherinvestmentsofmillionwhichareclassifiedas level includesmillionandmillionofnoncurrentassetsforthefiscalyearsendingdecemberanddecember respectively includesmillionandmillionofnoncurrentliabilitiesforthefiscalyearsendingdecemberanddecember respectively includescrosscurrencyinterestrateswapsandinterestrateswaps classifiedasnoncurrentotherassets seenotesandforfinancialassetsandliabilitiesheldatcarryingamountontheconsolidatedbalancesheet johnsonjohnsonannualreport borrowings thecomponentsoflongtermdebtareasfollows effective effective dollarsinmillions rate rate monthliborfrndue notesdue notesdue monthliborfrndue notesdue debenturesdue notesdue debenturesdue notesdue notesduebeurobeuro notesdue zerocouponconvertiblesubordinateddebenturesdue debenturesdue notesdue notesdue debenturesdue notesdue notesduemmgbpmmgbp notesdue debenturesdue notesdue notesdue debenturesdue debenturesdue notesdue notesdue subtotal lesscurrentportion totallongtermdebt weightedaverageeffectiverate translationrateatdecember translationrateatdecember theexcessofthefairvalueoverthecarryingvalueofdebtwasbillioninandbillionin includesthereopeningoftheseissues fairvalueofthenoncurrentdebtwasestimatedusingmarketpriceswhichwerecorroboratedbyquotedbrokerprices andsignificantotherobservableinputs thecompanyhasaccesstosubstantialsourcesoffundsatnumerousbanksworldwideinseptemberthe companysecuredanewdaycreditfacilitytotalcreditavailabletothecompanyapproximatesbillionwhich expiresonseptemberinterestchargedonborrowingsunderthecreditlineagreementsisbasedoneitherbids providedbybankstheprimerateorlondoninterbankofferedratesliborplusapplicablemarginscommitmentfees undertheagreementsarenotmaterial johnsonjohnsonannualreport throughoutthecompanycontinuedtohaveaccesstoliquiditythroughthecommercialpapermarketshortterm borrowingsandthecurrentportionoflongtermdebtamountedtoapproximatelybillionattheendofofwhich billionwasborrowedunderthecommercialpaperprogramtheremainderprincipallyrepresentslocalborrowingby internationalsubsidiaries thecompanyhasashelfregistrationwiththeussecuritiesandexchangecommissionthatenablesthecompanyto issuedebtsecuritiesandwarrantstopurchasedebtsecuritiesonatimelybasisthecompanyissuedbondsinnovember foratotalofbillionforgeneralcorporatepurposesthisincludedthereopeningoftheandbonds issuedindecember aggregatematuritiesoflongtermobligationscommencinginare dollarsinmillions incometaxes theprovisionfortaxesonincomeconsistsof dollarsinmillions currentlypayable ustaxes internationaltaxes totalcurrentlypayable deferred ustaxes internationaltaxes totaldeferred provisionfortaxesonincome acomparisonofincometaxexpenseattheusstatutoryrateofinandtothecompanys effectivetaxrateisasfollows dollarsinmillions us international earningsbeforetaxesonincome taxrates usstatutoryrate internationaloperationsexcludingireland irelandandpuertoricooperations researchandorphandrugtaxcredits usstateandlocal usmanufacturingdeduction ustaxoninternationalincome ustaxbenefitonassetbusinessdisposals allother effectivetaxrate johnsonjohnsonannualreporttheincreaseintheeffectivetaxrateascomparedtowasattributabletothefollowingthedivestitureofthe orthoclinicaldiagnosticsbusinessatanapproximateeffectivetaxratelitigationaccrualsatlowtaxratesthemixof earningsintohighertaxjurisdictionsprimarilytheustheaccrualofanadditionalyearofthebrandedprescriptiondrug feewhichisnottaxdeductibleandadditionalustaxexpenserelatedtoaplannedincreaseindividendsfromcurrent yearforeignearningsascomparedtotheprioryeartheseincreasestotheeffectivetaxratewerepartiallyoffsetby ataxbenefitofbillionassociatedwiththeconormedsystemsdivestiture theeffectivetaxratewasreducedbyataxbenefitassociatedwiththewriteoffofassetsfortaxpurposes associatedwithsciosincandtheinclusionofboththeandbenefitfromtheresearchanddevelopmenttax creditandthecontrolledforeigncorporationlookthroughprovisionsbecausethoseprovisionswereenactedintolawin januaryandwereretroactivetojanuary theeffectivetaxratewasalsoreducedasthecompanyadjusteditsunrecognizedtaxbenefitsasaresultofithe federalappealscourtsdecisioninomjpharmaceuticalsincslitigationregardingcreditsunderformersectionof theinternalrevenuecodeseenotetotheconsolidatedfinancialstatementsforadditionalinformationandiia settlementofsubstantiallyallissuesrelatedtothecompanysusinternalrevenueserviceauditoftaxyears theimpactofthesettlementisreflectedintheustaxoninternationalincomeandtheallotherlineitemswithin theabovereconciliation theitemsnotedabovereflectthekeydriversoftheratereconciliation thecompanyhassubsidiariesoperatinginpuertoricoundervarioustaxincentives temporarydifferencesandcarryforwardsforandwereasfollows deferredtax deferredtax dollarsinmillions asset liability asset liability employeerelatedobligations stockbasedcompensation depreciation nondeductibleintangibles internationalrdcapitalizedfortax reservesliabilities incomereportedfortaxpurposes netoperatinglosscarryforwardinternational miscellaneousinternational miscellaneousus totaldeferredincometaxes themillioninwasnetofavaluationallowancerelatedtobelgiumofmillionthemillioninwasnet ofavaluationallowancerelatedtobelgiumofmillion thedifferencebetweenthenetdeferredtaxonincomeperthebalancesheetandthenetdeferredtaxaboveisincludedin taxesonincomeonthebalancesheetthecompanyhaswhollyownedinternationalsubsidiariesthathavecumulativenet lossesthecompanybelievesthatitismorelikelythannotthatthesesubsidiarieswillrealizefuturetaxableincome sufficienttoutilizethesedeferredtaxassets thefollowingtablesummarizestheactivityrelatedtounrecognizedtaxbenefits dollarsinmillions beginningofyear increasesrelatedtocurrentyeartaxpositions increasesrelatedtopriorperiodtaxpositions decreasesrelatedtopriorperiodtaxpositions settlements lapseofstatuteoflimitations endofyear johnsonjohnsonannualreport theunrecognizedtaxbenefitsofbillionatdecemberifrecognizedwouldaffectthecompanysannual effectivetaxratethecompanyconductsbusinessandfilestaxreturnsinnumerouscountriesandcurrentlyhastaxaudits inprogresswithanumberoftaxauthoritiestheirshascompleteditsauditforthetaxyearsthroughhowever therearealimitednumberofissuesremainingopenforpriortaxyearsgoingbacktoinothermajorjurisdictions wherethecompanyconductsbusinesstheyearsremainopengenerallybacktotheyearthecompanybelievesit ispossiblethatauditsmaybecompletedbytaxauthoritiesinsomejurisdictionsoverthenexttwelvemonthshoweverthe companyisnotabletoprovideareasonablyreliableestimateofthetimingofanyotherfuturetaxpaymentsrelatingto uncertaintaxpositions thecompanyclassifiesliabilitiesforunrecognizedtaxbenefitsandrelatedinterestandpenaltiesaslongtermliabilities interestexpenseandpenaltiesrelatedtounrecognizedtaxbenefitsareclassifiedasincometaxexpensethecompany recognizedaftertaxinterestexpenseofmillionmillionandmillioninandrespectively thetotalamountofaccruedinterestwasmillionandmillioninandrespectively employeerelatedobligations attheendofandemployeerelatedobligationsrecordedontheconsolidatedbalancesheetswere dollarsinmillions pensionbenefits postretirementbenefits postemploymentbenefits deferredcompensation totalemployeeobligations lesscurrentbenefitspayable employeerelatedobligationsnoncurrent prepaidemployeerelatedobligationsofmillionandmillionforandrespectivelyareincludedin otherassetsontheconsolidatedbalancesheets pensionsandotherbenefitplans thecompanysponsorsvariousretirementandpensionplansincludingdefinedbenefitdefinedcontributionand terminationindemnityplanswhichcovermostemployeesworldwidethecompanyalsoprovidespostretirement benefitsprimarilyhealthcaretoalleligibleusretiredemployeesandtheirdependents manyinternationalemployeesarecoveredbygovernmentsponsoredprogramsandthecosttothecompanyisnot significant retirementplanbenefitsforemployeeshiredbeforejanuaryareprimarilybasedontheemployeescompensation duringthelastthreetofiveyearsbeforeretirementandthenumberofyearsofserviceinthecompanyannounced thattheusdefinedbenefitplanwasamendedtoadoptanewbenefitformulaeffectiveforemployeeshiredonorafter januarythebenefitsarecalculatedusinganewformulabasedonemployeecompensationovertotalyearsof serviceinternationalsubsidiarieshaveplansunderwhichfundsaredepositedwithtrusteesannuitiesarepurchased undergroupcontractsorreservesareprovided thecompanydoesnotfundretireehealthcarebenefitsinadvanceandhastherighttomodifytheseplansinthefuture thecompanyusesthedateofitsconsolidatedfinancialstatementsdecemberanddecember respectivelyasthemeasurementdateforallusandinternationalretirementandotherbenefitplans johnsonjohnsonannualreportnetperiodicbenefitcostsforthecompanysdefinedbenefitretirementplansandotherbenefitplansforand includethefollowingcomponents retirementplans otherbenefitplans dollarsinmillions servicecost interestcost expectedreturnonplanassets amortizationofpriorservicecostcredit amortizationofnettransitionobligation recognizedactuariallosses curtailmentsandsettlements netperiodicbenefitcost amountsexpectedtoberecognizedinnetperiodicbenefitcostinthecomingyearforthecompanysdefinedbenefit retirementplansandotherpostretirementplans dollarsinmillions amortizationofnettransitionobligation amortizationofnetactuariallosses amortizationofpriorservicecredit unrecognizedgainsandlossesfortheuspensionplansareamortizedovertheaverageremainingfutureserviceforeach planforplanswithnoactiveemployeestheyareamortizedovertheaveragelifeexpectancytheamortizationofgains andlossesfortheotherusbenefitplansisdeterminedbyusingacorridorofthegreaterofthemarketvalueof assetsortheprojectedbenefitobligationtotalunamortizedgainsandlossesinexcessofthecorridorareamortizedover theaverageremainingfutureservice priorservicecostsbenefitsfortheuspensionplansareamortizedovertheremainingfutureserviceofplanparticipants atthetimeoftheplanamendmentpriorservicecostbenefitfortheotherusbenefitplansisamortizedovertheaverage remainingservicetofulleligibilityageofplanparticipantsatthetimeoftheplanamendment theweightedaverageassumptionsinthefollowingtablerepresenttheratesusedtodeveloptheactuarialpresentvalue ofprojectedbenefitobligationfortheyearlistedandalsothenetperiodicbenefitcostforthefollowingyear retirementplans otherbenefitplans worldwidebenefitplans discountrate expectedlongtermrateofreturnonplanassets rateofincreaseincompensationlevels thecompanysdiscountratesaredeterminedbyconsideringcurrentyieldcurvesrepresentinghighqualitylongterm fixedincomeinstrumentstheresultingdiscountratesareconsistentwiththedurationofplanliabilities theexpectedratesofreturnonplanassetassumptionsrepresentthecompanysassessmentoflongtermreturnson diversifiedinvestmentportfoliosgloballytheassessmentisdeterminedusingprojectionsfromexternalfinancialsources longtermhistoricalaveragesactualreturnsbyassetclassandthevariousassetclassallocationsbymarket formeasurementofusretirementbenefitobligationsthemortalityassumptionwasupdatedtoanewlyestablished mortalitytableresultinginanincreasetotheprojectedbenefitobligation thefollowingtabledisplaystheassumedhealthcarecosttrendratesforallindividuals healthcareplans healthcarecosttrendrateassumedfornextyear ratetowhichthecosttrendrateisassumedtodeclineultimatetrend yeartheratereachestheultimatetrendrate johnsonjohnsonannualreport aonepercentagepointchangeinassumedhealthcarecosttrendrateswouldhavethefollowingeffect onepercentage onepercentage dollarsinmillions pointincrease pointdecrease healthcareplans totalinterestandservicecost postretirementbenefitobligation thefollowingtablesetsforthinformationrelatedtothebenefitobligationandthefairvalueofplanassetsatyearend andforthecompanysdefinedbenefitretirementplansandotherpostretirementplans otherbenefit retirementplans plans dollarsinmillions changeinbenefitobligation projectedbenefitobligationbeginningofyear servicecost interestcost planparticipantcontributions amendments actuarialgainslosses divestituresacquisitions curtailmentssettlementsrestructuring benefitspaidfromplan effectofexchangerates projectedbenefitobligationendofyear changeinplanassets planassetsatfairvaluebeginningofyear actualreturnonplanassets companycontributions planparticipantcontributions settlements divestituresacquisitions benefitspaidfromplanassets effectofexchangerates planassetsatfairvalueendofyear fundedstatusendofyear amountsrecognizedinthecompanysbalancesheetconsistofthefollowing noncurrentassets currentliabilities noncurrentliabilities totalrecognizedintheconsolidatedbalancesheetendofyear amountsrecognizedinaccumulatedothercomprehensiveincomeconsistof thefollowing netactuarialloss priorservicecostcredit unrecognizednettransitionobligation totalbeforetaxeffects accumulatedbenefitobligationsendofyear johnsonjohnsonannualreportotherbenefit retirementplans plans dollarsinmillions changesinplanassetsandbenefitobligationsrecognizedinother comprehensiveincome netperiodicbenefitcost netactuarialgainloss amortizationofnetactuarialloss priorservicecostcredit amortizationofpriorservicecostcredit effectofexchangerates totalrecognizedinothercomprehensiveincomebeforetax totalrecognizedinnetperiodicbenefitcostandothercomprehensiveincome thecompanyplanstocontinuetofunditsusqualifiedplanstocomplywiththepensionprotectionactof internationalplansarefundedinaccordancewithlocalregulationsadditionaldiscretionarycontributionsaremadewhen deemedappropriatetomeetthelongtermobligationsoftheplansforcertainplansfundingisnotacommonpracticeas fundingprovidesnoeconomicbenefitconsequentlythecompanyhasseveralpensionplansthatarenotfunded inthecompanycontributedmillionandmilliontoitsusandinternationalpensionplansrespectively thefollowingtabledisplaysthefundedstatusofthecompanysusqualifiednonqualifiedpensionplansand internationalfundedandunfundedpensionplansatdecemberanddecemberrespectively usplans internationalplans qualifiedplans nonqualifiedplans fundedplans unfundedplans dollarsinmillions planassets projectedbenefitobligation accumulatedbenefitobligation overunderfundedstatus projectedbenefitobligation accumulatedbenefitobligation planswithaccumulatedbenefitobligationsinexcessofplanassetshaveanaccumulatedbenefitobligationprojected benefitobligationandplanassetsofbillionbillionandbillionrespectivelyattheendofand billionbillionandbillionrespectivelyattheendof thefollowingtabledisplaystheprojectedfuturebenefitpaymentsfromthecompanysretirementandotherbenefitplans dollarsinmillions projectedfuturebenefitpayments retirementplans otherbenefitplans thefollowingtabledisplaystheprojectedfutureminimumcontributionstotheunfundedretirementplanstheseamounts donotincludeanydiscretionarycontributionsthatthecompanymayelecttomakeinthefuture dollarsinmillions projectedfuturecontributions eachpensionplanisoverseenbyalocalcommitteeorboardthatisresponsiblefortheoveralladministrationand investmentofthepensionplansindetermininginvestmentpoliciesstrategiesandgoalseachcommitteeorboard considersfactorsincludinglocalpensionrulesandregulationslocaltaxregulationsavailabilityofinvestmentvehicles separateaccountscommingledaccountsinsurancefundsetcfundedstatusoftheplansratioofactivestoretirees johnsonjohnsonannualreport durationofliabilitiesandotherrelevantfactorsincludingdiversificationliquidityoflocalmarketsandliquidityofbase currencyamajorityofthecompanyspensionfundsareopentonewentrantsandareexpectedtobeongoingplans permittedinvestmentsareprimarilyliquidandorlistedwithlittlerelianceonilliquidandnontraditionalinvestmentssuch ashedgefunds thecompanysretirementplanassetallocationattheendofandandtargetallocationsforareas follows percentof target planassets allocation worldwideretirementplans equitysecurities debtsecurities totalplanassets determinationoffairvalueofplanassets theplanhasanestablishedandwelldocumentedprocessfordeterminingfairvaluesfairvalueisbaseduponquoted marketpriceswhereavailableiflistedpricesorquotesarenotavailablefairvalueisbaseduponmodelsthatprimarily useasinputsmarketbasedorindependentlysourcedmarketparametersincludingyieldcurvesinterestratesvolatilities equityordebtpricesforeignexchangeratesandcreditcurves whiletheplanbelievesitsvaluationmethodsareappropriateandconsistentwithothermarketparticipantstheuseof differentmethodologiesorassumptionstodeterminethefairvalueofcertainfinancialinstrumentscouldresultinadifferent estimateoffairvalueatthereportingdate valuationhierarchy theauthoritativeliteratureestablishesathreelevelhierarchytoprioritizetheinputsusedinmeasuringfairvaluethelevels withinthehierarchyaredescribedinthetablebelowwithlevelhavingthehighestpriorityandlevelhavingthelowest afinancialinstrumentscategorizationwithinthevaluationhierarchyisbaseduponthelowestlevelofinputthatis significanttothefairvaluemeasurement followingisadescriptionofthevaluationmethodologiesusedfortheinvestmentsmeasuredatfairvalue shortterminvestmentscashandquotedshortterminstrumentsarevaluedattheclosingpriceortheamountheld ondepositbythecustodianbankotherinvestmentsarethroughinvestmentvehiclesvaluedusingthenetassetvalue navprovidedbytheadministratorofthefundthenavisbasedonthevalueoftheunderlyingassetsownedbythe fundminusitsliabilitiesandthendividedbythenumberofsharesoutstandingthenavisaquotedpriceinamarket thatisnotactiveandclassifiedaslevel governmentandagencysecuritiesalimitednumberoftheseinvestmentsarevaluedattheclosingpricereportedon themajormarketonwhichtheindividualsecuritiesaretradedwherequotedpricesareavailableinanactivemarket theinvestmentsareclassifiedwithinlevelofthevaluationhierarchyifquotedmarketpricesarenotavailableforthe specificsecuritythenfairvaluesareestimatedbyusingpricingmodelsquotedpricesofsecuritieswithsimilar characteristicsordiscountedcashflowswhenquotedmarketpricesforasecurityarenotavailableinanactivemarket theyareclassifiedaslevel debtinstrumentsalimitednumberoftheseinvestmentsarevaluedattheclosingpricereportedonthemajormarket onwhichtheindividualsecuritiesaretradedwherequotedpricesareavailableinanactivemarkettheinvestmentsare classifiedaslevelifquotedmarketpricesarenotavailableforthespecificsecuritythenfairvaluesareestimatedby usingpricingmodelsquotedpricesofsecuritieswithsimilarcharacteristicsordiscountedcashflowsandareclassified aslevelleveldebtinstrumentsarepricedbasedonunobservableinputs equitysecuritiescommonstocksarevaluedattheclosingpricereportedonthemajormarketonwhichtheindividual securitiesaretradedsubstantiallyallcommonstockisclassifiedwithinlevelofthevaluationhierarchy commingledfundstheseinvestmentvehiclesarevaluedusingthenavprovidedbythefundadministratorthenav isbasedonthevalueoftheunderlyingassetsownedbythefundminusitsliabilitiesandthendividedbythenumberof sharesoutstandingassetsinthelevelcategoryhaveaquotedmarketpriceinamarketthatisnotactive johnsonjohnsonannualreport insurancecontractstheinstrumentsareissuedbyinsurancecompaniesthefairvalueisbasedonnegotiatedvalue andtheunderlyinginvestmentsheldinseparateaccountportfoliosaswellasconsideringthecreditworthinessofthe issuertheunderlyinginvestmentsaregovernmentassetbackedandfixedincomesecuritiesingeneralinsurance contractsareclassifiedaslevelastherearenoquotedpricesnorotherobservableinputsforpricing otherassetsotherassetsarerepresentedprimarilybylimitedpartnershipsandrealestateinvestmentsaswellas commercialloansandcommercialmortgagesthatarenotclassifiedascorporatedebtotherassetsthatareexchange listedandactivelytradedareclassifiedaslevelwhileinactivelytradedassetsareclassifiedaslevelmostlimited partnershipsrepresentinvestmentsinprivateequityandsimilarfundsthatarevaluedbythegeneralpartnerscertainof theselimitedpartnershipsaswellasanyotherassetsvaluedusingunobservableinputsareclassifiedaslevel thefollowingtablesetsforththeretirementplansinvestmentsmeasuredatfairvalueasofdecemberand december quotedprices significant inactive significant marketsfor observable unobservable identicalassets inputs inputs level level level totalassets dollarsinmillions shortterminvestmentfunds governmentandagencysecurities debtinstruments equitysecurities commingledfunds insurancecontracts otherassets investmentsatfairvalue thecompanysotherbenefitplansareunfundedexceptforuscommingledfundslevelofmillionand millionatdecemberanddecemberrespectivelyandmillionandmillionofusshortterm investmentfundslevelatdecemberanddecemberrespectively thefairvalueofjohnsonjohnsoncommonstockdirectlyheldinplanassetswasmillionoftotalplan assetsatdecemberandmillionoftotalplanassetsatdecember levelgainsandlosses thetablebelowsetsforthasummaryofchangesinthefairvalueoftheplanslevelassetsfortheyearsended decemberanddecember debt equity commingled insurance total dollarsinmillions instruments securities funds contracts assets level balancedecember realizedgainslosses unrealizedgainslosses purchasessalesissuancesandsettlementsnet balancedecember realizedgainslosses unrealizedgainslosses purchasessalesissuancesandsettlementsnet transfersinoutandexchangeratechanges balancedecember johnsonjohnsonannualreport savingsplan thecompanyhasvoluntaryksavingsplansdesignedtoenhancetheexistingretirementprogramscoveringeligible employeesthecompanymatchesapercentageofeachemployeescontributionsconsistentwiththeprovisionsofthe planforwhichhesheiseligibletotalcompanymatchingcontributionstotheplansweremillionmillionand millioninandrespectively capitalandtreasurystock changesintreasurystockwere treasurystock amountsinmillionsexcepttreasurystocksharesinthousands shares amount balanceatjanuary employeecompensationandstockoptionplans issuanceofcommonstockassociatedwiththeacquisitionofsynthesinc repurchaseofcommonstock balanceatdecember employeecompensationandstockoptionplans repurchaseofcommonstock balanceatdecember employeecompensationandstockoptionplans repurchaseofcommonstock balanceatdecember includesrepurchaseofcommonstockassociatedwiththeacquisitionofsynthesinc aggregatesharesofcommonstockissuedwereapproximatelysharesattheendofand cashdividendspaidwerepershareincomparedwithdividendsofpershareinandper sharein onjulythecompanyannouncedthatitsboardofdirectorsapprovedasharerepurchaseprogramauthorizing thecompanytopurchaseuptobillionofthecompanyssharesofcommonstockasofdecember billionhasbeenrepurchasedundertheprogramsharerepurchaseswilltakeplaceontheopenmarketfromtimetotime basedonmarketconditionstherepurchaseprogramhasnotimelimitandmaybesuspendedforperiodsordiscontinued atanytimeanysharesacquiredwillbeavailableforgeneralcorporatepurposesthecompanyintendstofinancethe sharerepurchaseprogramthroughavailablecash accumulatedothercomprehensiveincome componentsofothercomprehensiveincomelossconsistofthefollowing gain total gain loss accumulated foreign loss employee currency benefit derivatives comprehensive dollarsinmillions translation securities plans hedges incomeloss january netchanges december netchanges december netchanges december johnsonjohnsonannualreportamountsinaccumulatedothercomprehensiveincomearepresentednetoftherelatedtaximpactforeigncurrency translationisnotadjustedforincometaxeswhereitrelatestopermanentinvestmentsininternationalsubsidiariesfor additionaldetailsoncomprehensiveincomeseetheconsolidatedstatementsofcomprehensiveincome detailsonreclassificationsoutofaccumulatedothercomprehensiveincome gainlossonsecuritiesreclassificationsreleasedtootherincomeexpensenet employeebenefitplansreclassificationsareincludedinnetperiodicbenefitcostseenoteforadditional details gainlossonderivativeshedgesreclassificationstoearningsarerecordedinthesameaccountasthe hedgedtransactionseenoteforadditionaldetails internationalcurrencytranslation fortranslationofitssubsidiariesoperatinginnonusdollarcurrenciesthecompanyhasdeterminedthatthelocal currenciesofitsinternationalsubsidiariesarethefunctionalcurrenciesexceptthoseinhighlyinflationaryeconomieswhich aredefinedasthosewhichhavehadcompoundcumulativeratesofinflationoformoreduringthepastthreeyears orwhereasubstantialportionofitscashflowsarenotinthelocalcurrency inconsolidatinginternationalsubsidiariesbalancesheetcurrencyeffectsarerecordedasacomponentofaccumulated othercomprehensiveincomethisequityaccountincludestheresultsoftranslatingcertainbalancesheetassetsand liabilitiesatcurrentexchangeratesandsomeaccountsathistoricalratesexceptforthoselocatedinhighlyinflationary economiesthetranslationofbalancesheetaccountsforhighlyinflationaryeconomiesarereflectedintheoperating results arollforwardofthechangesduringandforforeigncurrencytranslationadjustmentsisincludedin note netcurrencytransactiongainsandlossesincludedinotherincomeexpensewerelossesofmillionmillion andmillioninandrespectively earningspershare thefollowingisareconciliationofbasicnetearningspersharetodilutednetearningspershareforthefiscalyearsended decemberdecemberanddecember inmillionsexceptpershareamounts basicnetearningspershareattributabletojohnsonjohnson averagesharesoutstandingbasic potentialsharesexercisableunderstockoptionplans lesssharesrepurchasedundertreasurystockmethod convertibledebtshares acceleratedsharerepurchaseprogram adjustedaveragesharesoutstandingdiluted dilutednetearningspershareattributabletojohnsonjohnson thedilutednetearningspersharecalculationincludedthedilutiveeffectofconvertibledebtthatisoffsetbytherelated reductionininterestexpenseofmillionaftertaxforandmillionforyearsand thedilutedearningspersharecalculationforandincludedallsharesrelatedtostockoptionsastheexercise priceofalloptionswaslessthantheaveragemarketvalueofthecompanysstockdilutednetearningspersharefor excludedmillionsharesrelatedtostockoptionsastheexercisepriceoftheseoptionswasgreaterthantheir averagemarketvaluewhichwouldresultinanantidilutiveeffectondilutedearningspershare thedilutedearningspersharecalculationforthefiscalyearsendeddecemberanddecember includedthedilutiveeffectofmillionsharesandmillionsharesrespectivelyrelatedtotheacceleratedshare repurchaseprogramassociatedwiththeacquisitionofsynthesincseenotetotheconsolidatedfinancial statementsforadditionaldetails johnsonjohnsonannualreport rentalexpenseandleasecommitments rentalsofspacevehiclesmanufacturingequipmentandofficeanddataprocessingequipmentunderoperatingleases wereapproximatelymillionmillionandmillioninandrespectively theapproximateminimumrentalpaymentsrequiredunderoperatingleasesthathaveinitialorremainingnoncancelable leasetermsinexcessofoneyearatdecemberare dollarsinmillions total commitmentsundercapitalleasesarenotsignificant commonstockstockoptionplansandstockcompensationagreements atdecemberthecompanyhadstockbasedcompensationplansthesharesoutstandingareforcontracts underthecompanysstockoptionplanthelongtermincentiveplanandthelongtermincentive planthelongtermincentiveplanexpiredaprilalloptionsandrestrictedsharesgrantedsubsequentto thatdatewereunderthelongtermincentiveplanunderthelongtermincentiveplanthecompanymay issueuptomillionsharesofcommonstockplusanysharescanceledexpiredforfeitedornotissuedfromthe longtermincentiveplansubsequenttoaprilsharesavailableforfuturegrantsunderthelongterm incentiveplanweremillionattheendof thecompensationcostthathasbeenchargedagainstincomefortheseplanswasmillionmillionand millionforandrespectivelythetotalincometaxbenefitrecognizedintheincomestatementfor sharebasedcompensationcostswasmillionmillionandmillionforand respectivelythetotalunrecognizedcompensationcostwasmillionmillionandmillionfor andrespectivelytheweightedaverageperiodforthiscosttoberecognizedwasyearsyearsand yearsforandrespectivelysharebasedcompensationcostscapitalizedaspartofinventorywere insignificantinallperiods thecompanysettlesemployeebenefitequityissuanceswithtreasurysharestreasurysharesarereplenishedthroughout theyearforthenumberofsharesusedtosettleemployeebenefitequityissuances stockoptions stockoptionsexpireyearsfromthedateofgrantandvestoverserviceperiodsthatrangefrommonthstoyearsall optionsaregrantedattheaverageofthehighandlowpricesofthecompanyscommonstockonthenewyorkstock exchangeonthedateofgrant thefairvalueofeachoptionawardwasestimatedonthedateofgrantusingtheblackscholesoptionvaluationmodel thatusestheassumptionsnotedinthefollowingtableexpectedvolatilityrepresentsablendedrateofyeardaily historicalaveragevolatilityrateandaweekaverageimpliedvolatilityratebasedonatthemoneytradedjohnson johnsonoptionswithalifeofyearshistoricaldataisusedtodeterminetheexpectedlifeoftheoptiontheriskfreerate wasbasedontheustreasuryyieldcurveineffectatthetimeofgrant theaveragefairvalueofoptionsgrantedwasandinandrespectivelythefair valuewasestimatedbasedontheweightedaverageassumptionsof riskfreerate expectedvolatility expectedlifeinyears dividendyield johnsonjohnsonannualreportasummaryofoptionactivityundertheplanasofdecemberdecemberanddecemberand changesduringtheyearsendingonthosedatesispresentedbelow aggregate intrinsic weighted value outstanding average dollarsin sharesinthousands shares exerciseprice millions sharesatjanuary optionsgranted optionsexercised optionscanceledforfeited sharesatdecember optionsgranted optionsexercised optionscanceledforfeited sharesatdecember optionsgranted optionsexercised optionscanceledforfeited sharesatdecember thetotalintrinsicvalueofoptionsexercisedwasmillionmillionandmillioninand respectively thefollowingtablesummarizesstockoptionsoutstandingandexercisableatdecember sharesinthousands outstanding exercisable average average average exercise exercise exercisepricerange options life price options price averagecontractualliferemaininginyears stockoptionsoutstandingatdecemberanddecemberwereandanaveragelifeofyears andandanaveragelifeofyearsrespectivelystockoptionsexercisableatdecemberand decemberwereatanaveragepriceofandatanaveragepriceofrespectively restrictedshareunitsandperformance shareunits thecompanygrantsrestrictedshareunitswhichvestoverserviceperiodsthatrangefrommonthstoyearsthe companyalsograntsperformanceshareunitswhicharepaidinsharesofjohnsonjohnsoncommonstockafterthe endofathreeyearperformanceperiodwhetheranyperformanceshareunitsvestandtheamountthatdoesvestistied tothecompletionofserviceperiodsthatrangefrommonthstoyearsandtheachievementoverathreeyearperiodof threeequallyweightedgoalsthatdirectlyalignwithorhelpdrivelongtermtotalshareholderreturnsalesadjusted operationalearningspershareandrelativetotalshareholderreturnthenumberofsharesactuallyearnedattheendof thethreeyearperiodwillvarybasedonlyonactualperformancefromtoofthetargetnumberofperformance shareunitsgranted johnsonjohnsonannualreport asummaryoftherestrictedshareunitsandperformanceshareunitsactivityundertheplansasofdecemberis presentedbelow outstanding outstanding restricted performance sharesinthousands shareunits shareunits sharesatjanuary granted issued canceledforfeited sharesatdecember granted issued canceledforfeited sharesatdecember granted issued canceledforfeited sharesatdecember theaveragefairvalueoftherestrictedshareunitsgrantedwasandinand respectivelyusingthefairmarketvalueatthedateofgrantthefairvalueofrestrictedshareunitswasdiscountedfor dividendswhicharenotpaidontherestrictedshareunitsduringthevestingperiodthefairvalueofrestrictedshareunits issuedwasmillionmillionandmillioninandrespectively theweightedaveragefairvalueoftheperformanceshareunitsgrantedwasandin andcalculatedusingtheweightedaveragefairmarketvalueforeachofthethreecomponentgoalsatthedateof grant thefairvaluesforthesalesandearningspersharegoalsofeachperformanceshareunitwereestimatedonthedateof grantusingthefairmarketvalueofthesharesatthetimeoftheawarddiscountedfordividendswhicharenotpaidonthe performanceshareunitsduringthevestingperiodthefairvaluefortherelativetotalshareholderreturngoalofeach performanceshareunitwasestimatedonthedateofgrantusingthemontecarlovaluationmodelthefairvalueof performanceshareunitsissuedinwasmillionduetoacceleratedvestinginaccordancewiththeplan documentnoperformanceshareunitsvestedinand segmentsofbusinessandgeographicareas salestocustomers dollarsinmillions consumer unitedstates international total pharmaceutical unitedstates international total medicaldevices unitedstates international total worldwidetotal johnsonjohnsonannualreportpretaxprofit identifiableassets dollarsinmillions consumer pharmaceutical medicaldevices total lessexpensenotallocatedtosegments generalcorporate worldwidetotal additionstoproperty depreciationand plantequipment amortization dollarsinmillions consumer pharmaceutical medicaldevices segmentstotal generalcorporate worldwidetotal salestocustomers longlivedassets dollarsinmillions unitedstates europe westernhemisphereexcludingus asiapacificafrica segmentstotal generalcorporate othernonlonglivedassets worldwidetotal seenoteforadescriptionofthesegmentsinwhichthecompanyoperates exportsalesarenotsignificantinthecompanyhadonewholesalerdistributingproductsforallthreesegmentsthatrepresented approximatelyofthetotalconsolidatedrevenuesinandthecompanydidnothaveacustomerthatrepresented oftotalrevenues amountsnotallocatedtosegmentsincludeinterestincomeexpensenoncontrollinginterestsandgeneralcorporateincome expenseincludescurrencyrelatedexpenseofbillionassociatedwiththeacquisitionofsynthesincin generalcorporateincludescashcashequivalentsandmarketablesecurities includesnetlitigationexpenseofmillioncomprisedofmillionmillionandmillioninthemedicaldevices pharmaceuticalandconsumersegmentsrespectivelyincludesmillionofinprocessresearchanddevelopmentexpense comprisedofmillionandmillioninthepharmaceuticalandmedicaldevicessegmentsrespectivelythemedicaldevices segmentincludesanetgainofmillionfromthedivestitureoftheorthoclinicaldiagnosticsbusinesssynthesintegration costsofmillionandmillionexpenseforthecostassociatedwiththedepuyasrhipprogramincludesanadditional yearofthebrandedprescriptiondrugfeeofmillioninthepharmaceuticalsegment includesmillionofnetlitigationexpensecomprisedofmillionandmillioninthemedicaldevicesand pharmaceuticalsegmentsrespectivelyincludesmillionofsynthesintegrationtransactioncostsinthemedicaldevices segmentincludesmillionofinprocessresearchanddevelopmentexpensecomprisedofmillionandmillioninthe pharmaceuticalandmedicaldevicessegmentsrespectivelythemedicaldevicessegmentalsoincludesmillionexpensefor thecostassociatedwiththedepuyasrtmhipprogramincludesmillionofincomerelatedtootheradjustmentscomprisedof millionandmillionintheconsumerandpharmaceuticalsegmentsrespectively includesmillionofnetlitigationexpensecomprisedofmillionandmillioninthepharmaceuticalandmedical devicessegmentsrespectivelyincludesmillionofinprocessresearchanddevelopmentexpensecomprisedof millionandmillioninthepharmaceuticalandmedicaldevicessegmentsrespectivelyincludesmillionofsynthes integrationtransactioncostsinthemedicaldevicessegmentincludesmillionofassetwritedownsandotheradjustments comprisedofmillionmillionandmillioninthepharmaceuticalconsumerandmedicaldevicessegments respectivelythemedicaldevicessegmentalsoincludesmillionexpenseforthecostassociatedwiththedepuyasrhip program longlivedassetsincludepropertyplantandequipmentnetforandofand respectivelyandintangibleassetsandgoodwillnetforandofandrespectively johnsonjohnsonannualreport selectedquarterlyfinancialdataunaudited selectedunauditedquarterlyfinancialdatafortheyearsandaresummarizedbelow dollarsinmillionsexceptpershare first second third fourth first second third fourth data quarter quarter quarter quarter quarter quarter quarter quarter segmentsalestocustomers consumer pharmaceutical medicaldevices totalsales grossprofit earningsbeforeprovisionfortaxeson income netearningsattributabletojohnson johnson basicnetearningspershareattributable tojohnsonjohnson dilutednetearningspershare attributabletojohnsonjohnson thefirstquarterofincludessynthesintegrationcostsofmillionaftertaxmillionbeforetaxandamilliontax benefitassociatedwithconormedsystems thesecondquarterofincludeslitigationexpenseofmillionaftertaxmillionbeforetaxandsynthesintegration costsofmillionaftertaxmillionbeforetax thethirdquarterofincludesanadditionalyearofthebrandedprescriptiondrugfeeofmillionafterandbeforetax litigationexpenseofmillionaftertaxmillionbeforetaxsynthesintegrationcostsofmillionaftertaxmillion beforetaxandmillionaftertaxmillionbeforetaxforcostsassociatedwiththedepuyasrhipprogramadditionally thefiscalthirdquarterofincludesanetgainofbillionaftertaxbillionbeforetaxforthedivestitureoftheortho clinicaldiagnosticsbusiness thefourthquarterofincludeslitigationexpenseprimarilyrelatedtoproductliabilityandpatentlitigationofmillionafter taxmillionbeforetaxsynthesintegrationcostsofmillionaftertaxmillionbeforetaxandmillionaftertax millionbeforetaxfromimpairmentofinprocessresearchanddevelopment thefirstquarterofincludessynthesintegrationtransactioncostsofmillionaftertaxmillionbeforetaxandnet litigationexpenseofmillionaftertaxmillionbeforetax thesecondquarterofincludesnetlitigationexpenseofmillionaftertaxmillionbeforetaxandsynthes integrationtransactioncostsofmillionaftertaxmillionbeforetax thethirdquarterofincludesnetlitigationexpenseofmillionaftertaxmillionbeforetaxsynthesintegration transactioncostsofmillionaftertaxmillionbeforetaxandmillionaftertaxmillionbeforetaxfrom impairmentofinprocessresearchanddevelopment thefourthquarterofincludesnetlitigationexpenseofmillionaftertaxmillionbeforetaxsynthesintegration transactioncostsmillionaftertaxmillionbeforetaxmillionaftertaxmillionbeforetaxfromimpairmentof inprocessresearchanddevelopmentandmillionaftertaxmillionbeforetaxforcostsassociatedwiththedepuyasr hipprogramandamilliontaxbenefitassociatedwithsciosinc businesscombinationsanddivestitures certainbusinesseswereacquiredformillionincashandmillionofliabilitiesassumedduringthese acquisitionswereaccountedforusingtheacquisitionmethodandaccordinglyresultsofoperationshavebeenincluded inthefinancialstatementsfromtheirrespectivedatesofacquisition theacquisitionsincludedcovagenagaprivatelyheldbiopharmaceuticalcompanyspecializinginthe developmentofmultispecificproteintherapeuticsthroughthefynomabtechnologyplatformaliosbiopharmainca privatelyheldclinicalstagebiopharmaceuticalcompanyfocusedondevelopingtherapiesforviraldiseasesandthe orslelectrolytereadytodrinkbrandfromjagdaleindustriesltdtheexcessofpurchasepriceovertheestimatedfair valueoftangibleassetsacquiredamountedtomillionandhasbeenassignedtoidentifiableintangibleassets johnsonjohnsonannualreportwithanyresidualrecordedtogoodwillofthisamountapproximatelymillionhasbeenidentifiedasthevalueof iprdassociatedwiththeacquisitionsofcovagenagandaliosbiopharmaincthevalueoftheiprdwascalculated usingcashflowprojectionsdiscountedfortheinherentriskintheprojects theiprdrelatedtotheacquisitionofaliosbiopharmaincaliosofmillionisassociatedwithalioslead compoundalanorallyadministeredantiviraltherapyfortreatmentofinfantswithrespiratorysyncytialvirusrsv aprobabilityofsuccessfactorofwasusedtoreflectinherentclinicalandregulatoryriskthediscountrateapplied wastheiprdrelatedtotheacquisitionofcovagenagofmillionisassociatedwithcovagenslead compoundcovacurrentlyinphasebstudyforpsoriasisandholdingpotentialasatreatmentforabroadrangeof inflammatorydiseasesincludingrheumatoidarthritisaprobabilityofsuccessfactorofwasusedtoreflectinherent clinicalandregulatoryriskthediscountrateappliedwas certainbusinesseswereacquiredformillionincashandmillionofliabilitiesassumedduringthese acquisitionswereaccountedforusingtheacquisitionmethodandaccordinglyresultsofoperationshavebeenincluded inthefinancialstatementsfromtheirrespectivedatesofacquisition theassumedliabilitiesprimarilyrepresentthefairvalueofthecontingentconsiderationwhichmaybepayablerelatedto theacquisitionofaragonpharmaceuticalsincaspertermsoftheagreementadditionalpaymentsofuptomillion maybepaidinthefuturebasedonreachingpredeterminedmilestones theacquisitionsincludedflexiblestentingsolutionsincaleadingdeveloperofinnovativeflexibleperipheral arterialvenousandbiliarystentsshanghaielskermotherbabycoltdababycarecompanyinchinaandaragon pharmaceuticalsincaprivatelyheldpharmaceuticaldiscoveryanddevelopmentcompanyfocusedondrugstotreat hormonallydrivencancers theexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedtomillionandhas beenassignedtoidentifiableintangibleassetswithanyresidualrecordedtogoodwillofthisamountapproximately millionhasbeenidentifiedasthevalueofiprdassociatedwiththeacquisitionsofaragonpharmaceuticalsincand flexiblestentingsolutionsinc theiprdrelatedtotheacquisitionofaragonpharmaceuticalsincofmillionisassociatedwitharagons androgenreceptorantagonistprogramfortreatmentofhormonallydrivencancersthevalueoftheiprdwascalculated usingcashflowprojectionsdiscountedfortheinherentriskinsuchprojectsprobabilityofsuccessfactorsrangingfrom wereusedtoreflectinherentclinicalandregulatoryriskthediscountrateappliedwastheiprd relatedtotheacquisitionofflexiblestentingsolutionsincofmillionisassociatedwiththeapprovalforperipheral vascularindicationsincludingthesuperficialfemoralarteryindicationaprobabilityofsuccessfactorofwasused andadiscountraterangingbetweenwasapplied certainbusinesseswereacquiredformillionincashandstockandmillionofliabilitiesassumedduring theseacquisitionswereaccountedforusingtheacquisitionmethodandaccordinglyresultsofoperationshave beenincludedinthefinancialstatementsfromtheirrespectivedatesofacquisition theacquisitionsincludedsynthesincaglobaldeveloperandmanufactureroforthopaedicsdevicesguangzhou biosealbiotechcoltdadeveloperofbiologiccombinationsaddressingmoderatetoseverehemostasisangiotech pharmaceuticalsincintellectualpropertyandknowhowrelatedtothequilltmknotlesstissueclosuredevice corimmungmbhadeveloperofaphaseiitreatmentforchfcalibramedicalincadeveloperofauniquewearable threedayinsulinpatchforconvenientanddiscreetmealtimedosingforpeoplewithdiabeteswhotakemultipledaily injectionsofinsulinspectrumvisionllcafullservicedistributorofcontactlensesservingrussiawithfacilitiesinthe ukraineandkazakhstanandmarketingauthorizationstrademarksandpatentsextendingzyrtecrelatedmarketrights inaustraliaandcanada theexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedtomillionand hasbeenassignedtoidentifiableintangibleassetswithanyresidualrecordedtogoodwillofthisamountapproximately millionhasbeenidentifiedasthevalueofiprdassociatedwiththeacquisitionsofcorimmungmbhandsynthes inc theiprdrelatedtotheacquisitionofsynthesincofmillionisassociatedwithorthopaedicdevicesandtheiprd associatedwithcorimmunofmillionisrelatedtoachftreatmenttheseiprdvalueswerecalculatedusingthe cashflowprojectionsdiscountedfortheriskinherentinsuchprojectssynthesinchadaprobabilityofsuccessfactorof discountedusingaratecorimmunhadaprobabilityofsuccessfactorofdiscountedusingarate duringthecompanyrecordedachargeofbillionfortheimpairmentoftheinprocessresearchand developmentassociatedwithcorimmun johnsonjohnsonannualreport duringthefiscalsecondquarterofthecompanycompletedtheacquisitionofsynthesincaglobaldeveloperand manufactureroforthopaedicsdevicesforapurchasepriceofbillionincashandstockthenetacquisitioncostof thetransactionwasbillionbasedoncashonhandatclosingofbillion underthetermsoftheagreementeachshareofsynthesinccommonstockwasexchangedforchfincashand sharesofjohnsonjohnsoncommonstockbasedonthecalculatedexchangeratiotheexchangeratiowas calculatedonjuneandbasedontherelevantexchangerateandclosingpriceofjohnsonjohnsoncommon stockonthatdatethetotalfairvalueofconsiderationtransferredwasbillionwhentheacquisitionwascompleted onjunebasedontherelevantexchangerateandclosingpriceofjohnsonjohnsoncommonstockonthat datethetotalfairvalueoftheconsiderationtransferredwasbillionjanssenpharmaceuticalacompanyorganized underthelawsofirelandandawhollyownedsubsidiaryofjohnsonjohnsonusedcashonhandtosatisfythecash portionofthemergerconsideration thestockportionofthemergerconsiderationconsistedofsharesofjohnsonjohnsoncommonstockpurchasedby janssenpharmaceuticalfromtwobankspursuanttotwoacceleratedsharerepurchaseasragreementsdatedjune onjunejanssenpharmaceuticalpurchasedanaggregateofapproximatelymillionsharesof johnsonjohnsoncommonstockataninitialpurchasepriceofbillionundertheasragreementswithallofthe sharesdeliveredtojanssenpharmaceuticalonjuneduringthefiscalthirdquarterofthecompany settledtheremainingliabilitiesundertheasragreementsforbillionincashwhichwasrecordedasareductionto equity inadditionwhilethecompanybelievesthatthetransactionsundereachasragreementandaseriesofrelatedinternal transactionswereconsummatedinataxefficientmannerinaccordancewithapplicablelawitispossiblethattheinternal revenueservicecouldassertoneormorecontrarypositionstochallengethetransactionsfromataxperspectiveif challengedanamountuptothetotalpurchasepriceforthesynthessharescouldbetreatedassubjecttoapplicableus taxatapproximatelythestatutoryratetothecompanyplusinterest thefollowingtablesummarizestheconsiderationtransferredtoacquiresynthesincvaluedontheacquisitiondateof june dollarsinmillions cashmultiplychfbysharesofsynthescommonstockoutstandingbytheexchangeratea commonstockmultiplybysharesofsynthescommonstockoutstandingbyjjstockpriceb totalfairvalueofconsiderationtransferred synthescommonstockoutstandingofmillionsharesasoftheacquisitiondateandchfusdexchangerateof b johnsonjohnsonclosingstockpriceonthenewyorkstockexchangeasofacquisitiondateofpershare thecompanycontinuestoexecutetheintegrationplanstocombinebusinessessalesorganizationssystemsand locationsasaresultofwhichthecompanyhasandwillcontinuetoincurintegrationcosts theoperatingresultsofsyntheswerereportedinthecompanysfinancialstatementsbeginningonjunetotal salesandnetearningsforsynthesforthefiscalyearendeddecemberweremillionandmillion respectively thefollowingtableprovidesproformaresultsofoperationsforthefiscalyearendeddecemberasifsynthes inchadbeenacquiredasofthebeginningoftheperiodpresentedtheproformaresultsincludetheeffectofdivestitures andcertainpurchaseaccountingadjustmentssuchastheestimatedchangesindepreciationandamortizationexpenseon theacquiredtangibleandintangibleassetshoweverproformaresultsdonotincludeanyanticipatedcostsavingsor othereffectsoftheintegrationofsynthesincaccordinglysuchamountsarenotnecessarilyindicativeoftheresultsifthe acquisitionhadoccurredonthedatesindicatedorwhichmayoccurinthefuture unauditedproforma consolidatedresults dollarsinmillionsexceptpershareamounts netsales netearningsattributabletojohnsonjohnson dilutednetearningspershareattributabletojohnsonjohnson johnsonjohnsonannualreportthecompanyrecordedacquisitionrelatedcostsbeforetaxofmillionmillionandmillionin andrespectivelywhichwererecordedinotherincomeexpenseandcostofproductssold inconnectionwiththesynthesacquisitiondepuyorthopaedicsincagreedtodivestcertainrightsandassetsrelatedto itstraumabusinesstobiometincandcompletedtheinitialclosingforthistransactioninthefiscalsecondquarterof includingthosecountriesthatrepresentedthemajorityofsalesasofdecemberthetransactionhad closedworldwide withtheexceptionofthesynthesincacquisitionsupplementalproformainformationforandin accordancewithusgaapstandardsrelatedtobusinesscombinationsandgoodwillandotherintangibleassetsisnot providedastheimpactoftheaforementionedacquisitionsdidnothaveamaterialeffectonthecompanysresultsof operationscashflowsorfinancialposition duringthecompanydivestituresincludedtheorthoclinicaldiagnosticsbusinesstothecarlylegrouptheky brandtoreckittbenckisergroupplcintheusandcertainothermarketsandthebenecolbrandtoraisioplcin thegainsonthedivestituresofbusinesseswereapproximatelybillionthecompanycompletedthedivestiture ofitsorthoclinicaldiagnosticsbusinesstothecarlylegroupforapproximatelybillionandthecompanyrecorded apretaxnetgainofapproximatelybillionorthoclinicaldiagnosticsresultsareincludedinthecompanysmedical devicessegmentpretaxprofitasofdecembertheassetsclassifiedasheldforsalerelatingtotheortho clinicaldiagnosticscompaniesincountriesthathavenotcompletelyclosedduetolocalregulatoryrequirementswere millionofinventoryclassifiedasprepaidexpensesandotherontheconsolidatedbalancesheetandmillionof propertyplantandequipmentclassifiedasotherassetsontheconsolidatedbalancesheet duringthecompanydivestituresincludedwomenssanitaryprotectionproductsintheuscanadaandthe caribbeantoenergizerholdingsincrolaidstochattemincdoribaxrightstoshionogiandthesaleofcertain consumerbrandsandcertainpharmaceuticalproductsinthegainsonthedivestituresofbusinesseswere billionduringthecompanydivestituresincludedbystolicnebivololiprightstoforestlaboratoriesincthe traumabusinessofdepuyorthopaedicsinctobiometincthetherakosbusinesstoanaffiliateofgorescapital partnersiiilpthesaleofcertainconsumerbrandsandtherhogambusinessinthegainsonthedivestitures ofbusinesseswerebillion injanuaryadefinitiveagreementwasannouncedtodivesttheuslicenserightstonucyntatapentadol nucyntaertapentadolextendedreleasetabletsandnucyntatapentadoloralsolutionforapproximately billionthetransactionisexpectedtocloseinthefiscalsecondquarterofsubjecttocustomaryclosingconditions andcompletionoffinancing legalproceedings johnsonjohnsonandcertainofitssubsidiariesareinvolvedinvariouslawsuitsandclaimsregardingproductliability intellectualpropertycommercialandothermattersgovernmentalinvestigationsandotherlegalproceedingsthatarise fromtimetotimeintheordinarycourseoftheirbusiness thecompanyrecordsaccrualsforsuchcontingencieswhenitisprobablethataliabilitywillbeincurredandtheamount ofthelosscanbereasonablyestimatedasofdecemberthecompanyhasdeterminedthattheliabilities associatedwithcertainlitigationmattersareprobableandcanbereasonablyestimatedthecompanyhasaccruedfor thesemattersandwillcontinuetomonitoreachrelatedlegalissueandadjustaccrualsasmightbewarrantedbasedon newinformationandfurtherdevelopmentsinaccordancewithascfortheseandotherlitigationand regulatorymattersdiscussedbelowforwhichalossisprobableorreasonablypossiblethecompanyisunableto determineanestimateofthepossiblelossorrangeoflossbeyondtheamountsalreadyaccruedthesematterscanbe affectedbyvariousfactorsincludingwhetherdamagessoughtintheproceedingsareunsubstantiatedorindeterminate scientificandlegaldiscoveryhasnotcommencedorisnotcompleteproceedingsareinearlystagesmatterspresent legaluncertaintiestherearesignificantfactsindisputeortherearenumerouspartiesinvolvedamountsaccruedforlegal contingenciesoftenresultfromacomplexseriesofjudgmentsaboutfutureeventsanduncertaintiesthatrelyheavilyon estimatesandassumptions inthecompanysopinionbasedonitsexaminationofthesemattersitsexperiencetodateanddiscussionswithcounsel theultimateoutcomeoflegalproceedingsnetofliabilitiesaccruedinthecompanysbalancesheetisnotexpectedto haveamaterialadverseeffectonthecompanysfinancialpositionhowevertheresolutioninanyreportingperiodofone ormoreofthesematterseitheraloneorintheaggregatemayhaveamaterialadverseeffectonthecompanysresultsof operationsandcashflowsforthatperiod johnsonjohnsonannualreport productliability certainsubsidiariesofjohnsonjohnsonareinvolvedinnumerousproductliabilityclaimsandlawsuitsinvolvingmultiple productsclaimantsinthesecasesseeksubstantialcompensatoryandwhereavailablepunitivedamageswhilethese subsidiariesbelievetheyhavesubstantialdefensesitisnotfeasibletopredicttheultimateoutcomeoflitigationthe companyhasestablishedproductliabilityaccrualsincompliancewithascbasedoncurrentlyavailable informationwhichinsomecasesmaybelimitedinadditionproductliabilityaccrualscanrepresentprojectedproduct liabilityforthousandsofclaimsaroundtheworldeachindifferentlitigationenvironmentsandwithdifferentfactpatterns changestotheaccrualsmayberequiredinthefutureasadditionalinformationbecomesavailable themostsignificantofthesecasesincludethedepuyasrxlacetabularsystemanddepuyasrhipresurfacing systemthepinnacleacetabularcupsystempelvicmeshesandrisperdalasofdecemberinthe ustherewereapproximatelyplaintiffswithdirectclaimsinpendinglawsuitsregardinginjuriesallegedlydueto theasrxlacetabularsystemanddepuyasrhipresurfacingsystemwithrespecttothepinnacle acetabularcupsystemwithrespecttopelvicmeshesandwithrespecttorisperdal inaugustdepuyorthopaedicsincdepuyannouncedaworldwidevoluntaryrecallofitsasrxlacetabular systemanddepuyasrhipresurfacingsystemusedinhipreplacementsurgeryclaimsforpersonalinjuryhavebeen madeagainstdepuyandjohnsonjohnsonthenumberofpendinglawsuitsisexpectedtofluctuateascertainlawsuits aresettledordismissedandadditionallawsuitsarefiledcasesfiledinfederalcourtsintheunitedstateshavebeen organizedasamultidistrictlitigationintheunitedstatesdistrictcourtforthenortherndistrictofohiolitigationhas alsobeenfiledincountriesoutsideoftheunitedstatesprimarilyintheunitedkingdomcanadaandaustraliain novemberdepuyreachedanagreementwithacourtappointedcommitteeoflawyersrepresentingasrhip systemplaintiffstoestablishaprogramtosettleclaimswitheligibleasrhippatientsintheunitedstateswhohad surgerytoreplacetheirasrhipsknownasrevisionsurgeryasofaugustthissettlementcovered approximatelypatientsinfebruarydepuyreachedanadditionalagreementsubjecttofinaldocumentation whichwouldeffectivelyextendtheexistingsettlementprogramtoasrhippatientswhohadrevisionsurgeriesafter augustandpriortofebruarythissecondagreementisestimatedtocoverapproximately additionalpatientstheestimatedcostoftheseagreementsiscoveredbyexistingaccrualsthissettlementprogramis expectedtobringtoaclosesignificantasrhiplitigationactivityintheushowevermanylawsuitsintheuswill remainandthesettlementprogramdoesnotaddresslitigationoutsideoftheusthecompanycontinuestoreceive informationwithrespecttopotentialcostsassociatedwiththisrecallonaworldwidebasisthecompanyhasestablished accrualsforthecostsassociatedwiththedepuyasrhipprogramandrelatedproductliabilitylitigationupdatesto theseaccrualsmayberequiredinthefutureasadditionalinformationbecomesavailable claimsforpersonalinjuryhavealsobeenmadeagainstdepuyandjohnsonjohnsonrelatingtodepuyspinnacle acetabularcupsystemusedinhipreplacementsurgerythenumberofpendingproductliabilitylawsuitscontinuesto increaseandthecompanycontinuestoreceiveinformationwithrespecttopotentialcostsandtheanticipatednumberof casescasesfiledinfederalcourtsintheunitedstateshavebeenorganizedasamultidistrictlitigationintheunited statesdistrictcourtforthenortherndistrictoftexaslitigationhasalsobeenfiledincountriesoutsideoftheunited statesprimarilyintheunitedkingdomthecompanyhasestablishedanaccrualtocoverdefensecostsinconnection withproductliabilitylitigationassociatedwithdepuyspinnacleacetabularcupsystemchangestothisaccrualmay berequiredinthefutureasadditionalinformationbecomesavailable claimsforpersonalinjuryhavebeenmadeagainstethiconincethiconandjohnsonjohnsonarisingoutofethicons pelvicmeshdevicesusedtotreatstressurinaryincontinenceandpelvicorganprolapsethenumberofpendingproduct liabilitylawsuitscontinuestoincreaseandthecompanycontinuestoreceiveinformationwithrespecttopotentialcosts andtheanticipatednumberofcasescasesfiledinfederalcourtsintheunitedstateshavebeenorganizedasamulti districtlitigationintheunitedstatesdistrictcourtforthesoutherndistrictofwestvirginiainadditionclassactionsand individualpersonalinjurycasesorclaimshavebeencommencedinaustraliabelgiumcanadaenglandisraelitalythe netherlandsscotlandandvenezuelaseekingdamagesforallegedinjuryresultingfromethiconspelvicmeshdevices thecompanyhasestablishedanaccrualwithrespecttoproductliabilitylitigationassociatedwithethiconspelvicmesh productschangestothisaccrualmayberequiredinthefutureasadditionalinformationbecomesavailable claimsforpersonalinjuryhavebeenmadeagainstjanssenpharmaceuticalsincandjohnsonjohnsonarisingoutoftheuse ofrisperdalindicatedforthetreatmentofschizophreniaacutemanicormixedepisodesassociatedwithbipolaridisorder andirritabilityassociatedwithautismandrelatedcompoundsthenumberofpendingproductliabilitylawsuitscontinuesto increaseandthecompanycontinuestoreceiveinformationwithrespecttopotentialcostsandtheanticipatednumberof casesthecompanyhasestablishedanaccrualtocoverdefensecostsinconnectionwithproductliabilitylitigationassociated withrisperdalchangestothisaccrualmayberequiredinthefutureasadditionalinformationbecomesavailable johnsonjohnsonannualreportintellectualproperty certainsubsidiariesofjohnsonjohnsonaresubjectfromtimetotimetolegalproceedingsandclaimsrelatedto patenttrademarkandotherintellectualpropertymattersarisingoutoftheirbusinessesmanyofthesemattersinvolve challengestothecoverageandorvalidityofthepatentsonvariousproductsalthoughthesesubsidiariesbelievethatthey havesubstantialdefensestothesechallengeswithrespecttoallmaterialpatentstherecanbenoassuranceastothe outcomeofthesemattersandalossinanyofthesecasescouldpotentiallyadverselyaffecttheabilityofthese subsidiariestoselltheirproductsorrequirethepaymentofpastdamagesandfutureroyaltiesthemostsignificantof thesemattersaredescribedbelow medicaldevices injanuarytycohealthcaregrouplptycoandussurgicalcorporationnowcovidienplcfiledalawsuit againstethiconendosurgeryinceesintheunitedstatesdistrictcourtforthedistrictofconnecticutallegingthat eessharmonicshearsinfringedthreetycopatentsthecasewastriedinjulyandinmarchthecourt ruledthatsomeofeessharmonicshearsinfringedtycospatentsandorderedeestopaydamagesof approximatelymillionbutdeclinedtoorderinjunctivereliefeesappealedandindecembertheunited statescourtofappealsforthefederalcircuitreversedthedistrictcourtsrulingandfoundalltheassertedclaims invalidinjanuarytycofiledamotionforrehearinginjulycovidienfiledanotherpatentinfringementlawsuit againsteesintheunitedstatesdistrictcourtforthedistrictofconnecticutseekingdamagesandapreliminary injunctionallegingthateessnewestversionofitsharmonicscalpelstheharmonicaceshearsandthe harmonicaceshearsinfringedthethreetycopatentsassertedinthepreviouscasecovidienbroughtamotionfor apreliminaryinjunctionagainsttheharmonicaceshearsandinoctoberthedistrictcourtgranted covidiensmotionforapreliminaryinjunctioneesappealedandthecourtofappealsforthefederalcircuitgrantedees aninterimstayoftheinjunctiontheclaimsassertedbycovidieninthiscasearethesameclaimsthatweredeclared invalidindecemberbythecourtofappealsinthetycocasediscussedabove innovemberrochediagnosticsoperationsincetalrochefiledapatentinfringementlawsuitagainstlifescan inclifescanintheunitedstatesdistrictcourtforthedistrictofdelawarealleginglifescansonetouchlineof bloodglucosemonitoringsystemsinfringetwopatentsrelatedtotheuseofmicroelectrodesensorsrocheisseeking monetarydamagesandinjunctivereliefinseptemberlifescanobtainedafavorablerulingonclaimconstruction thatprecludedafindingofinfringementthecourtenteredjudgmentagainstrocheinjulyandrocheappealed thecourtofappealsreversedthedistrictcourtsrulingonclaimconstructionandremandedthecasetothedistrict courtfornewfindingsontheissueindecemberthedistrictcourtruledinlifescansfavorandreinstatedthe originalclaimconstructioninfebruaryrocheappealedtheruling injunerembrandtvisiontechnologieslprembrandtfiledapatentinfringementlawsuitagainstjohnson johnsonvisioncareincjjvcintheunitedstatesdistrictcourtfortheeasterndistrictoftexasallegingthatjjvcs manufactureandsaleofitsacuvueadvanceandacuvueoasyshydrogelcontactlensesinfringetheirus patentnothechangpatentrembrandtisseekingmonetaryreliefthecasewastransferredtotheunited statesdistrictcourtforthemiddledistrictoffloridainmaythejuryreturnedaverdictholdingthatneitherofthe accusedlensesinfringesthepatentrembrandtappealedandinaugusttheunitedstatescourtofappeals forthefederalcircuitaffirmedthedistrictcourtsjudgmentrembrandtaskedthedistrictcourttograntitanewtrial basedonallegednewevidenceandinjulythedistrictcourtdeniedrembrandtsmotionrembrandthasappealed thedistrictcourtsdenialofitsmotionforanewtrial indecemberthestateofisraelfiledalawsuitinthedistrictcourtintelavivjaffaagainstomrix biopharmaceuticalsincandvariousaffiliatesomrixinthelawsuitthestateclaimsthatanemployeeofagovernment ownedhospitalwastheinventoronseveralpatentsrelatedtofibringluetechnologythattheemployeedevelopedwhilehe wasagovernmentemployeethestateclaimsthathehadnorighttotransferanyintellectualpropertytoomrixbecauseit belongstothestatethestateisseekingdamagesplusroyaltiesonquixilandevicelproductsoralternatively transferofthepatentstothestatethecaseremainsactivebutnotrialdatehasbeenset inseptemberlifescaninclifescanfiledalawsuitagainstshastatechnologiesinstacarecorpandconductive technologiescollectivelyshastaintheunitedstatesdistrictcourtforthenortherndistrictofcaliforniaforpatent infringementforthemakingandmarketingofastripforuseinlifescansonetouchbloodglucosemetersshastahas allegedthatthethreelifescanpatentsinsuitareinvalidshastaalsochallengedthevalidityoftheassertedpatentsinthe unitedstatespatentandtrademarkofficeusptoandthepatentinfringementcasehasbeenstayedpendingthe outcomeoftheusptoproceedingsthevalidityoftwoofthepatentswasconfirmedbytheusptoandinaugust johnsonjohnsonannualreport theusptodeterminedthatthethirdpatentuspatentnothepatentisinvalidlifescanisappealing thatdecisionthepatentcasehasresumedonthetwootherpatentsinaprilshastabroughtcounterclaimsfor allegedantitrustviolationsandfalseadvertisingandthoseclaimshavebeenstayedpendingresolutionofthepatent infringementcaseinmaylifescanfiledapatentinfringementlawsuitagainstunistriptechnologiesllcunistrip intheunitedstatesdistrictcourtforthedistrictofnorthcarolinaallegingthatthemakingandmarketingofunistrips stripsinfringethesamepatentsassertedagainstshastaabovethatcasehasbeenstayedpendingtheoutcomeofthe appealoftheusptosdecisiononthevalidityofthepatentinjulyunistripbroughtalawsuitagainst lifescanintheunitedstatesdistrictcourtfortheeasterndistrictofpennsylvaniaallegingantitrustviolationsrelatingto marketingpracticesforlifescansstrips innovemberhowmedicaosteonicscorphowmedicaandstrykerirelandltdstrykerfiledapatent infringementlawsuitagainstdepuyorthopaedicsincdepuyintheunitedstatesdistrictcourtforthedistrictofnew jerseyalleginginfringementbydepuyspinnacleacetabularcupsystemandduralocacetabularcupsystemof apatentrelatingtoaduallockingmechanismfeatureinanacetabularcupsystemhowmedicaandstrykersought monetarydamagesandinjunctivereliefdepuyfiledacounterclaiminfebruaryassertingthatstrykerstrident acetabularhipsysteminfringesdepuysuspatentnodepuysoughtdamagesandinjunctivereliefinjune thecasewassettledanddismissed inmaymedtronicminimedincmedtronicpuertoricooperationscoandminimeddistributioncorp collectivelymedtronicminimedfiledapatentinfringementlawsuitagainstanimascorporationanimasintheunited statesdistrictcourtforthecentraldistrictofcaliforniaallegingthatanimassonetouchpingglucosemanagement systemandtheirirandirinsulinpumpsinfringenineoftheirpatentsmedtronicminimedsince withdrewtwoofthepatentsfromthelawsuitandisseekingmonetarydamagesandinjunctivereliefwithrespecttothe remainingpatentsinjulyanimasenteredintoasettlementofthislawsuit inseptemberbonuttiskeletalinnovationsllcbonuttianonpracticingentityfiledapatentinfringementlawsuit againstdepuymitekllcthedepuyinstitutellcnowdepuysynthesinstitutellcdepuyincnowdepuy synthesincanddepuyorthopaedicsinccollectivelydepuyintheunitedstatesdistrictcourtforthedistrictof massachusettsallegingthatdepuysmanufacturesaleandormethodofusingthesigmafamilyofpartialandtotal kneesystemsandthelcscompletekneesystemwillfullyinfringethreeofbonuttispatentsbonuttialsoalleges thatthemethodofusingcertainofdepuyssutureanchorswillfullyinfringefourofbonuttisotherpatentsinaugust thepartiesenteredintoasettlementoftheportionofthelawsuitrelatingtosutureanchors inmarchmedinolltdmedinolfiledapatentinfringementlawsuitagainstcordiscorporationcordisand johnsonjohnsonintheunitedstatesdistrictcourtforthesoutherndistrictofnewyorkallegingthatallofcordiss salesofthecypherandcypherselectstentsmadeintheunitedstatessincewillfullyinfringedfourof medinolspatentsdirectedtothegeometryofarticulatedstentsmedinolisseekingdamagesandattorneysfeesafter trialinjanuarythedistrictcourtdismissedthecasefindingmedinolunreasonablydelayedbringingitsclaimsand medinoldidnotappealthedecisioninseptemberthedistrictcourtdeniedamotionbymedinoltovacatethe judgmentandgrantitanewtrialmedinolisappealingthisdecision injanuarybaxterinternationalincbaxterhealthcarecorporationandbaxterhealthcaresacollectivelybaxter filedalawsuitagainstjohnsonjohnsonethiconincethiconferrosanmedicaldevicesasandpackaging coordinatorsincintheunitedstatesdistrictcourtforthenortherndistrictofillinoisallegingthatthemanufacture importationsaleandoruseofethiconssurgiflohemostaticmatrixfamilyofproductsinfringessixofbaxters patentsbaxterisseekingmonetarydamagesandinjunctivereliefinfebruarybaxteralsofiledacomplaintbefore theunitedstatesinternationaltradecommissionitcagainstthesamedefendantsallegingthattheimportationintothe unitedstatesofethiconssurgiflohemostaticmatrixfamilyofproductsviolatessectionofthetariffactof duetotheallegedinfringementoffourofitsproductsandisseekinganexclusionordertoenjointheimportation intotheunitedstatesofsuchproductsthedistrictcourtcasehasbeenstayedpendingtheoutcomeoftheitccase allthepatentsexpireinaugusttheitccasewastriedinjanuaryandthepartiesareawaitingadecision injunemyhealthincmyhealthfiledapatentinfringementlawsuitagainstlifescaninclifescanintheunited statesdistrictcourtfortheeasterndistrictoftexasalleginglifescansonetouchverioiqbloodglucose monitoringsysteminfringesmyhealthspatentrelatedtoamethodformonitoringandtreatingpatientsmyhealthis seekingmonetarydamagesandinjunctivereliefinaugustlifescanfiledamotiontodismissthelawsuitinoctober lifescanfiledaninterpartesreviewproceedingintheunitedstatespatentandtrademarkofficeseekingto invalidatemyhealthspatentindecemberlifescanmovedtostaythelawsuitpendingadecisionintheinter partesreviewproceeding johnsonjohnsonannualreportindecemberbonuttiskeletalinnovationsllcbonuttisueddepuysynthessalesincanddepuysynthes productsincintheunitedstatesdistrictcourtforthedistrictofmassachusettsallegingthatdepuysynthessproduct lineofspineimplantsinfringessixpatentsownedbybonuttigenerallycoveringwedgeimplantsandtheirmethodsof implantation pharmaceutical inmayabbottbiotechnologyltdabbottfiledapatentinfringementlawsuitagainstcentocorinccentocor nowjanssenbiotechincjbiintheunitedstatesdistrictcourtforthedistrictofmassachusettsallegingthat simponiinfringesabbottsuspatentnosandthesalfeldpatentsabbottwasseeking monetarydamagesandinjunctivereliefthepartieshavesettledthecase inaugustabbottgmbhcoabbottgmbhandabbottbioresearchcentercollectivelynowreferredtoas abbviefiledapatentinfringementlawsuitagainstcentocornowjbiintheunitedstatesdistrictcourtforthedistrictof massachusettsallegingthatstelarainfringestwounitedstatespatentsassignedtoabbottgmbhtrialwasheldin septemberandajuryreturnedaverdictinfavorofjbiinvalidatingabbviespatentclaimsabbvieappealedandin julythecourtofappealsforthefederalcircuitaffirmedthelowercourtsrulingalsoinaugustabbott gmbhandabbottlaboratorieslimitedcollectivelynowreferredtoasabbviebroughtapatentinfringementlawsuitin thefederalcourtofcanadaallegingthatstelarainfringesabbottgmbhscanadianpatentatrialwasheldin decemberinthecanadiancaseandthecourtruledinfavorofabbviefindingthattheassertedclaimswerevalid andinfringedbystelarajbiappealedthatdecisioninmayabbviesmotionforaninjunctionwasgrantedin partandjbialsoappealedthatdecisioninoctobertheappellatecourtoverturnedthefindingofliabilityremanded thecasetothetrialcourtforretrialandliftedtheinjunctioninadditiontotheusandcanadianlitigationsinaugust abbviefiledpatentinfringementlawsuitsrelatedtostelarainthenetherlandsswitzerlandandgermanythe partieshavesettledallofthecasesdiscussedaboverelatedtostelara inandnoramcoincnoramcoasubsidiaryofjohnsonjohnsonmovedtointerveneinseveralpatent infringementlawsuitsfiledintheunitedstatesdistrictcourtforthesoutherndistrictofnewyorkbypurduepharmalp andotherspurdueagainstnoramcooxycodonecustomersimpaxlaboratoriesincimpaxtevapharmaceuticalsusa inctevaandamnealpharmaceuticalsllcamnealwatsonlaboratoriesincfloridawatsonandandrxlabsllc andrxthelawsuitsareinresponsetothedefendantsrespectiveabbreviatednewdrugapplicationsseekingapproval tomarketgenericextendedreleaseoxycodoneproductsbeforetheexpirationofcertainpurduepatentsthreeofthe assertedpatentsrelatetooxycodoneandprocessesformakingoxycodoneandnoramcohasagreedtodefendthe lawsuitsonbehalfofimpaxtevaamnealwatsonandandrxinaprilwatsonandandrxenteredintoasettlement withpurduethetrialagainstimpaxandtevaaswellastwopartiesnotdefendedbynoramcotookplaceinseptember andnoramcodefendedtevaandimpaxinnovemberimpaxenteredintoasettlementwithpurduein januarythecourtissuedadecisioninvalidatingtherelevantpurduepatentsandsubsequentlydismissedthe lawsuitagainstamnealandotherpartiesnotdefendedbynoramcopurduehasappealedthecourtsdecisionin decembertevaenteredintoaconfidentialsettlementwithpurdueandtevasubsequentlymovedtohavethe appealdismissedasmootinviewofthesettlementpurduehasopposedtevasmotion inaugustdrjamesmswansonfiledalawsuitagainstalzacorporationalzainthenortherndistrictof californiaseekingtobeaddedasaninventoronthreealzaownedpatentsrelatingtoconcertaalternatively drswansonhasallegedthatthepatentsinsuitareinvalidasaresultofalzasallegedomissionofdrswansonasa namedinventorthelawsuitalsoincludesclaimsoffraudbreachoffiduciarydutyandunfaircompetitiondrswansonis seekingdamagesandanawardofunjustenrichmentalzafiledamotiontodismissdrswansonsclaimsaswellas counterclaimsforbreachofcontractandnegligentmisrepresentationthecourtgrantedthemotioninpartanddeniedit inpartalzafiledamotionforsummaryjudgmentontheissueofinventorshipandahearingwasheldinfebruary thepartiesareawaitingadecision johnsonjohnsonacquiredtheprostatecancerbusinessofaragonpharmaceuticalsincaragonincludingarn acompoundbeingtestedfortreatmentofprostatecancerinseptemberpriortotheacquisitioninmay medivationincmedivationhadsuedaragonandtheuniversityofcaliforniaseekingrightstoarnindecember thestatecourtgrantedsummaryjudgmenttoaragononmedivationsclaimsawardingtherightsofthearn compoundtoaragonandinjanuarythecourtdismissedthecaseagainstaragonmedivationhasappealed remicaderelatedcases inmarchhospirahealthcarecorporationhospirafiledanimpeachmentproceedingagainstthekennedyinstitute ofrheumatologykennedychallengingthevalidityofacanadianpatentrelatedtoremicadeafeldmanpatent johnsonjohnsonannualreport whichisexclusivelylicensedtojanssenbiotechincjbiinoctoberkennedyalongwithjbijanssenincand cilaggmbhinternationalbothaffiliatesofjbifiledacounterclaimforinfringementagainstcelltrionhealthcarecoltd celltrioninctogethercelltrionandhospirathecounterclaimallegesthattheproductsdescribedincelltrionsand hospirasmarketingapplicationstohealthcanadafortheirsubsequententrybiologicssebtoremicadewould infringethefeldmanpatentsownedbykennedydiscoveryinthepatentactionisongoingtrialhasbeenscheduledfor september injanuaryhealthcanadaapprovedcelltrionssebtoremicadeallowingcelltriontomarketitsbiosimilar versionofremicadeincanadaregardlessofthependingpatentactioninjunehospirareceivedapprovalfor itssebtoremicadeinjulyjanssenincjanssenfiledalawsuittocompelthecanadianministerofhealthto withdrawthenoticeofcomplianceforhospirassebbecausehospiradidnotserveanoticeofallegationonjanssento addressthepatentlistedbyjanssenonthepatentregisterifthenoticeofcomplianceiswithdrawnhospirawouldhave toserveanoticeofallegationandjanssencouldcommenceanapplicationtoprohibitissuanceofthenoticeof complianceuntilexpiryoftherelevantpatentahearinghasbeenscheduledformarch inseptemberjbiandnyulangonemedicalcenternyumedicalcenterreceivedanofficeactionfromthe unitedstatespatentandtrademarkofficeusptorejectingtheclaimsinuspatentnorelatingto remicadethepatentinareexaminationproceedinginstitutedbyathirdpartythepatentiscoownedby jbiandnyumedicalcenterandnyumedicalcentergrantedjbianexclusivelicensetonyumedicalcentersrights underthepatentcurrentlythepatentintheunitedstatesexpiresinseptemberjbirespondedtothat rejectionindecemberandinaugustjbiandnyumedicalcenterreceivedafurtherrejectionjbiresponded totherejectionbyfilingafurtheramendmentandinnovemberjbispetitiontoentertheamendmentwasgranted theapplicationwasreturnedtotheexaminerforissuanceofanewofficeactionwhichoccurredinfebruaryfurther rejectingthepatentjbihassixtydaystorespondtotherejectionjbibelievesthepatentisvalidwillrespondtothe latestofficeactiontodefendthepatentandifnecessaryjbiwillpursueallavailableappeals inmarchcelltrionfiledadeclaratoryjudgmentlawsuitagainstjbiintheunitedstatesdistrictcourtforthedistrict ofmassachusettsseekingtoinvalidatethepatentandtwootheruspatentsthatrelatetoremicadeandareco ownedbyjbiandnyumedicalcenterandexclusivelylicensedtojbicollectivelythelepatentsjbimovedtodismiss thecaseforlackofjurisdictionandcelltrionvoluntarilydismisseditslawsuitalsoinmarchcelltrionfiledalawsuit intheunitedstatesdistrictcourtforthesoutherndistrictofnewyorkagainstkennedyseekingtoinvalidatethree patentsownedbykennedythefeldmanpatentsthefeldmanpatentsarelicensedtojbiandalsorelateto remicadekennedymovedtodismissthecaseforlackofjurisdictionincludingfailuretocomplywiththeprocedural requirementsofthebiologicspricecompetitionandinnovationactthebpciaindecemberthecourtgranted themotion inaugusthospirainchospirafiledalawsuitintheunitedstatesdistrictcourtforthesoutherndistrictofnew yorkagainstjbinewyorkuniversitynyunyumedicalcenterandkennedyseekingtoinvalidatethefeldman patentshospiraallegesthatithasexclusiverightstomarketcelltrionsbiosimilarversionofremicadeintheunited statesifitisapprovedbythefdainoctoberjbinyuandnyumedicalcentermovedtodismissthiscasefor lackofjurisdictionincludingfailuretocomplywiththeproceduralrequirementsofthebpciaindecemberthe courtgrantedthemotion inaugustcelltrionfiledforfdaapprovaltomakeandsellitsownbiosimilarversionofremicadeinfebruary jbireceivedanoticeofcommercialmarketingfromcelltrioninaccordancewiththebpcianotifyingjbithat celltrionandorhospiraintendtobegincommercialmarketingofabiosimilarproductasearlyasdaysfromthedate ofthenoticethepartiesareproceedingwiththepatentresolutionproceduressetforthinthebpciajbibelievesthe patentsarevalidandwillenforcetherelevantpatents ifanyoftheleorfeldmanpatentsisfoundtobeinvalidanysuchpatentcouldnotbereliedupontopreventthe introductionofbiosimilarversionsofremicadethetimingofthepossibleintroductionofabiosimilarversionof remicadeintheunitedstateswouldbesubjecttoapprovalbythefdalossofexclusivitywilllikelyresultina reductioninsalesasbiosimilarversionsofremicadeareintroducedtothemarket litigationagainstfilersofabbreviatednewdrugapplicationsandas thefollowingsummarizeslawsuitspendingagainstgenericcompaniesthathavefiledabbreviatednewdrugapplications andaswiththefdaorundertakensimilarregulatoryprocessesoutsideoftheunitedstatesseekingtomarketgeneric formsofproductssoldbyvarioussubsidiariesofjohnsonjohnsonpriortoexpirationoftheapplicablepatentscovering thoseproductstheseandastypicallyincludeallegationsofnoninfringementinvalidityandunenforceabilityofthe johnsonjohnsonannualreportapplicablepatentsintheeventthesubsidiariesarenotsuccessfulintheseactionsorthestatutorymonthstaysofthe andasexpirebeforetheunitedstatesdistrictcourtrulingsareobtainedthethirdpartycompaniesinvolvedwillhavethe abilityuponapprovalofthefdatointroducegenericversionsoftheproductsatissuetothemarketresultinginthe potentialforsubstantialmarketshareandrevenuelossesforthoseproductsandwhichmayresultinanoncash impairmentchargeinanyassociatedintangibleasset prezista anumberofgenericcompanieshavefiledandasseekingapprovaltomarketgenericversionsofprezistain novembertibotecincnowtibotecllcandtibotecpharmaceuticalsnowjanssenrdirelandcollectively tibotecfiledapatentinfringementlawsuitagainstlupinltdlupinpharmaceuticalsinccollectivelylupinmylaninc andmylanpharmaceuticalsinccollectivelymylanintheunitedstatesdistrictcourtforthedistrictofnewjerseyin responsetolupinsandmylansrespectiveandasseekingapprovaltomarketgenericversionsoftibotecsprezista productbeforetheexpirationoftibotecspatentrelatingtoprezistalupinandmylaneachfiledcounterclaims allegingnoninfringementandinvalidityinjulytibotecfiledanotherpatentinfringementlawsuitagainstlupininthe unitedstatesdistrictcourtforthedistrictofnewjerseyinresponsetolupinssupplementtoitsandatoaddnew dosagestrengthsforitsproposedproductinaugusttibotecandgdsearlecompanygdsearlefileda patentinfringementlawsuitagainstlupinandmylaninresponsetotheirnoticelettersadvisingthattheirandasare seekingapprovaltomarketgenericversionsoftibotecsprezistaproductbeforetheexpirationoftwoadditional patentsrelatingtoprezistathattibotecexclusivelylicensesfromgdsearleinseptemberthecourt consolidatedtheabovelawsuitsreferredtohereasthefirstconsolidatedaction theapprovednewdrugapplicationforprezistawastransferredfromtibotecinctojanssenproductslpin decemberinandjanssenproductslpandjanssenrdirelandcollectivelyjanssenaddedseveral patentsthattheyownorexclusivelylicensefromgdsearletothefirstconsolidatedactionagainstmylanandlupinin junejanssenandgdsearledismissedtheirclaimsrelatingtothepatentsownedbygdsearleagainstlupin andmylanbasedonthosepartiesagreementnottoseekfdaapprovaloftheirrespectiveandasuntilthenovember expirationofthegdsearlepatentsafteratrialregardingtheremainingpatentsinthefirstconsolidatedaction thecourtissuedadecisioninaugustinfavorofjanssenholdingthattheassertedpatentsarevalidandwouldbe infringedbylupinsandmylansmarketingoftheirproposedproductslupinfiledanappeal inmaylupinnotifiedjanssenthatitfiledanandaseekingapprovaltomarketanewdosagestrengthofitsgeneric versionofprezistainresponsejanssenfiledapatentinfringementlawsuitintheunitedstatesdistrictcourtforthe districtofnewjerseyallegingthatlupinsnewdosagestrengthwouldinfringethesamepatentsthatjanssenisasserting againstlupinintheoriginalactioninmarchjanssenfiledapatentinfringementlawsuitagainstlupinintheunited statesdistrictcourtforthedistrictofnewjerseyalleginginfringementofunitedstatespatentnoinjanuary thecourtconsolidatedtheselawsuitsreferredtohereasthesecondconsolidatedactionandstayedthem pendinglupinsappealofthecourtsdecisioninthefirstconsolidatedaction janssenfiledapatentinfringementlawsuitagainstheterodrugsltdunitiiiandheterousaincinmarchinthe unitedstatesdistrictcourtforthedistrictofnewjerseyalleginginfringementofunitedstatespatentnos anddiscoveryinthiscaseisongoingandatrialdateissetforoctober janssenandgdsearlealsofiledpatentinfringementlawsuitsagainsttevapharmaceuticalsusaincandteva pharmaceuticalsltdcollectivelytevaintheunitedstatesdistrictcourtforthedistrictofnewjerseyinresponseto tevasandaseekingapprovaltomarketagenericversionofprezistabeforetheexpirationofcertainpatentsrelating toprezistathatjansseneitherownsorexclusivelylicensesfromgdsearleinmarchthepartiesenteredintoa settlementagreementandthelawsuitsagainsttevaweredismissed injulyjanssenfiledapatentinfringementlawsuitagainstmylanintheunitedstatesdistrictcourtforthedistrictof newjerseyalleginginfringementofunitedstatespatentnodiscoveryinthecaseinongoing inaugustjanssenfiledpatentinfringementlawsuitsagainstciplaltdandciplausainccollectivelyciplainthe unitedstatesdistrictcourtsforthedistrictsofnewjerseyanddelawareinresponsetociplasandaseekingapproval tomarketagenericversionofjanssensprezistaproductbeforetheexpirationofcertainofjanssenspatentsrelating toprezistaciplafiledcounterclaimsseekingdeclarationsofnoninfringementandinvalidityofthepatentsinsuit discoveryisongoing inresponsetoitsnoticeofallegationseekingapprovaltomarketagenericversionofprezistaincanadabeforethe expirationofcanadianpatentnojanssenincandjanssenrdirelandfiledanoticeofapplicationagainst mylanpharmaceuticalsulcinjulyindecemberjanssenrdirelandtransferreditsprezistapatentsto johnsonjohnsonannualreport janssensciencesirelanducandjanssensciencesirelanducwassubstitutedforjanssenrdirelandasplaintiffinthe abovereferencedactionsinjanuaryjanssenincandjanssensciencesirelanducfiledanoticeofapplication againsttevacanadalimitedinresponsetoitsnoticeofallegationseekingapprovaltomarketagenericversionof prezistabeforetheexpirationofcanadianpatentno ineachoftheabovelawsuitsjanssensoughtorisseekinganorderenjoiningthedefendantsfrommarketingtheirgeneric versionsofprezistabeforetheexpirationoftherelevantpatents concerta injunealzacorporationalzaandjanssenpharmaceuticalsincjpifiledpatentinfringementlawsuitsinthe unitedstatesdistrictcourtforthedistrictofdelawareagainstparpharmaceuticalsincparosmoticakereskedelmies szolgaltatokftosmoticaandnorwichpharmaceuticalsincnorwichinresponsetothosepartiesandasseeking approvaltomarketagenericversionofconcertabeforetheexpirationofunitedstatespatentnothe patentinadditioninseptemberparandosmoticafiledcounterclaimsagainstalzaandjpiseeking declarationsofinvalidityandnoninfringementofthepatentinsuitandnorwichfiledamotiontodismissnorwichwas dismissedfromthecaseinoctoberbasedonitsagreementtobeboundbytheoutcomeofthecasewith osmoticainmarchalzaandjpiamendeditscomplaintagainstparandosmoticatoassertinfringementofnewly issuedunitedstatespatentnothepatentinjunealzajpiandosmoticaenteredintoa settlementoftheactionandinseptemberalzajpiandparenteredintoasettlement inmayalzaandjpifiledapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictofwest virginiaagainstmylanincandmylanpharmaceuticalsincmylaninresponsetoitsandaseekingapprovaltomarketa genericversionofconcertabeforetheexpirationofthepatentmylanfiledcounterclaimsseekingdeclarations ofinvalidityandnoninfringementofthepatentsinsuit injunealzaandjpifiledapatentinfringementlawsuitinthedistrictofdelawareagainstsandozincinresponse toitsandaseekingapprovaltomarketagenericversionofconcertabeforetheexpirationoftheand patentssandozfiledcounterclaimsseekingdeclarationsofinvalidityunenforceabilityandnoninfringementofthepatents insuitindecemberthepartiesenteredintoasettlementagreementandthelawsuitwasdismissed indecemberjanssenincandalzafiledanoticeofapplicationagainstactavispharmacompanyactavisin responsetoitsnoticeofallegationseekingapprovaltomarketagenericversionofconcertabeforetheexpirationof canadianpatentno ineachoftheabovelawsuitsalzaandorjpiareseekinganorderenjoiningthedefendantsfrommarketingtheirgeneric versionsofconcertabeforetheexpirationoftheandorpatents nucyntaandnucyntaer injulyjanssenpharmaceuticalsincjpifiledpatentinfringementlawsuitsintheunitedstatesdistrictcourtfor thedistrictofnewjerseyagainstactaviselizabethllcactavisincandactavisllccollectivelyactavisaswellas alkemlaboratorieslimitedandascendlaboratoriesllccollectivelyalkemthepatentinfringementclaimsagainst actavisandalkemrelatetotheirrespectiveandasseekingapprovaltomarketagenericversionofnucyntaer beforetheexpirationofunitedstatesreissuepatentnothepatentunitedstatespatentno thepatentandastoactavisonlyunitedstatespatentnothepatentthelawsuitalsoincludes apatentinfringementclaimagainstalkeminresponsetoitsandaseekingapprovaltomarketagenericversionof nucyntabeforetheexpirationoftheandpatentsindecemberjpifiledanadditionalcomplaintinthe districtcourtofnewjerseyagainstalkemassertingunitedstatespatentnorelatedtoitsandaseeking approvaltomarketagenericversionofnucyntaerinaugustjpiamendedthecomplaintagainstalkemtoadd additionaldosagestrengths inoctoberjpireceivedaparagraphivnoticefromsandozincsandozwithrespecttonucyntarelatedto thepatentandaparagraphivnoticefromroxanelaboratoriesincroxanewithrespecttonucyntarelatedto theandpatentsinresponsetothosenoticesjpifiledanadditionalcomplaintintheunitedstatesdistrict courtforthedistrictofnewjerseyagainstroxaneandsandozassertingthepatentagainstsandozandthe andpatentsagainstroxaneinapriljpiandsandozenteredintoajointstipulationofdismissalofthecase againstsandozbasedonsandozsagreementnottoenterthemarketpriortotheexpirationoftheassertedpatentsin juneinresponsetoaparagraphivnoticefromroxanewithrespecttonucyntaerjpifiledacomplaint assertingtheandpatentsagainstroxane johnsonjohnsonannualreportinjulyinresponsetoaparagraphivnoticefromwatsonlaboratoriesincwatsonwithrespecttothe nucyntaoralsolutionproductandtheandpatentsjpifiledalawsuitintheunitedstatesdistrictcourtfor thedistrictofnewjerseyassertingtheandpatentsagainstwatson ineachoftheabovelawsuitsjpiisseekinganorderenjoiningthedefendantsfrommarketingtheirgenericversionsof nucyntaerandnucyntabeforetheexpirationoftheassertedpatents governmentproceedings likeothercompaniesinthepharmaceuticalandmedicaldevicesindustriesjohnsonjohnsonandcertainofits subsidiariesaresubjecttoextensiveregulationbynationalstateandlocalgovernmentagenciesintheunitedstatesand othercountriesinwhichtheyoperateasaresultinteractionwithgovernmentagenciesisongoingthemostsignificant litigationbroughtbyandinvestigationsconductedbygovernmentagenciesarelistedbelowitispossiblethatcriminal chargesandsubstantialfinesandorcivilpenaltiesordamagescouldresultfromgovernmentinvestigationsorlitigation averagewholesalepriceawplitigation johnsonjohnsonandseveralofitspharmaceuticalsubsidiariesthejjawpdefendantsalongwithnumerousother pharmaceuticalcompaniesaredefendantsinaseriesoflawsuitsinstateandfederalcourtsinvolvingallegationsthatthe pricingandmarketingofcertainpharmaceuticalproductsamountedtofraudulentandotherwiseactionableconduct becauseamongotherthingsthecompaniesallegedlyreportedaninflatedaveragewholesalepriceawpforthedrugs atissuepayorsallegedthattheyusedthoseawpsincalculatingproviderreimbursementlevelsmanyofthesecases bothfederalactionsandstateactionsremovedtofederalcourtwereconsolidatedforpretrialpurposesinamultidistrict litigationmdlintheunitedstatesdistrictcourtforthedistrictofmassachusetts theplaintiffsinthesecasesincludedthreeclassesofprivatepersonsorentitiesthatpaidforanyportionofthepurchase ofthedrugsatissuebasedonawpandstategovernmententitiesthatmademedicaidpaymentsforthedrugsatissue basedonawpinjuneafteratrialonthemeritsthemdlcourtdismissedtheclaimsoftwooftheplaintiffclasses againstthejjawpdefendantsinmarchthecourtdismissedtheclaimsofthethirdclassagainstthejjawp defendantswithoutprejudice awpcasesbroughtbyvariousattorneysgeneralhaveproceededtotrialagainstothermanufacturersseveralstate casesagainstcertainsubsidiariesofjohnsonjohnsonhavebeensettledincludingthecaseinalaskawhichsettledin aprilandcasesarestillpendinginillinoisnewjerseywisconsinutahandpennsylvaniathecasesinillinoisnew jerseyandwisconsinhavenotyetproceededtotrialinutahtheclaimsbroughtbytheattorneygeneralweredismissed bythecourtinbutthestatemayappealthedismissalaftertheconclusionofsimilarpendingmattersagainstother defendantstheawpcaseagainstthejjawpdefendantsbroughtbytheattorneygeneralofthecommonwealthof pennsylvaniawastriedincommonwealthcourtinthecourtfoundinthecommonwealthsfavorwithregardto certainofitsclaimsunderthepennsylvaniaunfairtradepracticesandconsumerprotectionlawutplenteredan injunctionandawardedmillioninrestitutionandmillionincivilpenaltiesthecourtfoundinthejjawp defendantsfavoronthecommonwealthsclaimsofunjustenrichmentmisrepresentationfraudcivilconspiracyandon certainofthecommonwealthsclaimsundertheutplthejjawpdefendantsappealedthecommonwealthcourts utplrulingandinjunethepennsylvaniasupremecourtvacatedthejudgmententeredbythecommonwealth courtandremandedthecaseforfurtherproceedingsonremandinjanuarythecommonwealthcourtdismissed themonetaryawardsagainstthejjawpdefendantswhichmaybeappealed risperdal innovemberjohnsonjohnsonanditssubsidiaryjanssenpharmaceuticalsincjpifinalizedpreviously disclosedsettlementagreementswiththeunitedstatesdepartmentofjusticeandfortyfivestatesresolvingfederal investigationsandstatemedicaidclaimsrelatedtopastpromotionalpracticesofrisperdalfromthrough andothermattersjpihadalsosettledallegedconsumerfraudclaimsinconnectionwiththesaleandmarketingof risperdalwiththirtysixstatesandthedistrictofcolumbiainseptemberinadditiontotheseactionsthe attorneysgeneralofseveralstatesbroughtactionsagainstjpirelatedtothesaleandmarketingofrisperdal seekingoneormoreofthefollowingremediesreimbursementofmedicaidorotherpublicfundsforrisperdal prescriptionswrittenforofflabelusecompensationfortreatingtheircitizensforallegedadversereactionsto risperdalcivilfinesorpenaltiesforviolationsofstatefalseclaimsactsorconsumerfraudstatutespunitivedamages orotherreliefrelatingtoallegedunfairbusinesspracticescertainoftheseactionsalsosoughtinjunctivereliefrelatingto thepromotionofrisperdalmanyoftheactionsandclaimsbroughtbythestateattorneysgeneralhavebeensettled eitherindividuallyoraspartofthesettlementsdescribedabove johnsonjohnsonannualreport fourstateshaveremainingclaimsinlitigationrelatedtorisperdaloneclaimisonremandinarkansasthecasein southcarolinaisonappealinkentuckyatrialhasbeensetforaprilandinmississippithecasehasnot progressedtotrialthecompanyhasnotaccruedanamountequaltothejudgmentobtainedinsouthcarolinatothe extentanystatehasanoutstandingmedicaidrelatedclaimnotresolvedbythesettlementsreferencedabovethe companyhasaccruedanamountapproximatelyequaltowhatthatstatewouldhavereceivedifithadparticipatedinthe relevantfederalsettlementstatecasesthatwenttojudgmentaftertrialarediscussedbelow intheattorneygeneralofwestvirginiacommencedalawsuitagainstjanssenpharmaceuticaincnowjpibased onclaimsofallegedconsumerfraudastoduragesicaswellasrisperdaljpiwasfoundliableanddamages wereassessedatmillionjpifiledanappealandinnovemberthewestvirginiasupremecourtofappeals reversedthetrialcourtsdecisionindecembertheattorneygeneralofwestvirginiadismissedthecaseasit relatedtorisperdalwithoutanypaymentthereafterjpisettledthecaseinsofarasitrelatedtoduragesic intheattorneygeneraloflouisianafiledamulticountcomplaintagainstjanssenpharmaceuticaincnowjpi johnsonjohnsonwaslateraddedasadefendantthecasewastriedinoctobertheissuetriedtothejurywas whetherjohnsonjohnsonorjpihadviolatedthestatesmedicalassistanceprogramintegritylawtheactthrough misrepresentationsallegedlymadeinthemailingofanovemberdearhealthcareprofessionalletterregarding risperdalthejuryreturnedaverdictthatjpiandjohnsonjohnsonhadviolatedtheactandawarded millionindamagesthetrialjudgesubsequentlyawardedtheattorneygeneralcounselfeesandexpensesintheamount ofmillioninjanuarythelouisianasupremecourtreversedthedistrictcourtsjudgmentinfavorofthe attorneygeneralandrenderedjudgmentinfavorofjohnsonjohnsonandjpiinaprilthelouisianasupreme courtdeniedtheattorneygeneralspetitionseekingarehearingoftheappellateargumentsresultinginfinaldismissalof thecase intheofficeofgeneralcounselofthecommonwealthofpennsylvaniafiledalawsuitagainstjanssen pharmaceuticaincnowjpionamulticountcomplaintrelatedtojanssenpharmaceuticassaleofrisperdaltothe commonwealthsmedicaidprogramthetrialoccurredinjunethetrialjudgedismissedthecaseafterthecloseof theplaintiffsevidencethecommonwealthfiledanappealandinjulythepennsylvaniaappealscourtupheldthe dismissalofthecommonwealthscase intheattorneygeneralofsouthcarolinafiledalawsuitagainstjohnsonjohnsonandjanssenpharmaceutica incnowjpionseveralcountsinmarchthematterwastriedtoajuryonliabilityonlyatwhichtimethelawsuit waslimitedtoclaimsofviolationofthesouthcarolinaunfairtradepracticesactincludingamongothersquestionsof whetherjohnsonjohnsonorjpiengagedinunfairordeceptiveactsorpracticesintheconductofanytradeor commercebydistributingthenovemberdearhealthcareprofessionalletterregardingrisperdalorintheiruse oftheproductsfdaapprovedlabelthejuryfoundinfavorofjohnsonjohnsonandagainstjpiinjunethe courtawardedcivilpenaltiesofapproximatelymillionagainstjpijpihasappealedthisjudgmentandthe companybelievesithasstrongargumentssupportingtheappealoralargumentontheappealtookplacebeforethe southcarolinasupremecourtinmarchandthepartiesareawaitingadecision inaprilinthelawsuitbroughtbytheattorneygeneralofarkansasthejuryfoundagainstbothjpiandjohnson johnsonandthecourtimposedpenaltiesintheamountofapproximatelybillioninjanuarythetrialcourt awardedattorneyfeesofapproximatelymillionjpiandjohnsonjohnsonappealedbothawardstothearkansas supremecourtandinmarchthearkansassupremecourtdismissedthestatesclaimunderthearkansas medicaidfraudfalseclaimsactaswellastheapproximatelybillioninpenaltiesandreversedandremandeda claimunderthearkansasdeceptivetradepracticesactinaprilthearkansassupremecourtrejectedapetition bythestateforrehearingonthecasetrialontheremandofthecaseisscheduledforjune mcneilconsumerhealthcare startinginjunemcneilconsumerhealthcaredivisionofmcneilppcincmcneilconsumerhealthcareand certainaffiliatesincludingjohnsonjohnsonthecompaniesreceivedgrandjurysubpoenasfromtheunitedstates attorneysofficefortheeasterndistrictofpennsylvaniarequestingdocumentsbroadlyrelatingtorecallsofvarious productsofmcneilconsumerhealthcareandthefdainspectionsofthefortwashingtonpennsylvaniaandlancaster pennsylvaniamanufacturingfacilitiesaswellascertaindocumentsrelatingtorecallsofasmallnumberofproductsof othersubsidiariesinadditioninfebruarythegovernmentservedmcneilppcincmcneilppcwithacivil investigativedemandseekingrecordsrelevanttoitsinvestigationtodetermineiftherewasaviolationofthefederalfalse claimsactthegrandjuryandfalseclaimsinvestigationsarecontinuingthecompaniesarecooperatingwiththe unitedstatesattorneysofficeinrespondingtotheseinvestigations johnsonjohnsonannualreportthecompanieshavealsoreceivedcivilinvestigativedemandsfrommultiplestateattorneysgeneralofficesbroadly relatingtothemcneilrecallissuesthecompaniescontinuetocooperatewiththeseinquirieswhicharebeing coordinatedthroughamultistatecoalitionifaresolutioncannotbereachedwiththismultistatecoalitionitispossible thatindividualstateattorneysgeneralofficesmayfilecivilmonetaryclaimsagainstthecompaniesinjanuarythe oregonattorneygeneralfiledacivilcomplaintagainstjohnsonjohnsonmcneilppcandmcneilhealthcarellcin statecourtallegingcivilviolationsoftheoregonunlawfultradepracticesactrelatingtoanearlierrecallofamcneilotc productinnovemberthestatecourtgrantedamotionbythecompaniestodismissoregonscomplaintinits entiretywithprejudiceindecemberoregonfiledanoticeofappealinthecourtofappealsofthestateof oregonoralargumenttookplaceinjulyandthepartiesareawaitingadecision opioidslitigation alongwithotherpharmaceuticalcompaniesjanssenpharmaceuticalsincjpihasbeennamedinanumberoflawsuits allegingclaimsrelatedtoopioidmarketingpracticesinmaysantaclaraandorangecountiesincaliforniathe countiesfiledacomplaintinstatecourtinorangecountycaliforniaagainstnumerouspharmaceuticalmanufacturers includingjpiallegingclaimsrelatedtoopioidmarketingpracticesincludingfalseadvertisingunfaircompetitionand publicnuisanceinjunethecityofchicagofiledacomplaintincookcountycircuitcourtagainstseveral pharmaceuticalmanufacturersincludingjpialleginganumberofclaimsrelatedtoopioidmarketingpracticesincluding consumerfraudviolationsandfalseclaimsthecasewaslaterremovedtotheunitedstatesdistrictcourtforthe northerndistrictofillinoisandindecemberdefendantsfiledamotiontodismissthecityofchicagosfirst amendedcomplaintforfailuretostateaclaiminseptemberthetennesseeattorneygeneraldivisionof consumeraffairsissuedarequestforinformationtojpirelatedtoopioidsmarketingpractices inseptembersynthesincsynthesreceivedacivilinvestigativedemandissuedpursuanttothefalseclaimsact fromtheunitedstatesattorneysofficefortheeasterndistrictofpennsylvaniathedemandsoughtinformation regardingallegationsthatfellowshipshadbeenofferedtohospitalsinexchangeforagreementstopurchaseproducts syntheshasproduceddocumentsandinformationinresponsetothedemandandiscooperatingwiththeinquiry inmayacclarentincacclarentreceivedasubpoenafromtheunitedstatesattorneysofficeforthedistrictof massachusettsrequestingdocumentsbroadlyrelatingtothesalesmarketingandallegedofflabelpromotionbyacclarent ofrelievastratusmicroflowspacerproductstheinvestigationiscontinuingandacclarentiscooperatingwiththe unitedstatesattorneysofficeinrespondingtothesubpoena inaugustdepuyorthopaedicsincdepuyincnowdepuysynthesincandjohnsonjohnsonservicesinc thecompaniesreceivedaninformalrequestfromtheunitedstatesattorneysofficeforthedistrictofmassachusetts andthecivildivisionoftheunitedstatesdepartmentofjusticetheunitedstatesfortheproductionofmaterialsrelating totheasrxlhipdeviceinjulytheunitedstatesnotifiedtheunitedstatesdistrictcourtforthedistrictof massachusettsthatithaddeclinedtointerveneinaquitamcasefiledpursuanttothefalseclaimsactagainstthe companiesthedistrictcourtissuedanorderinaugustthatpubliclyunsealedtheunitedstatesdeclination noticehoweverthecomplaintinthematterremainsundersealinadditioninoctoberagroupofstateattorneys generalissuedcivilinvestigativedemandsrelatingtothedevelopmentsalesandmarketingofseveralofdepuy orthopaedicsincshipproductsinjulytheoregondepartmentofjusticewhichwasinvestigatingthesematters independentlyoftheotherstatesannouncedasettlementofitsasrxlhipdeviceinvestigationforatotalpaymentof milliontothestateoforegon inoctoberjohnsonjohnsonwascontactedbythecaliforniaattorneygeneralsofficeregardingamultistate attorneygeneralinvestigationofthemarketingofsurgicalmeshproductsforherniaandurogynecologicalpurposesby johnsonjohnsonssubsidiaryethiconincethiconjohnsonjohnsonandethiconhavesinceenteredintoaseries oftollingagreementswiththestatesandthedistrictofcolumbiaparticipatinginthemultistateinvestigationandhave respondedtocivilinvestigativedemandsservedbycertainoftheparticipatingstates indecembertherakosinctherakosformerlyasubsidiaryofjohnsonjohnsonandpartoftheorthoclinical diagnosticsincocdfranchisereceivedaletterfromthecivildivisionoftheunitedstatesattorneysofficeforthe easterndistrictofpennsylvaniainformingtherakosthattheunitedstatesattorneysofficewasinvestigatingthesales andmarketingofuvadexmethoxsalenandtheuvarxtssystemduringtheperiodtothepresenttheunited statesattorneysofficerequestedthatocdandjohnsonjohnsonpreservedocumentsthatcouldrelatetothe investigationtherakoswassubsequentlyacquiredbyanaffiliateofgorescapitalpartnersiiilpinjanuaryocd andjohnsonjohnsonretaincertainliabilitiesthatmayresultfromtheinvestigationforactivitythatoccurredpriortothe johnsonjohnsonannualreport saleoftherakosinmarchtheunitedstatesattorneysofficerequestedthatjohnsonjohnsonproducecertain documentsandjohnsonjohnsoniscooperatingwiththerequestfollowingthedivestitureofocdjohnsonjohnson retainsocdsportionofanyliabilitythatmayresultfromtheinvestigationforactivitythatoccurredpriortothesaleof therakos inmayjanssenpharmaceuticalsincjpireceivedasubpoenafromtheatlantaregionalofficeofthedepartment ofhealthandhumanservicesofficeofinspectorgeneralseekingproductionofdocumentsandinformationregarding thesalesmarketingandpromotionalpracticesincludingtheremunerationofhealthcareprovidersrelatedto nucyntairandnucyntaerandanystudiesreportsandorcomplaintsregardingthesafetyandoractualor potentialsideeffectsofnucyntairandnucyntaerinoctobertheunitedstatesdepartmentofjustice dojinformedjpithatthegovernmentsinvestigationstemmedfromthefilingofaquitamcomplaintthatthedojhad formallydeclinedtointerveneinthequitamactionandthatthedojwasclosingitsinvestigationrelatedtonucynta irandnucyntaertheplaintiffinthequitamcomplaintfiledanoticeofdismissalandthecourtdismissedthequi tamactionindecember inrecentyearsjohnsonjohnsonhasreceivednumerousrequestsfromavarietyofunitedstatescongressional committeestoproduceinformationrelevanttoongoingcongressionalinquiriesitisthepolicyofjohnsonjohnsonto cooperatewiththeseinquiriesbyproducingtherequestedinformation generallitigation inseptemberjohnsonjohnsonfiledalawsuitagainstguidantcorporationguidantintheunitedstatesdistrict courtforthesoutherndistrictofnewyorkallegingthatguidantbreachedprovisionsofamergeragreementbetween johnsonjohnsonandguidantinjuneguidantfiledamotionforsummaryjudgmentandinjulythejudge deniedguidantsmotionthetrialconcludedinjanuaryandinfebruarybeforeadecisionwasissuedbythe courtjohnsonjohnsonandguidantenteredintoasettlementagreementpursuanttowhichguidantagreedtopay johnsonjohnsonmillionandagreedthatitwillnotsuejohnsonjohnsonoritsaffiliatesforpatentinfringement regardingcertainstentproductsjohnsonjohnsonwilldismissitsactionagainstguidantwithprejudicethecompany willrecordthistransactioninfiscalyear injunefollowingthepublicannouncementthatorthoclinicaldiagnosticsincocdhadreceivedagrandjury subpoenafromtheunitedstatesdepartmentofjusticeantitrustdivisioninconnectionwithaninvestigationthathas sincebeenclosedmultipleclassactioncomplaintswerefiledagainstocdbydirectpurchasersseekingdamagesfor allegedpricefixingthesecaseswereconsolidatedforpretrialpurposesintheunitedstatesdistrictcourtforthe easterndistrictofpennsylvaniaasinrebloodreagentantitrustlitigationinaugustthedistrictcourtgranteda motionfiledbyplaintiffsforclasscertificationinoctobertheunitedstatescourtofappealsforthethirdcircuit grantedocdspetitionforinterlocutoryreviewoftheclasscertificationrulingoralargumentontheappealwasheldin februaryandthepartiesareawaitingadecisionfollowingthedivestitureofocdjohnsonjohnsonretainsany liabilitythatmayresultfromthesecases inseptemberashareholderronaldmonkfiledalawsuitintheunitedstatesdistrictcourtforthedistrictofnew jerseyseekingclasscertificationandallegingthatjohnsonjohnsonandcertainindividualsincludingexecutiveofficers andemployeesofjohnsonjohnsonfailedtodisclosethatanumberofmanufacturingfacilitiesfailedtomaintaincurrent goodmanufacturingpracticesandthatasaresultthepriceofthecompanysstockdeclinedsignificantlyplaintiffsought topursueremediesunderthesecuritiesexchangeactoftorecoverhisallegedeconomiclossesindecember amotionbyjohnsonjohnsontodismisswasgrantedinpartanddeniedinpartinseptemberplaintifffiled asecondamendedcomplaintandjohnsonjohnsonandtheindividualdefendantsmovedtodismissplaintiffssecond amendedcomplaintinpartfollowingmediationthepartiesreachedanagreementinprincipletosettlethecaseandin julyfiledforpreliminaryapprovaloftheproposedsettlementinnovemberthecourtapprovedthe settlementthreepartiesthathadobjectedtothesettlementappealedthecourtsapprovalorderspriortothemediation fortheappealthepartiesagreedtodismisstheappealwithprejudiceandwithoutcostsagainstanypartytheunited statescourtofappealsforthethirdcircuitdismissedthecaseinapril inaprilomjpharmaceuticalsincomjprfiledalawsuitagainsttheunitedstatesinunitedstatesdistrictcourt forthedistrictofpuertoricoallegingoverpaymentoffederalincometaxesforthetaxyearsendednovember andnovemberomjprallegedthattheinternalrevenueserviceerroneouslycalculatedomjprstaxcredits undersectionofthetaxcodeomjprfiledamotionforsummaryjudgmentandtheunitedstatesfiledacross motionforsummaryjudgmentinoctoberthecourtgrantedamotionbytheunitedstatesforsummaryjudgment anddeniedamotionbyomjprforsummaryjudgmentomjprappealedthisdecisioninjunetheappellatecourt reversedthetrialcourtsdecisionandinstructedthetrialcourttoentersummaryjudgmentinfavorofomjpr johnsonjohnsonannualreportinseptemberjohnsonjohnsonjohnsonjohnsonincandmcneilconsumerhealthcaredivisionofjohnson johnsonincreceivedanoticeofcivilclaimfiledbynickfieldinthesupremecourtofbritishcolumbiacanadathe bccivilclaimthebccivilclaimisaputativeclassactionbroughtonbehalfofpersonswhoresideinbritishcolumbia andwhopurchasedduringtheperiodbetweenseptemberandinoraboutdecemberoneormorevarious mcneilinfantsorchildrensoverthecountermedicinesthatweremanufacturedatthefortwashingtonfacilitythebc civilclaimallegesthatthedefendantsviolatedthebcbusinesspracticesandconsumerprotectionactandother canadianstatutesandcommonlawsbysellingmedicinesthatwereallegedlynotsafeandoreffectiveordidnotcomply withcanadiangoodmanufacturingpracticestheclasscertificationhearingisscheduledforoctober inaugustunitedstatescustomsandborderprotectionissuedapenaltynoticeagainstjanssenorthollc janssenorthoassessingpenaltiesfortheallegedimproperclassificationofdarunavirethanolateprezistain connectionwithitsimportationintotheunitedstatesinoctoberjanssenorthosubmittedapetitionforreliefin responsetothepenaltynotice johnsonjohnsonoritssubsidiariesarealsopartiestoanumberofproceedingsbroughtunderthecomprehensive environmentalresponsecompensationandliabilityactcommonlyknownassuperfundandcomparablestatelocalor foreignlawsinwhichtheprimaryreliefsoughtisthecostofpastandorfutureremediation shareholderderivativeaction inseptembertwoshareholderderivativelawsuitswerefiledintheunitedstatesdistrictcourtforthedistrictof newjerseybydonovanspamerandthegeorgeleonfamilytrustnamingcurrentandformerdirectorsofjohnson johnsonasdefendantsandjohnsonjohnsonasthenominaldefendanttheselawsuitsallegethatthedefendants breachedtheirfiduciarydutiesintheirdecisionswithrespecttothecompensationofthechiefexecutiveofficerduring theperiodfromthroughandthatthedefendantsmademisleadingstatementsinthecompanysannualproxy statementsbothoftheselawsuitswerevoluntarilydismissedwithoutprejudicebutasimilarlawsuitthegeorgeleon familytrustvcolemanwasrefiledinjulythatlawsuitsoughtavarietyofreliefincludingmonetarydamages injunctivereliefandcorporategovernancereformsinjunetheboardofdirectorsofjohnsonjohnsonthe boardreceivedareportpreparedbyspecialindependentcounseltotheboardwhichinvestigatedtheallegations containedinthederivativeactionsfiledbydonovanspamerandbythegeorgeleonfamilytrustandinseveral shareholderdemandlettersthattheboardreceivedinandraisingsimilarissuesthereportrecommended thatjohnsonjohnsonrejecttheshareholderdemandsandtakewhateverstepsarenecessaryorappropriatetosecure dismissalofthederivativelitigationtheboardunanimouslyadoptedthereportsrecommendations inseptemberjohnsonjohnsonmovedtodismissorinthealternativeforsummaryjudgmentinthegeorge leonfamilytrustvcolemanbasedupontheboardsdeterminationinoctobertheplaintiffintheleonlitigation filedanamendedcomplaintandjohnsonjohnsonmovedtodismisstheamendedcomplaintorinthealternativefor summaryjudgmentbasedupontheboardsdeterminationinjunethecourtgrantedsummaryjudgmentinfavorof johnsonjohnson johnsonjohnsonannualreport report independent registered public accounting firm totheshareholdersandboardofdirectorsofjohnsonjohnson inouropiniontheaccompanyingconsolidatedbalancesheetsandtherelatedconsolidatedstatementsofearnings statementsofcomprehensiveincomestatementsofequityandstatementsofcashflowspresentfairlyinallmaterial respectsthefinancialpositionofjohnsonjohnsonanditssubsidiariesatdecemberanddecember andtheresultsoftheiroperationsandtheircashflowsforeachofthethreeyearsintheperiodendeddecember inconformitywithaccountingprinciplesgenerallyacceptedintheunitedstatesofamericaalsoinouropinionthe companymaintainedinallmaterialrespectseffectiveinternalcontroloverfinancialreportingasofdecember basedoncriteriaestablishedininternalcontrolintegratedframeworkissuedbythecommitteeofsponsoring organizationsofthetreadwaycommissioncosothecompanysmanagementisresponsibleforthesefinancial statementsformaintainingeffectiveinternalcontroloverfinancialreportingandforitsassessmentoftheeffectivenessof internalcontroloverfinancialreportingincludedintheaccompanyingmanagementsreportoninternalcontrolover financialreportingourresponsibilityistoexpressopinionsonthesefinancialstatementsandonthecompanysinternal controloverfinancialreportingbasedonourintegratedauditsweconductedourauditsinaccordancewiththestandards ofthepubliccompanyaccountingoversightboardunitedstatesthosestandardsrequirethatweplanandperform theauditstoobtainreasonableassuranceaboutwhetherthefinancialstatementsarefreeofmaterialmisstatementand whethereffectiveinternalcontroloverfinancialreportingwasmaintainedinallmaterialrespectsourauditsofthefinancial statementsincludedexaminingonatestbasisevidencesupportingtheamountsanddisclosuresinthefinancial statementsassessingtheaccountingprinciplesusedandsignificantestimatesmadebymanagementandevaluatingthe overallfinancialstatementpresentationourauditofinternalcontroloverfinancialreportingincludedobtainingan understandingofinternalcontroloverfinancialreportingassessingtheriskthatamaterialweaknessexistsandtesting andevaluatingthedesignandoperatingeffectivenessofinternalcontrolbasedontheassessedriskourauditsalso includedperformingsuchotherproceduresasweconsiderednecessaryinthecircumstanceswebelievethatouraudits provideareasonablebasisforouropinions acompanysinternalcontroloverfinancialreportingisaprocessdesignedtoprovidereasonableassuranceregardingthe reliabilityoffinancialreportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewith generallyacceptedaccountingprinciplesacompanysinternalcontroloverfinancialreportingincludesthosepoliciesand proceduresthatipertaintothemaintenanceofrecordsthatinreasonabledetailaccuratelyandfairlyreflectthe transactionsanddispositionsoftheassetsofthecompanyiiprovidereasonableassurancethattransactionsare recordedasnecessarytopermitpreparationoffinancialstatementsinaccordancewithgenerallyacceptedaccounting principlesandthatreceiptsandexpendituresofthecompanyarebeingmadeonlyinaccordancewithauthorizationsof managementanddirectorsofthecompanyandiiiprovidereasonableassuranceregardingpreventionortimelydetection ofunauthorizedacquisitionuseordispositionofthecompanysassetsthatcouldhaveamaterialeffectonthefinancial statements becauseofitsinherentlimitationsinternalcontroloverfinancialreportingmaynotpreventordetectmisstatementsalso projectionsofanyevaluationofeffectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmaybecomeinadequate becauseofchangesinconditionsorthatthedegreeofcompliancewiththepoliciesorproceduresmaydeteriorate pricewaterhousecoopersllp florhamparknewjersey february johnsonjohnsonannualreportmanagements report internal control financial reporting undersectionofthesarbanesoxleyactofmanagementisrequiredtoassesstheeffectivenessofthe companysinternalcontroloverfinancialreportingasoftheendofeachfiscalyearandreportbasedonthatassessment whetherthecompanysinternalcontroloverfinancialreportingiseffective managementofthecompanyisresponsibleforestablishingandmaintainingadequateinternalcontroloverfinancial reportingthecompanysinternalcontroloverfinancialreportingisdesignedtoprovidereasonableassuranceastothe reliabilityofthecompanysfinancialreportingandthepreparationofexternalfinancialstatementsinaccordancewith generallyacceptedaccountingprinciples internalcontrolsoverfinancialreportingnomatterhowwelldesignedhaveinherentlimitationsthereforeinternalcontrol overfinancialreportingdeterminedtobeeffectivecanprovideonlyreasonableassurancewithrespecttofinancial statementpreparationandmaynotpreventordetectallmisstatementsmoreoverprojectionsofanyevaluationof effectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmaybecomeinadequatebecauseofchangesin conditionsorthatthedegreeofcompliancewiththepoliciesorproceduresmaydeteriorate thecompanysmanagementhasassessedtheeffectivenessofthecompanysinternalcontroloverfinancialreportingas ofdecemberinmakingthisassessmentthecompanyusedthecriteriaestablishedbythecommitteeof sponsoringorganizationsofthetreadwaycommissioncosoininternalcontrolintegratedframework thesecriteriaareintheareasofcontrolenvironmentriskassessmentcontrolactivitiesinformationandcommunication andmonitoringthecompanysassessmentincludedextensivedocumentingevaluatingandtestingthedesignand operatingeffectivenessofitsinternalcontrolsoverfinancialreporting basedonthecompanysprocessesandassessmentasdescribedabovemanagementhasconcludedthatasof decemberthecompanysinternalcontroloverfinancialreportingwaseffective theeffectivenessofthecompanysinternalcontroloverfinancialreportingasofdecemberhasbeenauditedby pricewaterhousecoopersllpanindependentregisteredpublicaccountingfirmasstatedintheirreportwhichappears herein alexgorsky dominicjcaruso chairmanboardofdirectors vicepresidentfinance chiefexecutiveofficer chieffinancialofficer johnsonjohnsonannualreport summary operations statistical data dollarsinmillionsexceptpershare amounts salestocustomersus salestocustomersinternational totalsales costofproductssold sellingmarketingandadministrativeexpenses researchanddevelopmentexpense inprocessresearchanddevelopment interestincome interestexpensenetofportioncapitalized otherincomeexpensenet restructuring earningsbeforeprovisionfortaxesonincome provisionfortaxesonincome netearnings addnetlossattributabletononcontrolling interest netearningsattributabletojohnson johnson percentofsalestocustomers dilutednetearningspershareofcommon stock percentreturnonaverageshareholdersequity percentincreasedecreaseoverprevious year salestocustomers dilutednetearningspershare supplementarybalancesheetdata propertyplantandequipmentnet additionstopropertyplantandequipment totalassets longtermdebt operatingcashflow commonstockinformation dividendspaidpershare shareholdersequitypershare marketpricepershareyearendclose averagesharesoutstandingmillions basic diluted employeesthousands attributabletojohnsonjohnson johnsonjohnsonannualreportshareholder return performance graphs setforthbelowarelinegraphscomparingthecumulativetotalshareholderreturnonthecompanyscommonstockfor periodsoffiveyearsandtenyearsendingdecemberagainstthecumulativetotalreturnofthestandard poorsstockindexthestandardpoorspharmaceuticalindexandthestandardpoorshealthcareequipment indexthegraphsandtablesassumethatwasinvestedondecemberanddecemberineachof thecompanyscommonstockthestandardpoorsstockindexthestandardpoorspharmaceuticalindexand thestandardpoorshealthcareequipmentindexandthatalldividendswerereinvested year shareholder return performance jj vs indices johnson johnson sp index sp pharmaceucidcal index sp healthcare equipment index year cagr jj sp sp pharm sp hc equip johnsonjohnson spindex sppharmaceuticalindex sphealthcareequipmentindex year shareholder return performance jj vs indices johnson johnson sp index sp pharmaceucidcal index sp healthcare equipment index year cagr jj sp sp pharm sp hc equip johnsonjohnson spindex sppharmaceuticalindex sphealthcareequipmentindex johnsonjohnsonannualreport reconciliationofnongaapfinancialmeasures thetablesthatfollowareprovidedtoreconcilecertainfinancialdisclosuresinthechairmansletterandbusiness highlights change dollarsinmillionsexceptpersharedata 'vs ' 'vs ' earningsbeforeprovisionfortaxesonincomeasreported orthoclinicaldiagnosticsdivestiturenetgain litigationexpenses synthesintegrationtransactioncostsandcurrencyrelated additionalyearofbrandedprescriptiondrugfee inprocessresearchanddevelopment depuyasrhipprogram intangibleassetwritedowns earningsbeforeprovisionfortaxesonincomeasadjusted netearningsattributabletojohnsonjohnsonasreported orthoclinicaldiagnosticsdivestiturenetgain litigationexpenses synthesintegrationtransactioncostsandcurrencyrelated additionalyearofbrandedprescriptiondrugfee inprocessresearchanddevelopment depuyasrhipprogram taxbenefitassociatedwithconormedsystems sciostaxbenefit intangibleassetwritedowns netearningsattributabletojohnsonjohnsonasadjusted dilutednetearningspershareattributabletojohnsonjohnsonasreported orthoclinicaldiagnosticsdivestiturenetgain litigationexpenses synthesintegrationtransactioncostsandcurrencyrelated additionalyearofbrandedprescriptiondrugfee inprocessresearchanddevelopment depuyasrhipprogram taxbenefitassociatedwithconormedsystems sciostaxbenefit intangibleassetwritedowns dilutednetearningspershareattributabletojohnsonjohnsonasadjusted includesadjustmenttodeferredtaxassetrelatedtodeductibilitybytaxjurisdiction amountincludesinprocessresearchanddevelopmentchargeofmillionrelatedtobapineuzumabivoffsetbymillionreportedasnetloss attributabletononcontrollinginterest thecompanyprovidesearningsbeforeprovisionfortaxesonincomenetearningsattributabletojohnsonjohnsonandnet earningspershareattributabletojohnsonjohnsondilutedonanadjustedbasisbecausemanagementbelievesthatthese measuresprovideusefulinformationtoinvestorsamongotherthingsthesemeasuresmayassistinvestorsinevaluatingthe company'sresultsofoperationsperiodoverperiodinvariousperiodsthesemeasuresmayexcludesuchitemsassignificant costsassociatedwithacquisitionsrestructuringlitigationandchangesinapplicablelawsandregulationsincludingsignificant accountingortaxmattersthesespecialitemsmaybehighlyvariabledifficulttopredictandofasizethatsometimeshas substantialimpactonthecompany'sreportedresultsofoperationsforaperiodmanagementusesthesemeasuresinternally forplanningforecastingandevaluatingtheperformancesofthecompany'sbusinessesincludingallocatingresourcesand evaluatingresultsrelativetoemployeeperformancecompensationtargetsunlikeearningsbeforeprovisionfortaxesonincome netearningsattributabletojohnsonjohnsonandnetearningspershareattributabletojohnsonjohnsondilutedprepared inaccordancewithgaapadjustedearningsbeforeprovisionfortaxesonincomeadjustednetearningsattributableto johnsonjohnsonandadjustednetearningspershareattributabletojohnsonjohnsondilutedmaynotbecomparable withthecalculationofsimilarmeasuresforothercompaniesthelimitationsofusingthesenongaapfinancialmeasuresas performancemeasuresarethattheyprovideaviewofthecompany'sresultsofoperationswithoutincludingalleventsduringa periodsuchastheeffectsofanacquisitiontheorthoclinicaldiagnosticsdivestiturerestructuringlitigationandchangesin applicablelawsandregulationsincludingsignificantaccountingortaxmattersanddonotprovideacomparableviewofthe company'sperformancetoothercompaniesinthehealthcareindustryinvestorsshouldconsidernongaapfinancial measuresinadditiontoandnotasreplacementsfororsuperiortomeasuresoffinancialperformancepreparedinaccordance withgaap johnsonjohnsonannualreportoperational sales growth segment excluding acquisitions divestitures vs consumer pharmaceutical medicaldevices total operational wwasreported women'shealth sanitaryprotection women'shealth ky diagnostics orthoclinicaldiagnostics allotheracquisitionsanddivestitures wwopsexcludingacquisitionsanddivestitures operationalgrowthexcludestheimpactofcurrencytranslation operationalsalesgrowthexcludingthenetimpactofacquisitionsanddivestituresisanongaapfinancialmeasure investorsshouldconsidernongaapfinancialmeasuresinadditiontoandnotasreplacementsfororsuperiorto measuresoffinancialperformancepreparedinaccordancewithgaapduetothevariablenatureofacquisitionsand divestituresandtheimpacttheymayhaveontheanalysisofunderlyingbusinessperformanceandtrendsmanagement believesthatprovidingthismeasureenhancesaninvestorsunderstandingofthecompanysperformanceandmayassist intheevaluationofongoingbusinessoperationsperiodoverperiodthisnongaapfinancialmeasureispresentedto permitinvestorstomorefullyunderstandhowmanagementassessestheperformanceofthecompanyincludingfor internalevaluationoftheperformanceofthecompanysbusinessesandplanningandforecastingforfutureperiodsthe useofthisnongaapfinancialmeasureasaperformancemeasureislimitedinthatitprovidesaviewofthecompanys resultsofoperationswithoutincludingalleventsduringaperiodandmaynotprovideacomparableviewofthecompanys performancetothatofothercompaniesinthehealthcareindustry johnsonjohnsonannualreport board directors senior management alexgorsky alexgorsky chairmanboardofdirectors chiefexecutiveofficer chairmanexecutivecommittee marysuecoleman presidentemeritauniversityofmichigan dominicjcaruso vicepresidentfinance jamesgcullen chieffinancialofficer retiredpresidentandchiefoperatingofficer memberexecutivecommittee bellatlanticcorporation douglaskchia dscottdavis corporatesecretary chairmanandformerchiefexecutiveofficer assistantgeneralcounsel unitedparcelserviceinc stephenjcosgrove ianeldavis corporatecontroller chairmanrollsroyceholdingsplcformerchairman chiefaccountingofficer andworldwidemanagingdirector mckinseycompany joaquinduato worldwidechairmanpharmaceuticals susanllindquist memberandformerdirectorwhiteheadinstitutefor petermfasolo biomedicalresearchprofessorofbiology vicepresidentglobalhumanresources massachusettsinstituteoftechnology memberexecutivecommittee markbmcclellan jorgemesquita seniorfellowineconomicstudiesand worldwidechairmanconsumer directoroftheinitiativeonvalueand michelorsinger innovationinhealthcarebrookingsinstitution worldwidechairmanglobalorthopaedics annemmulcahy johnapapa formerchairmanandchiefexecutiveofficer treasurer xeroxcorporation sandraepeterson leofmullin groupworldwidechairman retiredchairmanandchiefexecutiveofficer memberexecutivecommittee deltaairlinesinc garyjpruden williamdperez worldwidechairmanglobalsurgery retiredpresidentandchiefexecutiveofficer wmwrigleyjrcompany michaelesneed vicepresidentglobalcorporateaffairs charlesprince retiredchairmanandchiefexecutiveofficer paulusstoffels citigroupinc chiefscientificofficer worldwidechairmanpharmaceuticals aeugenewashington memberexecutivecommittee vicechancellorofhealthsciencesdeanofthedavid geffenschoolofmedicineattheuniversityofcalifornia michaelhullmann losangelesuclachiefexecutiveofficerofthe vicepresidentgeneralcounsel uclahealthsystem memberexecutivecommittee ronaldawilliams kathrynewengel formerchairmanandchiefexecutiveofficer vicepresidentjohnsonjohnsonsupplychain aetnainc jessejwu chairmanjohnsonjohnsonchina johnsonjohnsonannualreportprincipaloffice commonstock johnsonjohnsononline onejohnsonjohnsonplaza listedonnewyorkstockexchange wwwjnjcom newbrunswicknewjersey stocksymboljnj shareholderrelationscontact wwwjnjcomournewscenter annualmeeting douglaskchia theannualmeetingofshareholders corporatesecretary wwwblogjnjcom willtakeplaceonthursdayaprilat thestatetheatrelivingstonavenuenew investorrelationscontact brunswicknewjerseythemeetingwill louisemehrotra wwwfacebookcomjnj conveneatameasternall vicepresidentinvestorrelations shareholdersasoftherecorddateof wwwtwittercomjnjcares februaryarecordiallyinvitedto wwwtwittercomjnjnews attendaformalnoticeofannualmeeting wwwyoutubecomjnj proxystatementandproxyhavebeenmade transferagentandregistrar availabletoshareholders questionsregardingstockholdingscertificatereplace wwwlinkedincomcompany menttransferdividendsandaddresschangesshould johnsonjohnson corporategovernance bedirectedto copiesofourannualreporton computershare formkfiledwiththesecuritiesand pobox toviewtheonlinejohnsonjohnson exchangecommissionproxy collegestationtx yearinreviewpleasegoto statementandthisannualreportare overnightcorrespondenceshouldbesentto wwwyearinreviewjnjcomorscanthis availableonlineatwwwinvestorjnjcomor computershare qrcode toshareholderswithoutchargeupon qualitycirclesuite writtenrequesttotheofficeofthe collegestationtx corporatesecretaryatourprincipal shareholderwebsite addressorbycalling wwwcomputersharecominvestor shareholderonlineinquiries onthecorporategovernancesectionofour httpswwwuscomputersharecominvestor websitewwwinvestorjnjcomshareholders contact canviewourfilingswiththesecuritiesand exchangecommissionincludingquarterly dividendreinvestmentplan reportsonformqandcurrentreports ourdividendreinvestmentplanallowsforfullor onformkrestatedcertificateof partialdividendreinvestmentandadditionalweekly incorporationbylawsprinciplesof cashinvestmentsuptoperyearin corporategovernancechartersoftheaudit johnsonjohnsoncommonstockwithoutpershare committeecompensationbenefits orservicechargesonstockpurchasesifyouare interestedinparticipatingintheplanandneedan committeenominatingcorporate enrollmentformandormoreinformationpleasecall governancecommitteeregulatory theplanadministratorcomputersharetrust compliancegovernmentaffairs companynaator committeeandsciencetechnology outsidetheusorgotowwwcomputersharecom sustainabilitycommitteepolicyonbusiness investor conductforemployeescodeofbusiness conductethicsformembersoftheboard hearingimpaired ofdirectorsandexecutiveofficersandother shareholderswhohaveinquiriesregardingstock corporategovernancematerialscopiesof relatedmatterscancommunicatedirectlywith thesedocumentsareavailabletoshareholders computersharetrustcompanynaviaa telecommunicationsdevicetddthetelephone withoutchargeuponwrittenrequesttothe numberforthisserviceisor corporatesecretaryatourprincipaladdress outsidetheus undersectionofthesarbanesoxleyact electronicdeliverynotification wearerequiredtofilecertificationssignedby ourproxystatementandthisannualreportare thechiefexecutiveofficerandthechief availableonourwebsiteatwwwinvestorjnjcom financialofficerasexhibitstoourformk annualreportscfmshareholderswhoarestill orformqforeachfiscalyearorquarter receivingpapercopiesofourproxystatementsand inadditionwearerequiredtosubmita annualreportsbymailcanelecttoreceiveinsteadan certificationsignedbythechiefexecutive emailthatwillprovidealinktothosedocumentson officertothenewyorkstockexchange theinternetshareholderswhoholdtheirsharesin withindaysfollowingtheannualmeeting theirownnamemayenrollintheelectronicproxyand ofshareholderscopiesofthecertifications annualreportaccessserviceforfutureannualmeetings filedforpreviousyearsarepostedonthe onlineatwwwcomputersharenacomgreen corporategovernancesectionofourwebsite thejohnsonjohnsonannualreport shareholderswhoholdtheirsharesbeneficiallyin andfuturecertificationswillbeposted containsmanyofthevaluabletrademarksand streetnamethatisinthenameofabankbrokeror promptlyuponfiling otherholderofrecordandwishtoenrollforelectronic tradenamesownedandusedbythejohnson accessmayregisteratenrollicsdeliverycomjnj johnsonfamilyofcompaniesintheunited statesandinternationallytodistinguish productsandservicesofoutstandingquality johnsonjohnson shareholder informationcaring world one person time inspires unites people scan qr code view digital version johnson johnson annual report